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Pll line 5 should read:
’’Specific uptake mechanisms for dopamine (Scatton et al 1985), 
and high affinity binding sites for dopaminergic ligands 
(Bernado and Prince 1982; Bischoff et al 1980; Dawson et al 
1985: Ouimet et al 1984) have been found in the hippocampus.
P40 line 8 should read:
However, two recent studies have reported that electrical 
stimulation of the fustigial nucleus results in widespread 
increases in cerebral blood flow while having little effect on 
cerebral glucose utilisation (Nagai et al 1983: Iadecola et
al 1985). This apparent uncoupling of the flow/glucose use 
relationship has been attributed to a direct neurogenic action 
upon the cerebral vasculature. Thus, both metabolic and 
neurogenic factors can significantly affect the cerebral 
circulation.
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SUMMARY
In recent years, two pharmacologically distinct subpopulations 
of dopamine receptor, designated and D2  have been found in brain 
and vascular tissue. The development of new classes of chemical 
compounds which discriminate between the subpopulations of dopamine 
receptor now permits the examination of dopaminergic mechanisms with 
a precision hitherto impossible. Of these, the benzazepine 
derivative SKF 38393 possesses a high degree of selectivity for the 
receptor while the partial ergoline LY 141865 (or as its 
biologically active enantiomer LY 171555) is a selective ^  agonist. 
These agents have been used extensively to examine anatomical 
distribution and neurochemical properties of the and D£ 
subpopulations in vitro. However, little is known about the effects 
of pharmacological manipulation of the and D£ receptor 
subpopulations upon the integrated activity of the brain in vivo.
The systemic administration of dopamine receptor agonists 
frequently results in pronounced cerebrovascular effects. However, 
the precise mechanism through which dopamine receptor agonists alter 
cerebral blood flow is unclear. Hitherto, two possible mechanisms 
have been proposed. According to one view dopamine receptor agonists 
may interact with specific dopamine receptive sites on 
cerebrovascular smooth muscle, altering the calibre of resistance 
vessels and thereby modify blood flow. Alternately, the agonists may 
modify the activity of neural tissue and, as a result of the 
homeostatic mechanisms which adjust the level of tissue perfusion to 
meet alterations in metabolic demand, indirectly modify-cerebral
blood flow. In the studies which form the basis of this thesis I 
have examined the relative importance of the metabolic and neurogenic 
components of the cerebrovascular response to dopaminergic agonists.
The thesis also addresses the role of and receptors on 
the integrated functional activity of the brain. The experiments, 
performed were threefold. The first series of experiments examined 
the vasomotor responses of individual cerebral arterioles lying on 
the pial surface of the anaesthetised cat brain to perivascular 
microinjections to dopamine receptor agonists and antagonists. The 
second set of experiments employed the 2-deoxyglucose quantitative 
autoradiographic technique to examine the influences exerted by 
dopamine receptor subtypes upon the integrated functional activity 
of the rat brain as reflected by altered rates of local; cerebral 
glucose utilisation. Finally, a third series of investigations 
employed an analogous quantitative autoradiographic technique (using 
carbon 14 iodoantipyrine as tracer) to examine the effects of the 
selective Dj and D 2  agonists SKF 38393 and LY 171555 upon local 
cerebral blood flow in the rat brain. These studies together with 
parallel 2-deoxyglucose investigations in rats, permitted the 
examination of the effects of and receptor activation upon the 
flow/glucose relationship. The direct perivascular microapplication 
of apomorphine and the selective and D2  agonists SKF 38393 and LY 
141865 provoked dose-related increases in pial arteriolar calibre. 
The rank order of potency, in terms of (the concentration producing 
50% of the maximum response) SKF 38393 > apomorphine > LY 141865, 
consistent with the hypothesis that dilatation of the 
cerebrovasculature is mediated via the receptor subtype. This
view was supported by studies with the putatively selective- 
antagonist SCH 23390. At the concentrations examined (10"”^  to 10”**M) 
SCH 23390 did not display any intrinsic vasomotor activity, nor did 
even high concentrations (10“^M) of SCH 23390 affect the non-specific 
dilatory response elicited by acidic cerebrospinal fluid. However, 
the co-administration of low concentrations of SCH 23390 (10 M) 
markedly attenuated the cerebrovascular dilatations produced by 
apomorphine or SKF 38393.
The intravenous administration of LY 171555 (0.1 - 5 mg/kg) 
affected dose-related increases in glucose utilisation within 21 of 
the 59 brain regions examined. The stimulation of local cerebral 
glucose use occurred predominately within those brain areas which 
subserve somatosensory and motor functions (sensory motor and frontal 
cortices, ventral and intralaminar thalamic nuclei, spinal nucleus of 
the trigeminal nucleus, and basal ganglia inter alia). Following the 
administration of LY 171555, there was evidence that glucose use 
became topographically heterogeneous with dose-related-increases 
occurring within the ventral portion of this nucleus. In only one 
brain area (the molecular layer of the hippocampus) was there 
evidence of a dose-related reduction in glucose use following the 
administration of this receptor agonist.
The putatively selective receptor agonist SKF 38393 (1 - 30 
mg/kg) provoked concentration-dependent alterations in glucose use 
in only two of the 59 brain areas examined; the anterior cingulate 
cortex and anteriomedial thalamic nucleus. The parallel reductions 
in glucose use observed within these two brain areas suggest that 
activation of receptors may play a role in the activity of this 
limbic thalamo-cortical circuit.
XVII
The patterns of altered glucose use elicited by SKF 38393 and 
LY 171555 were compared to that of the classical dopamine receptor 
agonist apomorphine. Visual inspection of the autoradiograms 
suggested that the pattern of alterations in glucose use elicited by 
apomorphine was broadly similar to that produced by LY 171555 
(markedly increased glucose use within frontal and sensory motor 
cortex, basal ganglia and other subcortical areas subserving 
somatosensory or motor function) but also contained features of the 
SKF 38393 response (reductions in glucose use within the anterior 
cingulate cortex and anteromedial thalamus). These data .are 
consistent with the view that apomorphine is a mixed agonist.
To permit a more critical evaluation of the metabolic responses 
elicited by these agonists a simple yet statistically rigorous system 
of data analysis has been devised (Ford et al. 1985). This method of 
data analysis describes the pattern of altered glucose for each drug 
treatment in terms of a rank order of regional responsiveness. This 
pharmacological 'fingerprint' of drug activity can be derived from 
the dose response relationship for each of the 59 brain regions 
examined using a simple arithmetic function. Evaluation of the 
functional profiles elicited by SKF 38393, LY 171555 and apomorphine 
revealed a markedly different pattern of response in response to each 
drug treatment.
The role of receptors on function-related glucose use in the 
CNS was further examined in a study of the effects of the selective 
Dj^  antagonist SCH 23390. The intravenous injection of SCH 23390 
(0.05 - 1 mg/kg) resulted in discrete alterations in local cerebral 
glucose utilisation. Following the administration of 0.1 mg/kg
significant increases in glucose use were found within the nucleus 
accumbens (+36%) and lateral habenular nucleus (+24%) while 
concomitant reductions occurred within the pars reticulata of the 
substantia nigra (+16%) and posterioventromedial nucleus of the 
thalamus (+14%). At the highest concentration examined (1 mg/kg) 
significant reductions in glucose use were within areas of the visual 
system and ventral thalamus. No significant alterations in glucose 
use were evident at 0.05 mg/kg. The prior administration of this low 
concentration of SCH 23390 (0.05 mg/kg) blocked the stereotyped 
gnawing and increases in glucose utilisation produced by LY 171555 
(0.5 mg/kg), however, although neither drug significantly altered 
glucose use within the anterior cingulate cortex and anteromedial 
thalamus per se, the interaction of these agents significantly 
reduced function - related glucose utilisation within these brain 
areas. Together these data indicate that although focal alterations 
in local cerebral glucose utilisation is initiated in all but a few 
brain areas by the receptor population, the expression of these 
alterations require the presence of functional (unblocked) 
receptors.
Under normal circumstances there is a close relationship 
between local cerebral glucose utilisation and local cerebral blood 
flow such that areas of high glucose utilisation exhibit high levels 
of blood flow while areas of low metabolic activity receive 
correspondingly low levels of blood flow. However, it remains to be 
established whether this relationship is affected by the 
administration of dopamine receptor agonists.
XIX
The administration of the agonist LY 171555 (0.5 mg/kg) 
significantly increased local blood flow in those brain areas in 
which, enhanced rates of glucose use had been observed previously 
(viz. sensory motor and frontal cortices, basal ganglia and ventral 
tier of thalamus). Within each of these brain areas, the magnitude 
of the increases in blood flow and glucose use were proportionately 
similar.
C
SKF 38393 (30 mg/kg) provoked little change in local blood flow 
within the vast majority of brain regions examined. However, the 
administration of this agonist did provoke significant reductions in <?- 
local blood flow within the anterior cingulate cortex and 
anteromedial thalamic nucleus. These observations are of crucial 
importance in evaluating the relative importance of the vascular and 
metabolic components of the circulatory response to dopamine receptor 
agonists. Although, SKF 38393 a potent dilator of cerebral vessels 
in situ, it provokes parallel reductions in blood flow and glucose 
use within two brain areas which contain receptors. These data 
clearly indicate that local metabolic activity is the primary 
determinant of cerebral blood flow. This view was supported by an 
examination of the overall relationship between blood flow and 
glucose use in SKF 38393 and LY 171555 treated animals. Neither SKF 
38393 nor LY 171555 significantly altered the overall relationship 
between blood flow and glucose use observed in saline treated control 
animals.
Further analysis revealed that both SKF 38393 and LY 171555 can 
produce focal uncoupling of the flow/glucose use relationship within 
particular subregions of the caudate nucleus. Disproportionately
XX
high levels of blood flow (relative to glucose use) observed within 
the ventrolateral portion of the caudate nucleus suggest that D£ 
receptors agonists may mediate vasodilatation by acting directly on 
the cerebral vasculature within this brain area.
SKF 38393 provoked significant reductions in blood flow at two 
of the three levels of the caudate nucleus exmined. In contrast SKF 
38393 had little effect upon local glucose use in any of the 
subregions of the caudate nucleus examined. However, the mechanisms 
underlying these responses are unclear.
This thesis contributes insight into two aspects of 
dopaminergic function in vivo. Firstly, the studies comprising this 
thesis represent a comprehensive examination of the relative 
importance of the vascular and metabolic components of the 
circulatory response to dopamine receptor agonists. They clearly 
demonstrate that in the vast majority of brain areas it is the local 
rates of metabolic activity which is the primary determinants of 
tissue perfusion perfusion, however, within some brain areas (i.e. 
subregions of the caudate nucleus) other factors (vasomotor actions 
or non-specific drug effects) may play a significant role in 
determining levels of tissue perfusion. Secondly, the studies 
contribute to the understanding of the functional role of dopamine 
systems in the brain as these roles are reflected in local cerebral 
glucose utilisation.
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CHAPTER I 
INTRODUCTION
1. Dopamine Receptors in Cerebral and Vascular Tissues
From inauspicious beginnings, almost 80 years ago, the view of 
dopamine has altered radically from being a precursor of 
noradrenaline possessing weak sympathomimetic activity to its present 
status as the most intensively studied of all the neurotransmitters, 
possessing important physiological roles in the control of limbic and 
motor function and in the maintenance of cardiovascular and endocrine 
homeostasis.
1*1 Historical Perspective
Dopamine (B — (3,4-dihydroxypheny1)ethylamine) was first 
synthesised in 1910 (Barger and Ewins, 1910; Mannich and Jacobsohn 
(1910). In that same year, 1910, Barger and Dale reported that 
dopamine provoked pressor responses in the spinal cat, although it 
proved to be fifty times less potent than noradrenaline. Early 
cardiovascular studies (Tainter, 1930) confirmed the weak 
sympathomimetic actions of dopamine reported by Barger and Dale and 
demonstrated that, like noradrenaline, the pressor actions of 
dopamine could be potentiated by cocaine and inhibited with the 
adrenergic blocking agent ergotoxine (Tainter, 1930). However, in 
the presence of ergotoxine, dopamine reduced blood pressure in the 
spinal cat, an action which was similar to that provoked by 
adrenaline in such preparations^-.
^FOOT NOTE. The vasodepressor effects of adrenaline in the presence 
of ergot alkaloids was first reported by Dale (1906) and subsequently 
shown to be due to an activation of dilatory B-adrenergic receptors
The first indications that dopamine may have a physiological 
role distinct from noradrenaline or adrenaline is generally 
attributed to Holtz and Credner (Holtz and Credner, 1942). These 
authors found that a vasodepressor response could be elicited in 
guinea-pigs and rabbits following low doses (<1 mg i.v.) of dopamine 
and that the pressor effects reported in earlier studies could be 
demonstrated only at high doses (>1 mg i.v.). This depressor effect 
was subsequently shown to be resistant to atropine, antihistamines 
and B-adrenergic blockers (McDonald and Goldberg, 1963; Hotlz et al. 
1963, 1964; McNay and Goldberg, 1966). However, at the time the 
authors suggested that the depressor effects were produced not by 
dopamine, but by 3,4-dihydroxy-phenylacetaldehyde (DOPAC), the 
aldehyde product formed from dopamine by monoamine oxidase.
Some 15 years later Blaschko noted that dopamine constituted up 
to 50% of the total catecholamine content of the splenic nerve 
(Blaschko, 1957). These levels were evidently not consistent with 
the prevalent view that dopamine was merely a metabolic precursor of 
noradrenaline and led Blaschko to postulate that dopamine may possess 
physiological actions in addition to its role as a biosynthetic 
intermediate. This view was rapidly confirmed by Horaykiewicz who 
demonstrated that the depressor effects of dopamine in the guinea- 
pig were due not to the action of DOPAC as suggested by Holtz and 
Credner, but to specific action of dopamine on the vasculature 
(Hornykiewicz, 1958).
At about the same time it was shown that dopamine levels in the 
brain was similar to that of noradrenaline (Montagu, 1957; Carlsson 
et al. 1958). Moreover, the finding that dopamine was concentrated
within the basal ganglia (Bertler and Rosengren, 1959; Carlsson 
1959) suggested that dopamine may have a neurotransmitter role in the 
CNS as well as in the peripheral vasculature.
In 1957 Carlsson reported that 1-dopa, a precursor of dopamine 
which unlike dopamine could cross the blood-brain barrier reversed 
the akinesia induced by neuroleptic doses of reserpine in mice 
(Carlsson et al. 1957). Later in a seminal paper, Carlsson (1959) 
demonstrated that administration of 1-dopa caused a marked increase 
in dopamine levels in the rabbit brain whereas noradrenaline levels 
were not markedly affected. He noted that reserpine, which depletes 
dopamine from the corpus striatum, produced a syndrome very similar 
to Parkinsonism, and was efficient in controlling the choreatic 
behaviours associated with lesions of the extrapyramidal system. The 
hypothesis that the "striatal dopamine system" was central to the 
pathophysiology of Parkinsonism was supported by clinical studies 
which identified profound reductions in striatal dopamine levels in 
patients suffering from idiopathic and postencephalitic Parkinsonism 
(Ehringer and Hornykiewicz, 1960) and by the demonstration of the 
beneficial effects of 1-dopa in these patients (Birkmayer and 
Hornykiewicz, 1961; Barbeau et al. 1961). The development of the 
Falck/Hillarp - histofluorescence technique demonstrated that 
dopaminergic neurones arise from the ventral mesencephalon to 
innervate the striatum (Anden et al. 1964; Bertler et al. 1964; 
Dahlstrom and Fuxe, 1966 a). With the development of more sensitive 
histochemical techniques (glyocylic acid, ALFA) and 
immunohistochemical techniques (Geffard et al. 1984) it has been 
possible to demonstrate the presence of a number of dopamine systems 
within the mammalian brain.
1.2 Distribution of Dopamine Systems in Cerebral Tissue
Central dopamine systems have been divided into three principle 
subsystems: a large mesotelencephalic system which encompasses the
nigrostriatal, mesocortical and mesolimbic pathways, and the smaller 
diencephalic system. In addition dense plexus of dopamine neurons 
have been found within the amacrine cells of the mammalian and fish 
retina, and within the periglomerular cells of the olfactory bulb. 
Although, the dopamine systems of the rat brain have been the most 
extensibly studied, there is considerable evidence to suggest that 
the dopamine systems are essentially the same in all mammalian 
species (Lindvall and Bjbrklund, 1984).
1.2.1 Mesotelencephalic Dopamine System
a) Mesostriatal System
The principle dopamine projection system, accounting for 
approximately 80% of brain dopamine, arises from the catecholamine 
cell groups of the ventral mesencephalon. The dopamine cells 
comprising this sytem are located predominately within the A9 cell 
group (of Dahlstrom and Fuxe, 1964) of the substantia nigra and the 
A10 cells of the ventral tegmental area (Anden et al. 1964, 1965; 
Bertler et al. 1964; Dahlstrom and Fuxe, 1964). The nigral neurons 
are found mainly within the pars compacta and pars lateralis of the 
substantia nigra, although a few perikayra are found scattered 
throughout the pars reticulata. Dopamine cells are also located 
within the A8 (Figure 1) cells of the retrorubral nucleus, however,
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since these cells project in the same manner as the nigral cells they 
are generally regarded as the caudal extension of the nigral dopamine 
cell group (BjBrklund and Lindvall, 1978, 1984; Ungerstedt, 1971; 
Nauta et al. 1978). Similarly, the non-nigral cells are not 
restricted to the ventral tegmental area but form a band medial to 
the substantia nigra which extends from the level of the 
supramammillary region caudal to the level of the superior cerebellar 
peduncles (BjBrklund and Lindvall, 1984). Recently it has been 
proposed that the separation of mesencephalic dopamine cells into 
nigral and non-nigral may be an artificial distinction (BjBrklund and 
Lindvall, 1984, see Table 1). These authors have argued that there 
are no clear anatomical boundaries between nigral and non-nigral 
cells. Moreover, a number of brain areas receive their dopaminergic 
input from both the substantia nigra and ventral tegmental area 
(Fallon and Moore, 1978; BjBrklund and Lindvall, 1978). The entire 
mesencephalic dopamine system is, therefore, considered to be an 
entity having a crude topographical order of projections to striatal, 
limbic and cortical areas (Lindvall and BjBrklund, 1984; Nauta and 
Domesick, 1984; Fallon and Moore, 1978; Loughlin and Fallon, 1984). 
However, it should be recognised that nigral cells send collaterals 
to a variety of brain regions, including the globus pallidus 
(Lindvall and BjBrklund, 1979, 1982) and subthalamic nucleus
(Lindvall and BjBrklund, 1984; Campbell et al. 1985). By contrast, 
dopamine cells emanating from the ventral tegmental area appear to 
innervate only one brain area (Fallon 1981; Loughlin and Fallon, 
1984).
Views of the mesencephalic dopamine system has recently been 
revised to encompass the concept of a 'ventral striatum' (Heimer and
Wilson, 1975). According to this view of the forebrain, the striatum 
can be regarded as comprising a dorsal (motor) division and a ventral 
(limbic) portion. The latter including not only the ventromedial 
portion of the caudate nucleus but also the nucleus accumbens, 
olfactory tubercle and portions of the amygdala lateral, central and 
basolateral nuclei inter alia (Heimer and Wilson, 1975; Kelly et al. 
1982; Nauta and Domesick, 1984) (Table 1). Recent studies have 
suggested that the ventral striatum receives its dopaminergic 
innervation from the ventral tegmental area whereas the dorsal 
striatum is supplied by the A9 cells of the substantia nigra 
(BjBrklund and Lindvall, 1984).
b) Mesolimbocortical Projections
The mesolimbocortical dopamine system comprises projections to 
limbic (septum, lateral habenular nucleus), allocortical (piriform 
cortex, amygdala and hippocampus) and neocortical (suprarhinal, 
supragenual pregenual and entorhinal cortices) brain areas.
Evidence for a catecholamine innervation of the lateral septum 
was first provided by Fuxe (1965). Though, this innervation was 
originally thought to be noradrenergic, more and more evidence has 
accrued which indicates that this innervation is in fact the terminal 
distribution of dopamine fibres originating in the medial part of 
the ventral tegmental area (Assaf and Miller, 1977; Carter and 
Fibiger, 1977; Lindvall and Steveni, 1978). Almost all of the 
dopaminergic input to the septum is restricted to the lateral nucleus 
(Lindvall and Steveni, 1978). Morphologically, septal neurons appear 
to be of two distinct types: one slender and varicose, that forms a
dense band outlining the fornix, and the other, smooth with few
TABLE 1
ORIGINS AND PROJECTIONS OF THE MESOTELENCEPHALIC DOPAMINE SYSTEM.
System Origin(s) Terminal Area
Niarostriatal
Dorsal A9 Dorsal Caudate Nucleus 
Globus Pallidus 
Subthalamic Nucleus
Ventral A8 Ventroposterior Caudate Nucleus
A10 Anteromedial Caudate Nucleus
Olfactory Tubercle
Bed Nucleus of Stria Terminalis
A10, A9, A8 Nucleus Accumbens
Mesolimbocortical
A10 Lateral Septum
A10, A9 Amygdala 
Olfactory Bulb 
Piriform Cortex 
Hippocampus
A10, A8 Entorhinal Cortex
A10 Lateral Habenuls.
A10 Dorsal Raphe Nucleus,
A10, A9 Locus Coeruleus
A10 Suprarhinal Cortex 
Pregenual Cortex
A9 Supragenual Cortex
Modified from BjBklund and Lindvall, 1984.
varicosites which form basket-like arrangements around the cell 
bodies and proximal dendrites of the dorsal portion of the lateral 
septum (Lindvall and BjBrklund, 1978 a,b). However, in a recent 
immunocytochemical study no differences in the ultrastructure of the 
dopamine immunoreactive profile of these two cells were observed 
(Onteniente et al. 1984).
A discrete plexus of dopamine fibres terminates in the medial
portion of the lateral habenula nucleus (Lindvall et al. 1974;
HBkfelt et al. 1976; Phillipson and Pycock, 1982; Skagerberg et al. 
1984). Studies with anterograde and retrograde tracers have
indicated that the dopaminergic innervation of the lateral habenula 
originates in the ventral tegmental area (Herkenham and Nauta, 1977; 
Phillipson and Griffith, 1980; Swanson, 1982; Skagerberg et al.
1984); a view which is supported by the loss of dopamine
fluorescence in the lateral habenula following lesions of the ventral 
tegmental area (Kizer et al. 1976; Phillipson and Pycock, 1982; 
Skagerberg et al. 1984). However, it should be emphasised that only 
a relatively minor portion of the mesohabenular projection is 
dopaminergic and that the habenula is also innervated by the 
periventricular dopamine system. It is, however, important to note 
that the lateral habenula is connected via polysynaptic pathways to a 
number of brain areas which receive a more extensive dopaminergic 
input (viz caudate nucleus, prefrontal and cingulate cortices and 
nucleus accumbens).
Biochemical studies have shown that bilateral 6-hydroxydopamine 
lesions of the noradrenaline input to the hippocampus resulting in an 
almost complete depletion of hippocampal noradrenaline, has little
effect upon the levels of DOPAC within this allocortical structure 
(Bischoff et al. 1979). However, if these lesions are combined with 
destruction of the ventral mesencephalon a significant reduction of 
DOPAC is observed in hippocampal tissue (Scatton et al. 1980). The 
presence of specific uptake mechanism for dopamine (Scatton et al.
1985) and of high affinity binding sites for dopaminergic ligands 
(Bernado and Prince, 1982; Bischoff et al. 1980; Dawson et al. 
1985; Ouimet et al. 1984). However, so far, anatomical studies have 
failed to demonstrate the presence of dopaminergic nerve terminals in 
the hippocampus.
The existence of dopaminergic neurons in cerebral cortex was 
first suggested by Thierry and her colleagues (Thierry et al. 1973
a), who found that lesions of cortical noradrenergic systems had 
little effect on cortical dopamine levels. Subsequently, reports 
from the same laboratory demonstrated the continued synthesis of 
dopamine in neocortex following lesions of noradrenergic systems 
(Thierry et al. 1973b, Berger et al. 1974). Shortly, thereafter, 
specific high affinity dopamine uptake sites (Tassin et al. 1974) and 
dopamine sensitive adenylate cyclase in cortical tissue (von Hungen 
and Roberts, 1973; Bockaert et al. 1977) were demonstrated.
The dopaminergic innervation of frontal neocortex is formed 
from the terminal ramifications of three mesotelencephalic projection 
systems: suprarhinal, pregenual and supragenual systems (Berger et
al. 1976, 1985; Berger, 1977; Beckstead, 1976; BjBrklund and 
Lindvall, 1978; Divac et al. 1978 a,b). It was soon recognised that 
these cortical areas also receive major anatomical projections from 
the mediodorsal thalamic nucleus and so correspond to areas of
prefrontal cortex (Divac et al. 1978 a,b). The dopaminergic 
innervation of prefrontal cortex has been observed in a variety of 
mammalian species, including man (Berger et al. 1977; Divac et al. 
1978 a). However, recent behavioural and hodological studies have 
indicated that in the rat it is the pregenual cortex (the area 
corresponding to B roadmans' area 32: Kreig, 1946) which corresponds
to the primate prefrontal cortex whilst the supragenual cortex (Area 
24) is more correctly termed anterior cingulate cortex (Leonard, 
1969; Krettel and Price, 1977; Berger et al. 1985). The 
dopaminergic projection to pregenual cortex terminates predominately 
in the deep cortical areas (Berger et al. 1974, 1976; Lindvall et 
al. 1974, 1978), whereas the dopaminergic innervation of the anterior 
cingulate cortex terminates in two distinct fields; a deep subfield 
which appears to be the caudal extension of the prefrontal system, 
and a superficial subfield in cortical layers I-III (Hokfelt et al. 
1974, 1977; Lindvall and BjBrklund 1974, 1978; Berger et al. 1985). 
Moreover, the dopaminergic innervation of the supra and pregenual 
cortices develop at different rates and arise from two anatomically 
distinct loci in the ventral mesencephalon (Lindvall et al. 1978; 
Lindvall and BjBrklund, 1984 a,b). On account of these differences 
it has been suggested that the prefrontal and supragenual dopamine 
systems may subserve different functional roles (BjSklund and 
Lindvall, 1984; Berger, 1985).
The dopaminergic innervation of suprarhinal cortex bears many 
similarities to that found in the pregenual system: originating in
the mesencephalic dopamine cells of the A10 area and terminating in 
the deep cortical layers of suprarhinal cortex. It too receives its
thalamic innervation primarily from the mediodorsal cortex and so is 
classified as prefrontal cortex (Divac et al. 1978 a,b).
A dopaminergic projection system from the ventral tegmental 
area and to a lesser extent from the retrorubral area (A8) terminates 
in a series of digit-like clusters in the ventral entorhinal cortex 
(Lindvall et al. 1974 a; Fallon and Moore, 1978 b; Swanson, 1982).
1.2.2 Diencephalic Dopamine System
While the mesotelencephalic system is generally associated with 
behavioural responsiveness and the initiation of movement, the 
dopamine cells of the diencephalon are believed to play an important 
role in neuroendocrine function (BjBrklund and Lindvall, 1984; 
Kaiser and Jain, 1985 for reviews). With the recent discovery of a 
diencephalospinal dopamine system it has been suggested that the 
dopamine systems of the diencephalon may also play a role in 
nociception, the regulation of sympathetic outflow, and the control 
of motor function at the level of the spinal cord (BjBrklund and 
Lindvall, 1984).
The descending diencephalospinal pathway originates primaily in 
the All cell group and terminates in clusters around preganglionic 
sympathetic neurones in the intermediate spinal gray and 
interomedialateral column of the spinal cord. High densities of 
dopamine neurones are also found within the central canal at the 
thoracic and upper lumber levels. Perikyra from the All cell group 
gives rise to ascending neurones innervating the habenula, dorsal 
hypothalamus and areas of the thalamus (pretectal area, 
parafascicular and paraventricular nuclei) (Lindvall et al. 1974 b, 
BjBrklund and Lindvall, 1984). From studies by Lindvall and his
associates (1974 b) it has been suggested that these ascending 
projections of the periventricular system may be formed from 
collaterals of the diencephalospinal system (BjBrklund and Lindvall, 
1984).
A system of short intradiencephalic dopamine projections 
(incertohypothalamic system) has been described which arises in the 
zona incerta and areas of the hypothalamus (Lindvall and BjBrklund, 
1974). The fibers of this system are distinguished from other 
diencephalic systems, being extensively arborised and weakly 
fluorescent. The similarities between the incertohypothalamic 
dopamine system and the dendritic network found in the substantia 
nigra has led to speculation that this system may represent the 
dendritic projections of the perventricular and spinal projection 
systems (BjBrklund and Lindvall, 1984).
The tuberoinfundibular systems arises in the arcuate nucleus 
and in the adjacent A12 cells of the paraventricular nucleus of the 
hypothalamus, and projects in an ordered manner to the median 
eminence and pituitary (pars intermedia and neural lobe) (Fuxe, 
1976).
The tuberal dopamine system has been implicated in the 
regulation of a number of adenohypophyseal hormones, most notably 
prolactin and melanocyte stimulating hormone (MSH). Increases in the 
circulating concentrations of these hormones selectively stimulate 
the activity of tuberal dopamine neurones. In turn, dopamine exerts 
a direct inhibitory action on the release of prolactin from the 
anterior pituitary and MSH from the pars intermedia (see BjBrklund 
and Lindvall, 1984 for discussion). The tuberohypophyseal dopamine
system has also been implicated in the control of other pituitary 
hormones including, growth hormone, thyroid stimulating hormone, 
luteinizing hormone and gonadotropin releasing hormone (Kaiser and 
Jain, 1985; BjBrklund and Lindvall, 1984 for reviews).
Control of hormone release from the pituitary may also be 
exerted by dopamine systems outwith the tuberoinfundibular system. 
Recent electrophysiological and pharmacological studies have 
suggested that dopamine can act not only at the level of the 
posterior pituitary, but at the level to stimulate the release of 
vasopressin and oxytocin but also at the level of the cell bodies of 
these neurosecretory neurones (i.e paraventricular and supraoptic 
nuclei) (BjBrklund and Lindvall, 1984).
1.2.3 Dopamine Systems in the Cerebral Vasculature
The presence of dopamine receptors in the cerebral vasculature 
is widely accepted (Goldberg et al. 1978; Brodde, 1982; Goldberg 
and Kohli, 1983). However, whether cerebral vessels receive a 
functional innervation from dopaminergic neurons, or whether the 
dopamine receptor mechanisms found on cerebral arteries are of purely 
pharmacological interest remains to be established.
Dopamine is widely distributed in peripheral vascular tissue as 
a biosynthetic precursor of noradrenaline (Goldberg et al. 1978), 
Kaiser and Jain, 1985). In these vascular tissues endogenous 
dopamine accounts for less than 4% of the total catecholamine content 
(Bell and Gillespie, 1981). In contrast, dopamine accounts for up to 
60% of the total catecholamine content of rat and bovine cerebral
microvessels (Head et al. 1980). Although the relatively high
proportion of dopamine in cerebral vessels would be consistent with a
dopaminergic innervation; the findings could equally be explained by
the presence of non-innervated storage sites (i.e. mast cells). To
obtain definitive evidence for a dopaminergic innervation of the
cerebral vasculature would require the histochemical demonstration of
neurons
processes from dopaminergic making synaptic connections with 
cerebrovascular smooth muscle. Dendrites from mono amine-containing 
neurons in the primate substantia nigra and raphe nuclei have been 
shown to make direct contact with the basement membrane of small 
arterioles and capillaries (Felten and Crutcher, 1979). 
Unfortunately, the histofluorescence technique employed (that of 
Falck and Hillarp, 1964) does not discriminate between dopamine 
containing neurons and those containing noradrenaline or serotonin 
(BjSklund and Lindvall, 1984). Since both serotoninergic and 
dopaminergic perikayra have been localised within both the substantia 
nigra and raphe nuclei (Steinbush, 1984) it is not possible to 
confirm the identity of these neurons.
The recent development of specific antibodies to dopamine 
(Geffard et al. 1984) and serotonin (Steinbush, 1984) offers the 
possibility of discriminating between catecholamine 
neurotransmitters. Specific antibodies raised against dopamine have 
been used to examine the possibility of a dopaminergic innervation of 
the rat cerebral vasculature. Preliminary reports have indicated 
that dopaminergic neurones within the substantia nigra and raphe 
nuclei do innervate cerebral arterioles (Steinbusch, 1986). Whether 
dopamine neurones in other brain areas innervate blood vessels 
remains to be determined.
1.3 Dopamine Receptor Pharmacology
1.3.1 Central and Peripheral Actions of Dopamine
Under normal physiological conditions dopamine does not cross 
the blood-brain barrier (Birkmayer and Hornykiewicz, 1961; Weiner, 
1980; Kaiser and Jain, 1985). Consequently, the pharmacology of 
central dopamine system must be inferred from the actions of indirect 
sympathomimetics (1-dopa, methylphenidate, amphetamine) or agents 
which interact with dopamine receptors.
L-dopa, the metabolic precursor of dopamine readily crosses the 
blood-brain barrier into the brain where it is rapidly taken up into 
cells and converted into dopamine (Caine and Sandler, 1970; Holtz, 
1959). In animals, the administration of 1-dopa evokes a 
characteristic range of responses. These actions include increased 
locomotor activity (Bartholini et al. 1969), and the reversal of 
reserpine-induced catalepsy (Carlsson et al. 1957) inter alia. In 
patients 1-dopa alleviates the motor deficits associated with 
Parkinson's disease although up to 1/3 of patients experience nausea 
and vomiting and abnormal involuntary movements, mainly buccolingual 
dyskinesias (Barbeau et al. 1971).
The indirect sympathomimetic agents amphetamine 1-dopa, and 
methylphenidate are thought to elicit their behavioural responses by 
an action primarily on central dopamine systems (Murikvad et al. 1968; 
Ross 1979). In rats the excitatory behaviours elicited by these 
agents is characterised by grooming, sniffing and licking at low 
concentrations with intense stereotyped gnawing and biting at higher 
concentrations. All these behavioural responses have been attributed
to the enhancement of dopaminergic activity within the striatum 
(Munkvad et al. 1968; Costall and Naylor, 1981; Seeman, 1981).
There is now considerable evidence to suggest that the 
aporphine derivative, apomorphine acts primarily as a dopamine 
receptor agonist (for reviews see Seeman, 1981; Neumeyer et al. 
1981; Costall and Naylor, 1981; Kaiser and Jain, 1985; Kebabian 
and Caine, 1979; Creese et al. 1983 a,b).
Results from in vivo studies show that apomorphine provokes 
behavioural and biochemical responses characteristic of dopamine 
receptor activation (viz. contralateral rotation in 6-hydroxydopamine 
lesioned rats, stereotyped behaviours, emesis, reduction in the rate 
of dopamine turnover, and inhibition of prolactin release). In
q
vitro, apomorphine displaces H dopamine from homogenates of rat and 
bovine striata (Seeman, 1981), inhibits the release of acetylcholine 
and activates dopamine sensitive adenyl cyclase (Greengard, 1974; 
Anden et al. 1967; Kebabian et al. 1972; Setler et al. 1978). 
Despite its potent behavioural and endocrine actions apomorphine 
displays only weak agonist effects on vascular dopamine receptors 
(Goldberg, 1978; Brodde, 1982) or in the dopamine sensitive adenyl 
cyclase assays (Kebabian et al. 1972; Greengard, 1974; Goldberg, 
1978). Anomolous pharmacological profiles were also reported for the 
ergot derivatives bromocryptine and lergotrile (Lew et al. 1977; 
Spano et al. 1979). In addition to their marked adrenergic actions 
these agents possess many dopamine-like actions (stereotypy, 
reduction in prolactin release and contralateral rotation in rats 
with 6-hydroxy-dopamine induced lesioned). However, both 
bromocryptine and lergotrile failed to dilate the renal vasculature 
and behaved as antagonists of dopamine stimulated adenyl cyclase (Lew 
et al. 1977; Spano et al. 1977, 1979). Taken together these
findings appear inconsistent with the view that dopamine receptor 
agonists effect their behavioural and physiological actions through a 
single population of cyclase linked dopamine receptors. Anomolous 
actions on dopamine mechanisms have also been reported for the 
neuroleptic agents. In particular the substituted benzamide 
derivative, sulpiride (Spano et al. 1979) displays many of the 
characteristics of classical neuroleptics such as inhibition of 
apomorphine-induced changes in locomotor activity, production of 
catalepsy and increases in the brain concentrations of HVA and DOPAC 
have been reported for sulpiride. Yet this drug has minimal effects 
on dopamine sensitive adenylate cyclase (Spano et al. 1979).
1.3.2 Concept of Dopamine Receptor Subtypes
The concept of multiple dopamine receptors was first suggested 
by York In 1970. Subsequently, the existence of multiple classes of 
dopamine receptors has frequently been preferred to account for the 
often disparate actions of dopamine-like agents under a variety of 
experimental conditions. However, the variety of experimental 
approach employed has resulted in a bewildering array of dopamine 
receptor terminologies. Indeed in the intervening years there have 
been sone ten different classification systems, each porrecting from 
one to as many as four receptor subtypes (for reviews see Kebabian 
and Caine, 1979; Costall and Naylor, 1981; Goldberg and Kohli, 
1981; Seeman, 1981). Fortunately, there is emerging a consensus of 
opinion that in both central and peripheral systems dopamine 
receptors exist as two pharmacologically distinct entities, and, 
although some dubiety has persisted as to whether the dopamine 
receptors of cerebral tissue are identical to those on vascular
smooth muscle (Goldberg and Kohli, 1981, 1983) there is now a growing 
acceptance that the receptors at both sites are the same (Kebabian et 
al. 1984; Goldberg et al. 1986).
As this thesis is primarily concerned with the effects of 
dopaminergic mechanisms on the relationship between cerebral blood 
flow and metabolic rate, and examines the characteristics of the 
dopamine receptors on both vascular and neural tissues it is 
imperative that there is conformity in the classification system used 
to describe both sites.
a) Dopamine Receptors in Cerebral Tissue
In 1979 Kebabian and Caine presented evidence for the existence 
of two distinct subclasses of dopamine receptor in cerebral tissue 
based on the ability of dopamine receptor agonists and antagonists to 
interact with adenylate cyclase. This classification system was 
proposed by Kebabian in 1978 but using an alpha, beta terminology 
analogous to that of the adrenergic system. This terminology was 
discontinued to prevent confusion with the adrenergic system. In 
this scheme, the stimulation of one receptor, designated D^, provoked 
and increase in adenyl cyclase activity whereas the second receptor, 
designated D£, appeared to be unrelated to the activity of adenyl 
cyclase. This classification was subsequently modified to include 
the possibility of a dopamine D2  receptor mediating inhibition of 
cyclase activity (Tsurata et al. 1981; Stoof and Kebabian, 1981). 
Release of parathyroid hormone was associated with the Dj^  receptor 
activation whereas inhibition of prolactin release and apomorphine 
induced emesis in dogs were attributed to D2  mediated effects. Based 
on these criteria the dopamine receptor agonist apomorphine behaved
as a weak agonist at the D^ site while having full and potent agonist 
actions at the D£ site, whereas the benzamide class of neuroleptics, 
particularly sulpiride, were potent inhibitors and considered to be 
prototype D£ receptor antagonists.
Ligand bindings studies have obvious attractions. They are 
simple to perform and permit direct measurements of agonist - 
antagonist interactions. Furthermore, when used in conjunction with 
selective lesioning techniques binding studies permit the 
identification and separation of pre- and postsynaptic receptors and 
the examination of supersensitivity phenomena. Consequently, within
3 qsix years of the introduction of H-halopendol and H-dopamine 
(Seeman et al. 1975) as the first dopamine ligands, a "state of the 
art" review could report the binding characteristics of dopamine 
receptors as defined by 30 different ligands; encompassing over 
twelve hundred publications (Seeman, 1981). However, as Seeman 
observed the literature was far from consistent with some authors 
reporting up to five different dopamine receptors; a fact which was 
complicated further by the use of confusing and often contradictory 
terminologies (see Table 2).
Fortunately, much of the controversy has been resolved with the 
realisation that both the D^ and D£ can exist as two interconvertible 
states whose affinity can be regulated by guanyl nucleotides (Sibley 
et al. 1982; Leff and Creese, 1983; Caron et al. 1982). GTP- 
dependent alterations in affinity have also been reported in the 
adenylate cyclase system (Kebabian et al. 1979) and it has recently 
been reported that J>2 mediated inhibition of adenylate cyclase 
correlates with the high affinity D£ site (Creese et al. 1983) in the 
anterior pituitary (McDonald et al. 1984).
Thus, there would appear to be a convergence between dopamine
TABLE 2
DOPAMINE RECEPTOR CLASSIFICATION SYSTEMS 1982-1986.
1982
Authors Approach Classification
Kebabian and Caine Cyclase
h
Goldberg et al. Drug Potency Series TA X V & 2
Creese et al. Ligand Binding “i h °3
D2Hgh
Seeman et al. Ligand Binding Di D&j D2 % D4
Sokoloff et al. Ligand Binding D4 °3 d2
Adapted from Seeman, 1982.
1986
Authors Approach Classification
Kebabian et al. Cyclase Di : D2
Goldberg et al. Drug Potency Series m 2
Creese et al. Ligand Binding Djlcw
Seeman et al. Ligand Binding Djlo® D1hiSh D21^ D2hi®h
Sokoloff et al. Ligand Binding D1 D2lOT;— D2hiSh D4
From Creese and Leff, 1986; Goldberg et al. 1986; Protais et al. 1986; 
Seeman et aL 1985, 1986; Stoof and Kebabian, 1984.
receptor terminologies as characterised by ligand binding or cyclase 
activation models (Table 2).
b) Dopamine Receptors in the Peripheral Vasculature
The existence of specific dopamine receptors have been 
demonstrated on vascular and gastrointestinal smooth muscle, on 
postsynaptic sympathetic nerves and on autonomic ganglia (Goldberg et 
al. 1978; Goldberg and Kohli, 1981). Dopamine receptors at these 
sites have also been subdivided into two distinct populations by 
examining the potency series of a large number of agonists and 
antagonists (Goldberg and Kohli, 1979). Thus one receptor, 
designated the DA^ receptor, mediated smooth muscle relaxation while 
the DA2  subserved the presynaptic inhibition of noradrenaline release 
from sympathetic nerve terminals (Golberg and Kohli, 1979).
Considerable overlap exists between the classification system 
of Goldberg and Kohli (1979) and that proposed by Kebabian and Caine 
(1979). The order of potency for agonists at the DA^ receptor (A- 
6,7,DTN = Dopamine > epinine > dipropyldopamine > apomorphine) is 
similar to that reported for adenyl cyclase activation (Goldberg et 
al. 1978; Kebabian and Caine, 1979; Goldberg and Kohli, 1984). 
Apomorphine is a weak partial agonist at both Dj and DA^ while 
exerting potent agonist effects at both D2  and DA2 . Emesis and the 
inhibition of prolactin secretion can also be mediated by drugs 
acting via receptors designated D 2  and DA 2  in the two 
classifications.
The major source of controversy between the two receptor 
classification systems concerns the role of sulpiride in antagonising 
the effects of dopamine. Sulpiride, a potent antagonist at the D2
receptor has little effect on dopamine-stimulated adenyl cyclase 
(Kebabian and Caine, 1979; Langer and Dubocovich, 1979). In 
contrast, sulpiride inhibits both DA^ and DA£ receptors (Goldberg and 
Kohli, 1981). The underlying reason for the discrepancy between the 
two classification systems may lie in the different experimental 
approaches used to characterise the two receptor subtypes. The 
classification system of Kebabian and Caine (1979) was based 
primarily on studies in vitro whereas that of Goldberg and Kohli 
(1979) is based upon investigations performed in vivo. However, when 
sulpiride was examined in isolated vessel preparations it displayed 
extremely weak antagonistic properties at the DAj receptor (Hilditch 
and Drew, 1981; Schmidt and Imbs, 1980).
1.3.3 Agents Discriminating Between D^ and D£ Receptors
The investigation of dopamine receptor subtypes has been 
greatly facilitated by the recent development of pharmacological 
agents which can discriminate between the two dopamine 
subpopulations.
Selective Dj Receptor Agonists
The most selective D^ receptor agonist presently available is 
2,3,4,5, tetrahydro-7,8-dihydroxy-l-phenyl -lH-3-benzazepine (SKF 
38393 (Figure 2).
In the dopamine sensitive adenyl cyclase system SKF 38393 
displays a higher affinity than dopamine or the classical dopamine 
receptor agonist apomorphine (Setler et al. 1978; Stoof and 
Kebabian, 1981, 1982; Scatton, 1982); however, like apomorphine,
FIGURE 2
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Chemical structures of the dopamine receptor agonists and 
antagonists studied within this thesis.
SKF 38393 displays only partial agonist activity at the cyclase 
(Setler et al. 1978). Both SKF 38393 and apomorphine promote 
contralateral circling in rats with lesions of the nigrostriatal 
dopamine pathway (Setler et al. 1978; Gershanik et al. 1983). In 
contrast to apomorphine SKF 38393 does not promote the characteristic 
physiological or behavioural responses normally associated with the 
administration of dopamine receptor agonists (Setler et al. 1978), 
although a mild behavioural stimulation characterised by an increased 
incidence of sniffing and grooming has been reported (Waddington et 
al. 1982; Molloy and Waddington, 1983, 1984).
Biochemical studies, in vitro, have provided additional 
evidence in support of the selectivity of SKF 38393. Even at 
concentrations 1000 fold greater than required to stimulate adenyl 
cyclase, SKF 38393 fails to affect striatal acetylcholine turnover 
(Scatton, 1982; Stoof and Kebabian, 1982; Plantje et al. 1983). In 
vivo SKF 38393 has no effect on striatal dopamine or acetylcholine 
turnover at concentrations of 30 mg/kg).
Similarly, SKF 38393 relaxes vascular smooth muscle by acting 
as a partial agonist at the vascular receptor (Pendleton et al. 
1978; Hahn and Wardell, 1980; Schmidt et al. 1982; Brodde, 1982). 
These vasomotor responses appear to be selectively mediated via the 
receptor as they are not affected by muscarinic, a  or p -  
adrenergic, or histamine receptor antagonists (Hahn and Wardell, 
1980; Pendleton et al. 1978).
A structural analogue of SKF 38393, fenoldopam (SKF 82526$ is a 
full and potent agonist at the vascular dopamine receptor (Hahn et 
al. 1982; Lockhandwala and Steenberg, 1984); however, its poor 
penetration of the blood brain barrier and doubts as to its 
selectivity (Sibley et al. 1982; Stoof and Kebabian, 1984) make it
less suitable for investigating the effects on cerebral function of 
receptor stimulation.
Selective D£ Agonists
The partial ergdine derivative trans(+)-4,4a,5,6,7,8,8a,9- 
octahydro-5-propyl-2H-pyrozolo-[3,4g] quinoline (LY 141865, Figure 3) 
displays many of the behavioural and biochemical actions 
characteristic of dopamine receptor agonists, however, unlike 
apomorphine LY 141865 does not stimulate adenylate cyclase (Table 3). 
LY 141865 also discriminates between the DA^ and DA£ in vascular 
tissues.
Studies in peripheral and neural tissues have demonstrated that 
LY 141865 displays little affinity for adrenergic, muscarinic, 
histamine and serotonin receptor (Hahn and McDonald, 1984 b; Hahn, 
et al. 1982; Ruffolo and Shaar, 1983; Wong et al. 1983; Cohen et 
al. 1984).
Selective D^ Antagonists
The first selective Dj antagonist was SCH 23390, the 7-chloro 
derivative of SKF 38393 (Iorio et al. 1981). SCH 23390 displays many 
of the actions of a "typical" neuroleptic in behavioural tests. It 
suppresses conditioned avoidance responses in rats and primates 
(Iorio et al. 1983), blocks the stereotyped produced by a variety of 
dopamine receptor agonists (Iorio et al. 1983; Christensen et al. 
1984 a,b; Mailman et al. 1984; Molloy and Waddington, 1984) and 
protects against lethal doses of methamphetamine (Iorio et al. 1983). 
However, unlike "classical" dopamine receptor antagonists SCH 23390
Se
le
ct
iv
it
y 
of 
Do
pa
mi
ne
 
Re
ce
pt
or
 
Ag
on
is
ts
vO *CM i—iin CM * 1—1
vO CO CM CM •>oo 0i CM CO i—i coi-i CO < t •* ■^v CM OO •i 1-4CO CM m (X CO •—4 00 •104 04 (14 v^CM 04 04 1—1 04 CM
> CO CO •u CO CO • > CM > i—l•H cO CO o co CO •i-4 S •H 04P 4J (U 04 <0 •H 04 4J d 4J >O d u u CO d O O •HcO o o <v 04 o CO o CO 4-4
d a d 4-4 0 04 d in d OH P H CO W P H vO M <
04
.3
P.d0
1 
■S'
<oOv
CO
00
CO
P iCO
o
CO
cn
CM
CO
•H
do
00d COi—1 CMCO •i•H m4J <}• CM OVd CO 0% »—4cO 0% i—4 >v Ov(XrH i—4 (X i—4v_^ 04 04 >V OV 04CO CO 4J t-4 CO
s CO CO O CO CO04 04 04 •i-4 04
d d d CO do O O 04 04 Oi—i 04 d 4-4 0 0400 P H CO m P
*
o
ov
ovCM
■uCO
•i-4
do
00
CO
in
00
0%
VO
CM
4-4
CM CO
0% •t-4
co d v o
CM o 1-4
S 00 A
d <5
o 1— 4
•*
co
o cO 04
m • H >
l 4-4 • H
o d 4-4
o CO O
P <5
voCM
m
i—io O CMcO CO CO 4-4•H •V •» 034-4 OV •Hd CM CM o dCO * n CM o<X CM OV Ov OV 2 CO vo'w' CM CM CM CM CM d < CM04 04 04 04 04 04
2 > > > f> > ■1C o i—4 >•H •H •r4 •r4 •H 2 CO •H4-4 4-4 4-1 4-4 4-4 CM •H 4-1m O O O O o 4-4 OCO CO CO cO CO CO ft d COd d d d d m co CO dH H H H H i—4 co P H
1—1 d
<3 o(-1 p d •H04 Vi' o CQ
> •H CO
o /-s d 4J •Hd d i—l CO o *rl 004 d P /n d •H rQ CO
> d CM o 4-4 •rl dCO O H P •H CO ,d COd 04 d W i—4 w 4-4 H d do CO d 04 d O O cO H H•i-4 CO d d •H w 04 <3 t-44-4 i—l H •i-4 T3 •H d 04 O OO o i—4 >v d 4-4 o t-4 P i •i-4 •H
<J >v O (X d •H d d CO 4-4 4-4O > id !>v •rl 04 04 d U P IXi—l W o 4-4 4-4 (X IX 04 CO cO cOCO i—4 i—i O CO O •d d •H id i-l d dd >v o v^ 04 •H CO d i—4 IX d d >v >v4-1 d cO 4-4 d CO r-4 CO 4-1 CO •H o CO COd 04 IX 04 04 04 O w 1 1 d CO 0404 TO o O 4-4 0 u •r4 Pd W a) co d M-lo < p <3 CO W p P co CO P > P O
do•H4J
cO
Bo
14-1
doo
>»
4J•H
CW14-4
<
O
P*
Co
nt
./
Re
fe
re
nc
es
•
00 •
ON CM
I—l 00
ON
A I—l
• • fl •
CM NO •H • A i—l
oo 00 0 00 fl • 00
ON ON 44 fl CO ON
I—l I—l co ON •H 00 I—l •
A •—I A ON 00• • • u fl • I—l •
<N I—1 I—1 • fl • A i—i iH ON
00 R) fl i-H s i—i 0 00 • fl rH
on 00 fl 63 ON rH
i—l 4-> 4-1 ON nd r—1 fl 44 A
0 0 I—l fl 44 nd 0 A
A fl 0 fl A 44 fl
fl fl 4-1 A fl P 0 fl •r4
o o no fl p p 0 44 P44 4-1 •H fl 0 0 U4 rH CO fl 0
4-1 4-1 B g I—l I—l O 0 fl P 44
fl fl ifl 0 •r4 44 O 44 44 fl CO
O O O 0 0 0 44 •H •r4 CO 0
CO CO CO CO CO CO CO H H H rs
• • • • • • • • • • •
in VO 00 ON o i—l CM co
CM CM CM CM CM CM co co CO CO CO
•
CO
•
00 00
ON ON •
I—l I—l
• oo• A A in ON
A 00 60 00 i—i
P P ON
<t 0 0 •—I A
00 A A fl
ON fl fl A • o
i—l 0 0 nd I—l 4-1 •
0 0 fl 00 60 co•i 44 44 Q ON fl • 00
no • • CO CO s I—l •H i—1 ONr—1 CM i—l 60 nd oo I—l
fl 00 00 nd *o •H • no ON
fl ON ON fl fl N r—1 fl l-l • •
O i—l I—l fl fl fl ts iH
Q nd • fl 00
O • • fl fl fl 44 nd I—l ON
S t—1 I—l i—l i—1 fl 0 fl fl 44 I—l
RJ fl fl fl fl 0
rO £ > 0 P 44 A
fl 4-1 4-1 nd rd •H 0 0 0 0 fl
fl 0 0) fl fl N >N i—l •r-| o
fl fl fl 0 >N >N 44 44
fl fl CO A ifl 0 8 o 0 fl 44M A A A 63 fl m A fl fl
fl fl b O o O 0 V fl i—1 O
W w M A A S a O p4 CO
• • • • • • • • • • •
co sf m VO 00 ON o rH CM CO
rH I—l i—i i—l i—i I—l rH CM CM CM CM
• •
o • • fl
00 i-H co •
on 00 00 CM
I—l • o\ ON 00 00• VO I—l ON ON•I r-* 00 rH • I—1
,fl ON • * A m
4-1 ON I—l CO •H •r4 A A
o i—i 00 rH iH 44 ON nd
03 A ON ifl ,fl 44 • i-H iH• 144 1—1 • o o O fl
r—i CM 63 63 •r4 • flfl • fl 0 • r*. P ON rH O
Rl CM A I—l ON nd nd fl i—i fl n
00 4J fl i—i fl fl s o
CO ON 0) nd fl fl A 44 s
O rH fl 44 A nd nd 0
i—l 44 fl 0 60 60 60 fl P nd
fl A P P P P fl fl 44 fl
o 0 0 0 P 0 0 0 60 0 fl
A, T) fl CO 0 A A A P fl fl
o nd i—l 0 H nd nd 0 0 0 fl
o O >N 0 i—l i-l rH i—i 15 0 tn A
fl P fl P fl O O o O P fl fl
W PQ PS o Fn O O O O O O w
• • • • • • • • • • • •
•—I CM CO in vo 00 ON O rH CN
rH i—l H
does not cause hyperprolactinaemia or prevent apomorphine - induced 
emesis in dogs (Iorio et al. 1983; Christensen et al. 1984 a).
Biochemical studies indicated that SCH 23390 inhibits 
mediated cyclase activation at low nanomolar concentrations (Iorio et 
al. 1983; Hyttel, 1983; Itoh et al. 1984) whereas concentrations 
100 fold higher are required to reverse D£ mediated inhibition of 
adenyl cyclase (Itoh et al. 1984).
Ligand binding studies suggest that SCH 23390 is even more
O
selective for receptors. Competititon studies using H-piflutixol 
and H-spiperone as ligands for the and receptor population 
respectively report a preference for the site which ranges from 
500 to around 1500 fold (Hyttel et al. 1983; Christensen et al. 1984 
a; Cross et al. 1983 b; O'Boyle et al. 1984). The selectivity 
of SCH 23390 is also attested by the report that chronic treatment 
with cataleptic doses of SCH 23390 up-regulate but not J>2 
receptors within the rat striatum (Creese and Chen, 1985).
A similar degree of selectivity has been reported for vascular 
dopamine receptors. SCH 23390 is a potent inhibitor of the vascular 
D A | receptor (Hilditchet al. 1984; Goldberg et al. 1984) but is 
ineffective at DA£ receptors at concentrations up to 200 fold higher 
(Hilditch et al. 1984).
In addition to being a very weak D£ antagonist SCH 23390 
displays little affinity for and B adrenergic receptors,
muscarinic, histamine or benzodiazepine receptors (Hyttel 1983; 
Cross et al. 1983 b, Goldberg et al. 1984; Christensen et al. 1984
b). An affinity at 5 HT2  and receptors has been demonstrated, but 
at concentrations more than 20 fold higher than that required to 
block the receptor (Hyttel et al. 1983; Cross et al. 1983; 
Ohlstein and Berkowitz, 1985).
1.3.4 Dopamine Receptors Subtypes in the Cerebral Vasculature
a) In Vitro Studies
In both peripheral and cerebral vessels the contractile 
activity of dopamine is mediated via a  -adrenergic (Goldberg et al. 
1978; Toda, 1976) and serotoninergic mechanisms (Edvinsson et al. 
1978). However, if these contractile effects provoked by dopamine 
are blocked by high doses of phenoxybenzamine a dose-related 
relaxation can be demonstrated in the cerebral and in a number of 
other vascular beds (Goldberg and Toda, 1975; Goldberg et al. 1978; 
Brodde, 1982).
In the isolated cat middle cerebral artery pretreated with 
phenoxybenzamine, dopamine and a number of dopamine receptor agonists 
promote a dose-related relaxation of feline cerebral arteries 
(Edvinsson et al. 1978). The potency of these agonists was of the 
order; epinine > dopamine > apomorphine > piribedil; data 
consistent with a mediated relaxation. Furthermore, dopamine- 
induced relaxation could be attenuated by bulbocapnine, a 
predominately antagonist, thereby providing tentative evidence for 
the existence of a dopamine receptor mediating the relaxation of 
feline cerebral vessels.
Similarly, a dopamine Dj receptor mediated relaxation of 
isolated human basilar arteries has been proposed (Forster et al. 
1982), although in this preparation the selective D^ receptor agonist 
SKF 38393 was found to be some 88 fold less potent than dopamine.
The evidence for a D^-mediated relaxation of rabbit middle 
cerebral arteries is not compelling. Using the perfusion approach, 
Oudart and his colleagues (1981) found that the order of potency for
dopamine receptor agonists was; bromocryptine > dopamine = piribedil 
> apomorphine. Since both bromocryptine and piribedil have been 
shown to be inactive at other vascular sites (Goldberg and Kohli, 
1981) it would appear that dopamine induced relaxation reported by 
Oudart et al. (1981) is probably not of the Dj type. Moreover, the 
small concentrations of dopamine in rabbit cerebral microvessels 
(Head et al. 1980) would suggest that dopaminergic mechanisms may 
exert less influence in the cerebral circulation of the rabbit than 
in other species.
b) Limitations of In Vitro Studies of Cerebrovascular Reactivity
The use of in vitro methods for investigating cerebrovascular 
dopamine systems is subject to severe criticism. Firstly, the 
physiological relevance of dopamine responses is questionable on the 
grounds that the large extracerebral vessel used in isolated vessel 
preparations (middle cerebral or basilar) are not representative of 
cerebrovasculature as a whole as characterised by their morphological 
composition (McCulloch and Edvinsson, 1984; Purves, 1972) or 
contribution to total cerebrovascular resistance (<7%; Tuor and 
Farrar, 1985). Secondly, the necessary inclusion of high 
concentrations of alpha-adrenergic antagonists (i.e. 
phenoxybenzamine) in the bathing medium to inhibit contractile 
mechanisms, may fundamentally compromise attempts to characterise the 
dopamine receptor subtype mediating relaxation of cerebrovascular 
smooth muscle. For, in addition to its adrenergic and serotoninergic 
blocking properties, phenoxybenzamine can ..interact with a number of 
other receptor populations including both and dopamine 
receptors producing complete blockage of D£ sites but only a
partially inhibition at receptors (Marchias and Bockaert, 1980; 
Creese et al. 1983).
The vasomotor reactivity of cerebral vessels in their normal 
physiological enrivonment was first examined in the mid 1930's (see 
Purves, 1972 for historical perspective). Indeed, until the advent 
of isolated vessel preparations more than 30 years later, 
cerebrovascular reactivity could be successfully examined only by 
studying the vessels in situ. However, despite the recent popularity 
of isolated vessel preparations, in situ studies still offer a number 
of significant advantages over in vitro methods. The normal 
physiological tone of vessels in situ, circumvents the need to 
preconstrict vessels when investigating dilator mechanisms. More 
importantly, by directly applying pharmacological agents onto small 
(<250 urn diameter) pial arterioles it is possible to characterise 
receptor populations mediating vasomotor responses on resistance 
vessels; it is the small arterioles and not the major inflow tract 
vessels (the vessels most commonly used in isolated vessel 
preparations) which primarily determine cerebral blood flow.
In the present study, vasomotor responses of small individual 
arterioles lying on the pial surface of the cat brain to subarachnoid 
perivascular microapplication of the synthetic dopamine receptor 
agonists, SKF 38393, LY 141865 and apomorphine were investigated. 
The resulting hypothesis that dilatation of the feline pial 
arterioles is mediated via the receptor subtype was subsequently 
tested using the putative selective receptor antagonist SCH 23390.
2. CEREBRAL BLOOD FLOW/OXIDATIVE METABOLISM AND BRAIN FUNCTION
2.1 BASIC CONCEPTS
a) Blood Flow/Oxidative Metabolism and Brain Function
The vast array of electrical and chemical processes which 
sustain the structural and functional integrity of all biological 
systems are energy consuming. In most tissues the energy generating 
substrate, ATP, can be derived from the oxidative catabolism of a 
variety of substrates (viz glucose, lipids, protein). However, under 
non-pathological conditions, the blood brain barrier excludes all 
potential energy generating substrates, save glucose, from cerebral 
tissue (Sokoloff, 1986), with the result that energy generation in 
cerebral tissue is derived almost exclusively from the oxidative 
catabolism of glucose. In cerebral tissue the reserves of glucose and 
oxygen are not sufficient to sustain normal cerebral metabolism for 
more than a few minutes (SiesjU, 1978). Consequently, the brain is 
entirely dependent upon a continuous supply of substrates by the 
blood. An adequate supply of substrate is ensured by homeostatic 
mechanisms which adjusts the rate of tissue perfusion to meet 
alterations in metabolic demand (Purves, 1972; Sokoloff, 1978 b; 
Kuschinsky, 1982 for reviews). Thus the measurement of blood flow or 
substrate utilisation (glucose or oxygen utilisation) can be used to 
assess metabolic activity in cerebral tissue.
The concept that metabolic activity can be used as an index of 
functional status in neural tissue was established by Gerard almost 
60 years ago (Gerard, 1927). In studies on the isolated nerve 
preparations Gerard demonstrated that oxygen consumption rose in
parallel with increasing firing rate. This relationship between 
firing rate and metabolic rate has been established in a variety of 
peripheral (Baker, 1965; Shanes and Berman, 1955; Larabee and 
Klingman, 1962) and central (Mcllwain and Bachelard, 1971) tissues in 
vitro. Similarly, qualitative studies in vivo have established that 
blood flow is altered with changing functional status. Illumination 
of the retina increases blood flow within components of the visual 
system, namely the lateral geniculate (Gerard, 1938) and visual 
(occipital) cortex (Schmidt and Hendrix, 1938). Similarly, increases 
in blood flow have been observed within areas of the olfactory or 
sensory motor systems following exposure to ammonia vapour or tactile 
stimulation (Purves, 1972 for discussion).
The first quantitative evidence that cerebral blood flow (CBF) 
and metabolic rate provided indices of functional status was provided 
by the nitrous oxide method, the so-called Kety-Schmidt technique 
(Kety and Schmidt, 1945, 1948 a). This approach entailed the subject 
inhaling nitrous oxide until equilibrium is reached between the 
tissue and blood nitrous oxide concentrations. Using the Fick 
principle it was possible to calculate global cerebral blood from the 
concentration of ^ 0  at saturation and the arteriovenous differences 
of the nitrous oxide during the process of saturation. Steady state 
cerebral oxygen consumption CMRq2  (or glucose utilisation) could then 
be calculated from the arteriovenous difference in oxygen (or 
glucose) and the value derived for cerebral blood flow using equation 
(1).
CMRq2 = CBF. (A - V)[02] (1)
In the late 1940's and in the 1950's this approach was widely used to
examine the effects of a variety of functional states upon cerebral 
blood flow and metabolic rate in man. These studies were able to 
demonstrate alterations in cerebral blood flow and oxygen consumption 
in association with gross changes in brain function; such as those 
associated with senility, diabetic coma, anaesthesia and convulsive 
states (Kety and Schmidt, 1948 b; Sokoloff and Kety, 1960; Lassen 
and Christensen, 1967). However, they were unable to detect the more 
subtle functional changes associated with sleep, sedation, 
schizophrenia, neuroleptic treatment and amphetamine induced 
psychosis (Kety, 1950, 1975; Mangold et al. 1955; Sokoloff, 1960). 
The apparent lack of change in cerebral metabolism under these 
conditions could be explained by highly focal alterations in 
functional and metabolic activity which were too small to be detected 
by global brain measurements (Kety, 1963 ). This view provided the 
impetus for the subsequent development of techniques for examining 
focal functional alterations in brain circulation and metabolism.
b) Local Cerebral Blood Flow
The assumption that a freely diffusible tracer in blood would 
be in near instantaneous equilibrium with cerebral tissue permitted 
the measurement of regional levels of blood flow from the rate of 
accumulation of tracer in each brain region (Kety, 1951). This 
mathematical advance permitted the development of techniques for 
measuring hemispheric blood flow from the clearance of radioactive 
®^Kr (Lassen and Ingvar, 1961) and later ^ ^ X e  (Glass and Harper, 
1963); regional blood flow with intracerebral hydrogen electrodes 
(Purves, 1972); or local cerebral blood flow based upon quantitative 
autoradiography (Landau et al. 1955; Freygang and Sokoloff, 1958;
Sakurada et al. 1978). In particular, the development of 
quantitative autoradiographic methods using at first 
trifluoroiodomethane (CF^I) (Landau et al. 1958), then ^C-antipyrine 
(Reivich, 1969) and more recently ^C-iodoantipyrine (Sakurada et al. 
1978) represented a major technological advance by permitting the 
rates of blood flow to be determined in all the structural components 
identifiable on the autoradiograms. Using CFgl as a tracer, 
Sokoloff (1957) demonstrated that retinal stimulation increased local 
blood flow throughout the neuroanatomical components of the visual 
system (superior colliculus, lateral geniculate and visual cortex), 
thus providing the first images of local functional activity within 
the brain. Subsequently, local cerebral blood flow measurements have 
been used to detect functional alterations under a variety of 
physiological and pharmacologically-induced conditions (Sokoloff, 
1978; McCulloch et al. 1982). However, it should be emphasised that 
blood flow is an accurate measure of functional status only if the 
normal relationship between blood flow and metabolic activity is 
maintained.
c) Local Cerebral Oxidative Metabolism
A major disadvantage of the aforementioned local blood flow 
techniques is their inability to isolate the local venous outflow and 
so precludes the determination of local metabolic rates. Until the 
mid 1970's when the 2-deoxyglucose technique was developed no 
compatible autoradiographic method was available for measuring 
metabolism. The major problems in developing an autoradiographic 
technique for measuring local metabolic rates lie partly in the 
unsuitability of the normal substrates, oxygen and glucose as
radiolabelled tracers and partly in the complex kinetics of cerebral
metabolism. The short half life of the radioisotopes of oxygen (t
1/2 = 123 seconds) its rapid conversion to C0£ and equally rapid loss
from the tissue makes oxygen a difficult species to use. Although a
15tomography - based technique employing O-oxygen as the tracer for 
measuring metabolic rate in humans has been developed (Frakowiak et 
al. 1980), the resolution capabilities of this technique
O
(aproximately 1.8 cm at present) are limiting, particularly when 
used in small laboratory animals.
A biochemical method for measuring local metabolic rates 
employing ^^C-glucose was developed in the early 1970's (Hawkins et 
al. 1974) and subsequently adapted for use with quantitative 
autoradiography (Hawkins et al. 1979). However, despite a series of 
modifications to the original model the validity of this technique 
remains in doubt. The main limitation with this model is in the use 
of glucose as the indicator substance. Once it has been metabolised 
to CO2  the radioactive label is rapidly lost from the tissue 
(Sacks, 1957). Loss of radiolabelled tracer from the could compromise 
the method by seriously underestimating glucose utilisation. In an 
attempt to minimise the loss of from the tissue proponents of 
this method have advocated that, the period of glucose use 
determination should be limited to around five minutes (Lu et al. 
1983; Hawkins et al. 1985). It is the necessity to adopt short 
measurement periods which is the fundamental flaw in the Hawkins 
method. Quantitative autoradiographic methods of this type calculate 
reaction rates from the concentration of radiolabelled product which 
has accumulated in the tissue at the end of the experimental period 
and the integrated specific activity of the tracer in brain tissue 
over the measurement period. Since the integrated specific activity
of glucose in cerebral tissue cannot be measured readily in conscious 
animals the integrated specific activity must be calculated from 
measurements made in arterial blood and corrected for the lag time in 
equilibration between blood and brain. In the case of glucose the 
kinetic parameters associated with the transport of hexoses across 
the blood brain barrier and into the tissue precursor pool cannot be 
defined accurately as they vary from region to region and from one 
experimental condition to another. Over short measurement periods 
small inaccuracies in estimating the values of the kinetic constants 
would be of sufficient magnitude to compromise the accuracy of the 
method. In theory, the contribution of the kinetic constants to the 
overall measurement could be minimised by extending the measurement 
period. However, if the time-course of the experiment was extended 
the accuracy of the measurements would be severely compromised by the 
loss of C0£ from the tissue. Thus the Hawkins method is of little 
value in measuring local rates of cerebral glucose utilisation.
The 2-deoxy-D-[*^C]-glucose molecule has proven to be a more 
suitable tracer for measuring local metabolic rate. The structural 
similarities between the molecules of 2-deoxyglucose (2-DG) and 
glucose enables 2-DG to enter the brain tissues and become 
metabolised through the first (rate limiting) step of the glycolytic 
pathway. However, once phosphorylated its metabolic product 2- 
deoxyglucose 6-phosphate is essentially trapped within the cell over 
the 45 minute measurement period. From a knowledge of the relative 
kinetic characteristics of glucose and deoxyglucose it is possible to 
calculate the local rates of glucose utilisation simultaneously in 
all components of the GNS visible on the autoradiograms (Sokoloff,
d) The Relationship Between Cerebral Blood Flow and Glucose Use
Determination of local rates of cerebral blood flow (Sakurada 
et al. 1978) and glucose utilisation (Sokoloff et al. 1977) by 
quantitative autoradiography has established that there is a local 
relationship between cerebral blood flow and glucose utilisation 
which is maintained under a variety of experimental conditions 
(Sokoloff, 1978; McCulloch and Kelly, 1982; Kelly and McCulloch, 
1982). However, recent studies have electrical stimulation of the 
fastigial nucleus results suggested that neuronal activation can 
effect increases in cerebral blood flow which are independent of 
changes in oxidative metabolism (Nagai et al. 1983; Iadecola et al. 
1985). Thus, neurogenic influences may provide additional influences 
on the cerebral circulation.
2.2 Dopamine Systems, Cerebral Blood Flow and Metabolism
a) Dopamine, Global Cerebral Blood Flow and Metabolism
By the mid 1970's it had become established that dopamine
increases blood flow in renal mesenteric and coronary vascular beds
by interacting with specific dopamine receptors on vascular smooth
85muscle. Using the JKr clearance approach in dogs von Esssen
reported that, blood flow increased in the cerebrovascular bed
following the intravenous infusion of dopamine (von Essen, 1974). 
Since no concomitant increases in cerebral oxygen consumption could 
be demonstrated von Essen postulated that dopamine increased cerebral 
blood flow by acting primarily on the cerebral vasculature. The 
discovery of specific dopamine receptors mediating relaxation of
cerebrovascular smooth muscle in the dog (Toda, 1976) and other 
species (Edvinsson et al. 1978, Forster et al. 1983, Toda, 1983) 
appeared to support the vascular hypothesis. However, it should be 
recognised that the von Essen study is flawed on a number of counts. 
First, as discussed previously, the physical and enzymatic components 
of the blood-brain barrier prevent dopamine from gaining access to 
receptors on cerebrovascular smooth muscle (Oldendorf, 1971). 
Secondly, the measurement of cerebral oxygen consumption requires the 
sampling of venous blood that is uncontaminated by extracerebral 
sources; however, the cerebrovascular anatomy of the dog with its 
numerous anastomotic connections between the intra and extracerebral 
circulations makes the sampling of uncontaminated venous blood 
virtually impossible (Purves, 1972). Finally, the variability of the 
data precluded statistical analysis.
Nevertheless, this study has become accepted into the body of 
literature and has been cited frequently as evidence that 
cerebrovascular dopamine receptors influence cerebral perfusion 
(Amenta et al. 1984; Carlsson and Johansson, 1978; Erkstrbm-Jodal 
et al. 1982; Goldberg, 1975; Toda, 1976).
In rats the systemic administration of the sympathomimetic 
agent amphetamine effected a 4-5 fold increase in cerebral blood 
flow. As this was far in excess of the 40% increase in oxygen 
consumption observed with this compound: a vascular action was 
proposed to account for the excessive perfusion (Carlsson et al. 
1975; Berntman et al. 1978).
In contrast to the results obtained in the rat the increase in 
cerebral metabolism observed following the administration of 
amphetamine to primates was proportionately similar to that of blood 
flow, thereby implicating that the action of amphetamine was
primarily via alterations in cerebral metabolism (McCulloch and 
Harper, 1977 a). These authors provided further evidence for the 
metabolic hypothesis from studies with the dopamine receptor agonists 
apomorphine and piribedil (McCulloch and Harper, 1977 b; McCulloch 
and Edvinsson, 1980) demonstrated parallel time courses for the 
increases in blood flow and oxygen consumption were demonstrated 
following the administration of these agonists. However, the fact 
that the increase in cerebral blood flow was up to twice that of 
oxygen consumption was not commented upon.
The use of techniques to measure global cerebral blood flow and 
metabolic rate has, therefore, provided little insight into the 
relative contributions of the vascular and neural receptors to the 
blood flow response.
b) Local Cerebral Glucose Utilisation
Application of the 2-deoxyglucose autoradiographic technique 
have provided the first images of the influences exerted by dopamine 
systems on integrated brain function. These studies employing a 
number of dopamine receptor agonists (apomorphine, bromocryptine, 1- 
dopa, amphetamine and methylphenidate) antagonists (haloperidol, 
pimozide, f luphenazine), as well as contingent and non-contingent 
stimulation of the A9 and A10 cell groups of the ventral 
mesencephalon, and selective lesion studies have evoked remarkably 
consistent patterns of altered glucose use. These patterns have 
served to support some current concepts about dopaminergic influences 
on brain function, questioned the validity of others, and suggested 
dopaminergic influences on hitherto unknown neuronal systems.
According to one view based on behavioural and neuroanatomical
studies central dopamine systems exert a widespread influence upon 
cerebral function (Bloom, 1984; BjfJrklund and Lindvall, 1984). 
Deoxyglucose studies have clearly demonstrated that this is not the 
case. The rate of glucose utilisation remains unaltered throughout 
the vast majority of brain areas irrespective of whether dopamine 
systems are manipulated by sytemic or intracerebral drug 
administration, stereotaxic lesions or electrical stimulation of the 
mesencephalic dopamine systems. A few studies have reported 
generalised reductions in glucose use following unilateral lesions of 
the nigrostriatal pathway (Schwartz et al. 1978; Kozlowski and 
Marshall, 1980). In the Schwartz study these global reductions 
probably reflect the extensive neuronal damage associated with large 
electrolytic lesions of the hypothalamus whilst the decreases 
observed in the Kozlowski and Marshall study were probably due to 
their inexplicable use of ether anaesthesia to facilitate the 
injection of deoxyglucose.
General anaesthesia is an integral feature of most 
electrophysiological and neurochemical studies performed in vivo. 
Indeed studies of cerebral dopamine systems in anaesthetised animals 
have contributed significantly to our current understanding of the 
influence of dopamine systems on brain function. However, general 
anaesthesia has profound effects on neural function (Siesj#, 1978; 
Fink, 1980), but more importantly the study of neuronal function in 
anaesthetised animals ray result In misleading information about the 
effects of dopaminergic manipulations upon cerebral function in 
conscious animals.
The influence of general anaesthesia upon dopamine systems has 
been highlighted by a recent study of the effects of apomorphine upon 
function-related glucose utilisation in the substantia nigra.
Systemic administration of apomorphine results in the inhibition of 
electrical activity within the dopaminergic neurones of the 
substantia nigra pars compacta (Bunney et al. 1973; Bunney and 
Chiodo 1984; Skirboll et al. 1979; Gallagher et al. 1978; Walters 
et al. 1983, 1986). Apparently at variance with data from these 
electrophysiological studies is the increased glucose use observed 
within the pars compacta following the administration of apomorphine 
to conscious animals (Brown and Wolf son, 1978; McCulloch et al. 1982 
b; Grome and McCulloch, 1981). However, if the apomorphine is 
administered to chloral hydrate anaesthetised rats a reduction in 
glucose use is observed within the pars compacta (Grome and 
McCulloch, 1981). In addition, the use of general anaesthesia 
reduces both the metabolic (Grome and McCulloch, 1981) and electrical 
activity (Bergstrtfm et al. 1984) in the globus pallidus following 
apomorphine administration and to attenuate dopaminergic transmission 
in prefrontal and anterior cingulate cortices (Roth et al. 1986). 
Anaesthetic influences may also account for the apparently 
contradictory effects of dopamine agonists upon corticostriate 
transmission in anaesthetised (Brown and Arbuthnott, 1983) and 
encephale isole cat preparations (Norcross and Spehlman, 1978). 
These divergent responses highlight the difficulties and potential 
pitfalls of extrapolating data obtained from anaesthetised animals to 
the conditions prevalent in the conscious state and emphasise the 
need to perform investigations in unanaesthetised preparations.
In an attempt to obviate the need for general anaesthesia some 
investigators have examined the influence of dopaminergic agents upon 
electrical activity in paralysed artificially ventilated animals 
(Bergstrom et al. 1984; Gessa and Mereu 1984; Onali et al. 1984). 
However, the use of this preparation is of equivocal value since
paralysis produces severe stress in animals (Ohata et al. 1981; 
Lacombe and Seylaz, 1984), which in itself has profound influences on 
dopaminergic transmission (Thierry et al. 1984; Glowinski et al. 
1984). The capacity to identify the functional consequences 
associated with the manipulation of dopamine systems humanely in 
conscious animals, constitutes a major advantage of the deoxyglucose 
method. The systemic administration of the dopamine receptor 
agonists apomorphine and bromocryptine and the sympathomimetic agents 
amphetamine, 1-dopa and methylphenidate consistently results in 
pronounced increases in glucose within those brain areas involved in 
the integrated control of motor function (sensory motor cortex, basal 
ganglia, ventral thalamus, cerebellum and inferior olivary complex 
inter alia (Bell et al. 1982; Brown and Wolfson, 1978; McCulloch et 
al. 1982 a; Pizzolato et al. 1985; Warner et al. 1982; Weschler et 
al. 1979). From these studies it is clear that alterations in 
glucose use do not merely reflect the topographical distribution of 
dopaminergic innervation or receptor density, rather, these changes 
reflect the influences exerted by dopamine receptor stimulation upon 
functionally related neuronal circuits (McCulloch, 1982). This view 
is endorsed by studies of the effects of dopaminergic stimulation on 
thalamo-cortical function. The pharmacological activation of central 
dopamine systems provoke marked increases in glucose use within 
sensory motor and frontal cortices. Although these cortical areas 
are thought to be devoid of dopaminergic innervation and receptor 
populations (BjSrklund and Lindvall, 1984; Altar et al. 1985; 
Jastrow et al. 1984), they are anatomically connected, via 
polysynaptic neuronal pathways, with the caudate nucleus. The 
evidence that the alterations in cortical glucose use is initiated at 
the caudate nucleus is twofold. The systemic administration of
apomorphine and other dopaminergic agents such as bromocryptine, 
amphetamine, methylphenidate and 1-dopa stimulates glucose 
utilisation within each component of the striatal — > pallidal— >  
ventrolateral thalamus — > cortex pathway. Furthermore, the 
laminar pattern of cortical glucose use following apomorphine 
administration corresponds with the topographical distribution of the 
cortical projections of the ventral thalamus (McCulloch et al. 1979; 
McCulloch, 1982).
With the notable exceptions of the anterior cingulate cortex, 
anterior thalamic nucleus and lateral habenular nucleus, the 
anatomical components of the limbic system do not display consistent 
alterations in glucose use following the administration of dopamine 
receptor agonists (Pizzolato et al. 1985; McCulloch et al. 1982 a; 
Orzi et al. 1983; Weschler et al. 1979). Widespread alterations in 
glucose use have been recorded within the limbic system following 
electrical stimulation of the ventral mesencephalon (Savaki et al. 
1983; Porrino et al. 1984 a; Esposito et al. 1984). However, the 
pattern of altered glucose use elicited by electrical stimulation may 
be viewed with circumspection as antidromic excitation of afferent 
fibres to the mesencephalon may stimulate non-dopaminergic components 
of the mesencephalic system, as well as the dopaminergic projections. 
In contrast, blockade of dopaminergic transmission, whether by 
neuroleptic treatment or selective lesions of the nigrostriatal 
pathway has generally had little effect upon glucose use within the 
extrapyramidal motor system, although some lesion studies have 
reported global reductions (Schwartz et al. 1976, 1978; Kozlowski 
and Marshall, 1980; Schwartzman and Alexander, 1985). Recently, the 
neurotoxin MPTP has been used in primates as a model of Parkinsonism 
(Schwartzman and Alexander 1985; Porrino et al. 1985). However,
unlike clinical Parkinsonism where minimal alterations in glucose use 
have been reported (Leenders et al. 1983; Rougement et al. 1983). 
MPTP treatment reduced glucose use within motor systems.
One consistent feature of dopamine receptor blockade has been 
observed within the lateral habenular nucleus. Elevated rates of 
glucose use occur within the lateral habenular nucleus following 
lesions of the nigrostriatal dopamine pathway (Wooten and Collins, 
1981; FenmetaL. 0979)), following depletion of catecholamine stores 
with reserpine (Palacios and Wiederhold, 1984), or following 
blockade of dopamine receptors with fluphenazine (Wooten, 1981), 
haloperidol (McCulloch et al. 1980 b, 1982 c; Pizzolato et al. 
1984), pimozide (Gomita and Gallistel, 1982; Gallistel et al. 1985), 
or YM09151-2 (Palacios and Wiederhold, 1985).
It is evident from the studies cited above that the 
manipulation of central dopamine systems produces characteristic 
profile of regions displaying altered rates of glucose use. 
Furthermore, a review of the literature on 2-deoxyglucose would 
suggest that the characteristic patterns of altered glucose use also 
produced by other classes of pharmacological agent (i.e. GABA 
agonists, a  -adrenergic muscarinic, agonists and antagonists) and 
that each pattern appears to be unique for each class of compounds 
possessing similar pharmacological actions (Sokoloff et al. 1983; 
Muller and Martin, 1984). These characteristic "fingerprints" could 
be used to construct a data base with which test compounds could be 
compared. Such an approach could prove invaluable in drug 
development by predicting the effects, and possible side effects 
associated with novel compounds. However, at present the 
construction of such a system represents major problems of data 
handling and analysis. The dose response curves for large numbers of
brain regions generates vast quantities of data (for example, the 
studies comprising this thesis required over 96,000 individual 
densitometrical. measurements). To simplify the analysis of such data 
a simple arithmetic function has been derived (Ford et al. 1985) and 
validated in this thesis which describes the dose response curve to 
drug administration for each brain region by a single value. These 
values can be ranked to reveal a "fingerprint" of responsiveness to 
each drug which can subsequently be compared with the profiles for 
other drug treatments.
c) Local Cerebral Blood Flow and the Flow/Glucose Use Relationship
The use of quantitative autoradiographic methods for assessing 
local cerebral blood flow (using ^C-iodoantipyrine as tracer) and 
glucose utilisation (with ^C-2-deoxyglucose) have established that 
flow and glucose use remain tightly coupled under most physiological 
and pharmacologically-induced conditions (Sokoloff, 1978). However, 
despite the remarkable spatial resolution afforded by these 
techniques their use for studying the influences of dopaminergic 
agents upon the flow-metabolism relationship has only added to the 
controversy, with studies advocating a primarily metabolic action 
(McCulloch and Kelly, 1982; McCulloch et al. 1982 a), others a mixed 
vascular and metabolic response (Ingvar et al. 1983), and a third 
group a vascular action (Leenders et al. 1985).
According to one study the administration of apomorphine 
produced focal alterations in cerebral blood flow, characterised by 
increases in tissue perfusion within extrapyramidal and sensory motor 
areas and decreases within the anterior cingulate cortex and lateral 
habenular nucleus (McCulloch et al. 1982a). The alterations in blood
flow were similar, both in magnitude and directions to the changes in 
glucose use observed under the same experimental conditions, with the 
result that the overall relationship between flow and glucose use 
remained intact and unaltered. This study was porrected as 
unambiguous evidence that the changes in cerebral blood flow produced 
by dopamine receptor agonists are the indirect consequence of drug- 
induced disturbances in local metabolic activity (McCulloch, 1984). 
However, this view has been challenged by studies reporting 
widespread increases in blood flow irrespective of the underlying 
metabolic responses (Ingvar et al. 1983; Leenders et al. 1985). In 
a study by Ingvar and his associates the administration of 
apomorphine resulted in elevated blood flow throughout the CNS; 
including the anterior cingulate cortex. Moreover, the circulatory 
response to apomorphine was associated with a marked topographical 
heterogeneous response in the caudate nucleus; characterised by 
prominent increases in flow in the lateral caudate (164%) whilst the 
more medial portion remained relatively unaffected (+17%). As these 
findings did not concur with the highly focal alterations in glucose 
use it was suggested that apomorphine may increase blood flow by 
stimulating cerebrovascular dopamine receptors in some (anterior 
cingulate cortex, lateral caudate) if not all brain areas (Ingvar et 
al. 1983). This conclusion has been criticised on the grounds that
a) no measurement of local cerebral glucose use was made under the 
same experimental conditions; and b) the comparison of local blood 
flow responses of anaesthetised rats with glucose use data from 
conscious animals is potentially flawed (vide infra).
Evidence for a direct vascular action of apomorphine has been 
obtained from studies in rats with lesions of the nigrostriatal 
pathway. The administration of apomorphine to lesioned animals
failed to significantly alter local cerebral glucose use within the 
caudate nucleus (Kozlowski and Marshall, 1980; Sagar and Snodgrass, 
1980). In contrast the topographical heterogeneity observed within 
the caudate nucleus (under similar experimental conditions) was more 
pronounced in lesioned animals (Ingvar et al. 1983). Consequently, 
it has been suggested that the enhanced circulatory response in the 
denervated caudate was due to stimulation of supersensitive vascular 
dopamine receptors. A similar conclusion has also been reached on 
the basis of tomographic studies in man (Leenders et al. 1983, 1985). 
In control subjects the administration of 1-dopa was associated with 
an increase in cerebral blood flow within the basal ganglia and 
overlying cortex; oxygen consumption in these areas remained 
relatively unaffected. This dissociation between flow and metabolism 
was more pronounced in patients suffering from striatal denervation 
as a result of Parkinsonism (Leenders et al. 1985). From the studies 
presented it is clear that, at present, no consensus exists 
concerning the relative importance of vascular dopamine receptors in 
the circulatory responses to systemically administered dopamine 
receptor agonists.
CHAPTER II
METHODS
1. PIAL VESSEL STUDIES
1.1 Surgical Preparation of Animals
Studies were performed on cats, of either sex, weighing 
between 2 and 4.5 kg. Anaesthesia was induced by an intravenous 
injection containing alphaxolone (6.75 mg/kg) and alphadolone (2.25 
mg/kg). After intubation, the animal was ventilated using a small 
animal respirator (Harvard Instruments). The right femoral artery 
and vein were cannulated to permit, respectively, the continuous 
monitoring of arterial blood pressure, and the administration of 
fluid or anaesthetic agents. During the subsequent course of the 
experiment anaesthesia was maintained with alpha-chloralose; an 
initial infusion of 60 mg/kg with additional doses when necessary to 
prevent the return of corneal reflexes. End tidal concentration of 
CO2  was continuously monitored with an infra red capnograph (Godart- 
Stratham, Model 17010) and arterial blood samples intermittently 
withdrawn for blood gas analysis (PCO2 , P® anc* oxysen tension).
In each cat mean arterial blood pressure was greater than 90 mm Hg. 
Core temperature was maintained at 38°C by a homeothermic heating 
blanket (GFP Model 8140).
The cat was placed in a stereotaxic frame and the head shaved. 
A longitudinal incision made in the scalp and ligated onto a metal 
ring (diameter = 6.5 cm), enabled the scalp to be elevated and filled 
with mineral oil to form an intact pool over the calvarium 
(approximately 1.5 cm deep). After the left temporalis muscle had 
been retracted, a craniotomy (2.5 x 1.5 cm) was made over the left 
parietal cortex using a saline cooled dental drill. The exposed 
cortex was bathed by warmed mineral oil, maintained at 38°C. 
Thereafter, the dura was carefully removed with the aid of a 
stereomicroscope (Bausch and Schott magnification range xlO - x70), 
the field being illuminated by Schott fibre optic systems. Bleeding 
from the cut dural edges was halted by bipolar diathermy of the 
bleeding sites.
1.2 Measurement of Vessel Calibre
Vascular calibre was measured using the method of Baez (1966). 
Individual pial vessels, lying on the convexity of the brain were 
viewed through the microscope at a magnification of either x 40 or x 
70. The image was passed through a Vickers AEI image splitting 
eyepiece to a close circuit television camera and visualised on a 
television monitor (Figure 3). Vascular diameter was measured from 
the degree of shear which has to be applied to the image splitting 
device in order to bring the two images of the vessel under 
investigation into apposition; the degree of shear having been 
calibrated against lengths of wire and thread of known diameter.
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1.3 Administration of Drugs
Agents under investigation (with the exception of SCH 23390) 
were dissolved in artificial cerebrospinal fluid, (C.S.F.), the 
composition of which was -
Na + 145 mM
K+ 3 it
Ca2+ 2.5 11
HC03 11 it
Cl” 142 11
SCH 23390 was initially dissolved in 100 ul of a 5% ethanol/25%
acetic acid solution and diluted in distilled water to form a stock
—9 • •solution of 10 M. Serial dilutions were performed, using artificial
CSF to yeild the desired injectate concentration. The ethanol/acetic
solution was diluted in a similar manner to yeild the appropriate
vehicle for comparison. Acidic CSF (pH 6.8) was prepared by altering
the concentrations of HCO^” and Cl” in the artificial CSF solution to
5 mM and 148 mM respectively. The pH of each solution was adjusted
to 7.18 by aeration with C02» under oil, to minimise changes in pH.
Micropipettes having a tip diameter of 8-10 uM, were filled under oil
with the solution to be examined, immediately prior to use.
The tip of the micropipette was positioned close to a
superficial pial arteriole, using a micromanipulator and using a
micromanipulator inserted through the arachnoid into the perivascular
space. Approximately 5 pi of the artificial CSF solution was
injected over fifteen seconds and any resulting changes in arteriolar
calibre monitored for up to three minutes after injection.
Microapplication of drugs was made at any particular site on only one 
occasion.
The maximum alteration in arteriolar calibre following drug 
administration was expressed as a percentage of the preinjection 
calibre.
1.4 Statistical Analysis
Drug-induced alterations in arteriolar calibre were compared 
with that evoked by artificial cerebrospinal fluid by Student's t- 
test with Bonferroni correction for multiple comparisons (Wallenstein 
et al. 1980). This form of analysis does not take into account 
inter-animal variability in vasomotor reactivity. However, analysis 
of variance on the data from each drug solution revealed that the 
variance observed within a single animal was invariably greater than 
that found between animals. In fact no significant inter-animal 
differences could be demonstrated with any of the drug concentrations 
examined.
2. AUTORADIOGRAPHIC STUDIES
2:1 Features Common to Local Blood Flow and Glucose Use Studies
Using Quantitative Autoradiography
Quantitative autoradiographic techniques were employed for the 
determination of local rates of cerebral glucose utilisation and 
blood flow in conscious, lightly restrained rats. The surgical 
preparation of these animals, the monitoring of the arterial 
concentrations of radiolabelled tracer, and the preparation and
analysis of autoradiograams are features common to both experimental 
approaches and so will be described separately.
2.1.1 Animal Preparation
a) Housing
Specific pathogen free male Sprague-Dawley rats, approximately 
ten weeks old (300 g) were obtained from registered animal suppliers 
(Charles River, U.K.) and housed, three to a cage, in a holding unit. 
Environmental conditions within the holding area were not strictly 
controlled, the animals were subjected to a natural day/night cycle. 
Food and water were freely available until the evening prior to 
study. At this time animals to be studied were transferred to a 
separate cage and fasted for a period of 12 to 15 hours prior to 
surgery.
b) Surgical Preparation
All surgical procedures were carried out under halothane 
anaesthesia of sufficient depth to prevent reflex responses to strong 
tactile stimuli. Anaesthesia was induced by placing the rat into a 
clear perspex box into which flowed the anaesthetic gas mixture (5% 
halothane in a nitrous oxide/oxygen mix: 70/30 v/v). Anaesthesia
was subsequently maintained throughout the period of surgery by 1-2% 
halothane delivered to the animal through a face mask.
Femoral vessels were exposed through a small incision 
(approximately 1 cm in diameter) made on either side of the groin 
overlying the femoral triangle. Wounds were infiltrated with a local
anaesthetic solution (Xylocaine: 2%) and the femoral vessels freed 
from connective tissue. Polythene cannulae (Portex: external
diameter 0.96 mm; internal diameter 0.58 mm), 15 cm long and filled 
with heparinised saline 10 I.U./ml) were inserted a distance of 2 cm 
into both femoral arteries and one femoral vein. The patency of each 
cannula was verified, the cannula secured and the wound sutured 
closed. Incision sites were smeared with a local anaesthetic gel, 
cushioned with gauze swabs, and the entire pelvic and abdominal area 
enveloped in a surgical stocking. A plaster of Paris bandage 
(Gypsona: 7.5 cm wide) applied over the pelvis and lower abdomen 
provided protection of the incision sites without encumbering normal 
respiration. The animal was lightly restrained by taping the plaster 
cast and the animals hindlimbs to a lead support brick. A 
temperature probe was inserted into the rectum to monitor core 
temperature and a pressure transducer (P23 ID Gould Stratham) 
attached to a chart recorder (Gould Stratham, Model 2202) was 
connected to one of the arterial femoral catheters to monitor blood 
pressure. Anaesthesia was discontinued and the rat allowed to 
recover for at least 2 hours prior to drug administration.
2.1.2 Experimental Analysis
a) Preparation of Autoradiograms
At the end of the sampling period the animal was sacrificed by 
decapitation and the brain rapidly excised as follows. A 
longitudinal midline incision was made at the level of the snout and 
extended in a caudal direction to the level of the forelimb. Skin 
and extracranial muscle were reflected to expose the skull. The
dorsal cranium was removed and the dura reflected to facilitate 
excision of the intact brain. After all adhering hair and bone 
fragments had been removed the brain was frozen in isopentane which 
had been precooled to -42°C in a mixture of acetone and dry ice. The 
time taken from sacrifice to immersion in isopentane did not exceed 5 
minutes. Over a bed of dry ice, the olfactory bulbs were removed and 
the brain affixed to a swivel-headed microtome chuck with a plastic 
embedding matrix (Lipshaw). The brain was then sealed in a 
polysterene box and stored in a cryostat at -22°C. From each brain 
approximately 900 coronal brain sections, precisely 20 jim thick, were 
cut in a cryostat. Of these, three sections in every ten were picked 
up onto glass cover slips and rapidly dried on a hotplate (65°C). 
The remaining seven sections were discarded or where necessary 
stained with cresyl violet for the histological identification of 
brain regions. Histological staining of brain sections for acetyl­
cholinesterase was performed using the Koell-Friedenwald thiocholine 
method as modified by Hardy et al. (1976). The coverslips were glued 
onto cards and placed, together with a set of ^^C-labelled epoxy 
resin standards (18-1880 nCi/g tissue equivalents) in light-tight 
cassettes. Autoradiograms were obtained by exposing blue-sensitive 
x-ray film (Kodak - GRS-A) to the brain sections and standards for 
approximately 10 days. Films were then processed in a Kodak 
automatic processor, according to the manufacturers' instructions.
b) Quantitative Densitometrical Analysis of Autoradiograms
Analysis of the resultant autoradiograms was performed using a 
computer-based microdensitometer system (Cambridge Instruments; 
Quantimet 720). With this system autoradiograms are magnified (x
5.6) and displayed on a video monitor. Optical density 
(OD) measurements are obtained either by placing a cursor (2.5 x
_ o  2 9
10 mm - 1800mm ) over the area of interest or circumscribing the 
region with a light pen attachment. Density values for each brain 
region are obtained by digitising the field of measurement into
O
picture points (pixels, 2.5 x 10 mm ) with each pixel ascribed to 
one of 64 grey levels. Thereafter, a density value is obtained by 
integrating the grey level value of each pixel on each of four scans. 
Bilateral measurements were made on at least six autoradiograms in 
which each brain area appears. Identification of brain areas was 
made with reference to the stereotaxic atlases of Konig and Klippel 
(1967); Pellagrino et al. (1967); Paxinos and Watson (1982). The 
■^C concentration for each brain region was calculated from the mean 
OD value, obtained from the bilateral measurement on at least six 
autoradiograms in which the region was defined, by reference to the 
calibration curve constructed from the optical density values of the 
standards.
A more detailed analysis of the effects of D^ and D£ receptor 
activation on local blood flow and glucose use in the caudate nucleus 
were obtained as follows. Densitometrical mesurements were made at 
three levels of the caudate nucleus; at the "head” (rostral) "body" 
(middle) and "tail" (caudal) of the nucleus (Figure 4). At each 
level bilateral, measurements were made on each of six adjacent 
sections by placing a 10 x 10 pixel square over fixed anatomical 
loci. Anterior measurements were made at the level of the genu of 
the corpus callosum (A9410 : Konig and Klippel, 1963); middle level 
at the lateral processes of the anterior commissure (A7470) and 
posterior at the level of the globus pallidus (A6280 - A6360). At 
both the anterior and middle levels optical density measurements were
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Densitometrical analysis was performed at three anatomically 
defined levels corresponding to the head (level 6), body (level 5) 
and tail (level 4) of the caudate nucleus. The caudate nucleus is 
defined by stipling on the right side of each diagram. The black 
squares on the left side of each figure indicate the precise 
locations at which densitometrical analysis was performed.
performed at fixed points on the four quadrants of the nucleus 
(Figure 4). The most caudal level (posterior) permitted only two 
measurements (dorsal and ventral).
Following the measurement of regional density levels, the mean 
density for the caudate nucleus at each level was calculated by 
encircling both caudata with a light-pen attachment.
c) Liquid Scintillation Analysis
The time course of ^C-labelled tracer is arterial blood was 
determined by liquid scintillation analysis of the plasma (glucose 
use) or whole blood samples (blood flow) obtained during the 
measurement period.
Aliquots of arterial plasma (18.7 +. 0.1 microlitres) were 
pipetted into plastic scintillation vials containing 1 ml of 
distilled water. To ensure accurate delivery, the residual plasma 
was eluted from the pipette tip by repeated flushing with the 
distilled water. A 10 ml aliquot of scintillation fluid (Pico-fluor 
30) was added to each vial and the radioactive emission analysed for 
periods of 4 minutes in a refrigerated liquid scintillation counter.
Raw data (cpm) for each sample were converted to 
disintegrations per minute (dpm) by reference to a quench calibration 
curve and the external standards ratio as described by Peng et al. 
(1977). A set of quench calibration standards analysed 
contemporaneously with each set of counts monitored the accuracy of 
the cpm to dpm conversion. For each experiment the mean of 4 
temporally spaced sets of counts was used to calculate the 
concentration in each sample.
Whole blood samples were bleached with hydrogen peroxide (0.4 
ml of 30% w/v H 2 O2 ) for 30 minutes to reduce the counting errors 
associated with colour quenching. Scintillation fluid was added and 
the samples left to stand at room temperature overnight to allow 
complete elution of the isotope from the filter discs. The samples 
were then processed as described above.
2.1.3 Data Analysis
The pharmacological studies presented in this thesis fall into 
three main categories: a) the analysis of drug effects on indices
of brain function, b) examination of agonist/antagonist 
interactions on function-related glucose use, and c) the comparison 
of different drug treatments on the relationship between local rates 
of cerebral blood flow and glucose utilisation.
a) Analysis of Drug Responses
The Bonferonni method was used to compare the effects of single 
concentrations of two different drug treatments. This modified t- 
test adjusts for multiple comparisons by assigning a significance 
threshold of P/M, where P is the probability value obtained from the 
tables of t-distribution and M is the number of comparisons being 
made, thus, for an experimental situation involving two comparisons 
(i.e. SKF 38393 vs control and LY 171555 vs control) the 
significance threshold would be set at 0.025.
Situations involving more complicated comparisons (dose- 
response curves) were analysed using the Scheffe extension of 
analysis of variance (ANOVAR) (Scheffe, 1959). The analysis of
variance approach is a more conservative statistical test than the 
Bonferonni method and so is less susceptible to attributing false 
significance in studies involving large numbers of comparisons.
b) Analysis of Drug Interactions
The interaction studies involving the D2  agonist LY 171555 and 
the D2  agonist LY 171555 and the D^ antagonist SCH 23390 presented 
particular problems for statistical analysis. In studies of this 
type the questions to be addressed are -
1) Does antagonist pretreatment alter the response to the agonist.
If, Yes
2) Is the effect of the antagonist pretreatment on the agonist 
respose homogeneous throughout the brain or is it restricted to 
a few brain regions.
They, therefore, require a more sophisticated analytical approach 
than was used to examine the effect of simple drug administration. 
An appropriate form of analysis would be to compare the differences 
in variance between a) glucose use in the agonist-treated group and 
its control group (saline) and b) the agonist/antgonist group and 
its respective control group (antagonist alone) i.e.
(agonist treatment - saline control) vs (agonist/antagonist -
antagonist alone).
Analysis of variance of this type can be performed using repeated 
measures approach (BMDP program P2V), treating the agonist and
agonist/antagonist groups as treatment variables, control or 
challenge groups as the grouping variables and the different 
brain regions as the trial factor. If inter-regional variability in 
response to pretreatment with antagonist is indicated by the ANOVAR 
study then the areas of interest can be identified by comparing the 
"interaction" group with the agonist treatment group for each brain 
areas using the students t-statistics.
c) Analysis of the Relationship Between Blood Flow and Glucose Use
The quantitative autoradiographic techniques described provide 
the ideal tools for investigating the effects of drug administration 
of the fundamental relationship between local rates of metabolic 
activity and tissue perfusion throughout the brain. However, in many 
of the early studies naive and inappropriate statistical methods were 
used to analyse the relationship between blood flow and glucose 
use (Sokoloff, 1981; Kuschinsky et al. 1981 a,b; Mies et al. 1981; 
Ohata et al. 1981; Pickard 1981). Invariably, these authors 
analysed the relationship between local blood flow and glucose use by 
evaluating the correlation coefficient derived from regression 
analysis. However, fundamental to the use of regression analysis is 
the assumption that all data points are statistically independent. 
Patently this cannot be the case in autoradiographic studies where 
multiple measurements are made in each brain.
A rigorous statistical method has been developed specifically 
for the analysis of flow/glucose studies which takes into account the 
correlation between flow and glucose use in the different brain
regions and the influences of inter-animal variability (McCulloch et 
al* 1982 a). In practice this approach is similar to that described 
for the analysis of agonist/antagonist interactions. Analysis of 
variance (of repeated measures form) was performed (BMDP program P2V 
statistical package) with blood flow and glucose use treatments taken 
as the levels of grouping variable and the 59 brain regions as the 
trial factor.
2.2 Measurement of Local Cerebral Blood Flow
Local rates of cerebral perfusion were measured using the 
autoradiographic ^^C-iodoantipyrine technique, as described by 
Sakurada et al. (1978).
2.2.1. Theory
The ^^C-iodoanipyrine technique, like many other methods for 
measuring cerebral blood flow, is based on the mathematical model 
developed by Kety for describing the exchange of inert gaseous tracer 
substances between blood and tissue (Kety, 1951, 1960). Kety's 
approach was to start with ”the Fick principle” which in this context 
can be started as, the rate of change of a biologically inert freely 
diffusible tracer at a time (T), is related to the arteriovenous 
difference of the tracer and the flow per unit weight of tissue
If it can be assumed that at the level of the capillary bed the 
tracer comes into instantaneous equilibrium betwen blood and tissue 
(Zuntz, 1897) then
(Ca - Cv) = m (Ca - Ci)
X
(4)
where X describes the tissue/blood partition coefficient and m is a
constant between 0 and 1 which represents the extent to which 
diffusion equilibrium is achieved as blood passes through the 
capillary bed. In the absence of arteiovenous shunting mechanisms, 
the value of m for a freely diffusible tracer would be unity.
If the tissue compartment under investigation is homogeneous 
with respect to a) perfusion rate and b) tracer access then 
equations (1) and (2) can be combined and integrated to yield an 
expression (3) which relates a clearance constant K to the time 
course of the tracer in arterial blood over the period time (t) to 
time (T); the local concentration of tracer in the tissue at time T 
and the tissue/blood partition coefficient (X).
arteriovenous shunts and limitations on free diffusion (i.e. m=l), 
then local rates of blood flow can be calculated from the clearance 
constant from the simple relationship
(^(T) K <!••*<«> dt
a
(5)
K flow per unit weight of tissue (6)
X
The Kety model was originally used in conjunction with the
I O 1
gaseous tracer I-trifluoroiodomethane (Landau et al. 1955; 
Freygang and Sokoloff, 1958; Kety 1960), and later with ^ C -  
antipyrine (Reivich et al. 1969); however, neither compound proved 
to be satisfactory as a tracer substance. The short half life ( 8  
days), and poor resolution characteristics of iodine labelled tracers 
make them unsuitable for routine use with quantitative 
autoradiography. Furthermore, the solubility of CF^I in blood varies 
with haematocrit and the tissue/blood partition coefficient varies 
markedly from region to region and from animal to animal (Reivich et 
al. 1969).
The introduction of ^^C-antipyrine as a tracer for measuring 
local cerebral blood flow appeared to overcome the problems of 
partition coefficient and isotope stability (Reivich et al. 1969), 
however, the uptake of ^C-antipyrine into cerebral tissue diffusion 
limited (i.e. m considerably less than 1) (Sakurada et al. 1978; 
Siesjft, 1978). The diffusion limitations of ^^C-antipyrine were 
overcome by the introduction of the 4-iodo derivative of *^C- 
antipyrine, iodoantipyrine (Sakurada et al. 1978). The high 
oil/water partition coefficient of iodoantipyrine make it a more 
freely diffusible tracer than ^C-antipyrine (Sakurada et al. 1978). 
In addition the brain/blood partition coefficient is uniformly 
constant throughout the CNS (0.79) and does not vary with haematocrit 
(Sakurada et al. 1978). The ^^C-iodontipyrine technique was, 
therefore, adopted as the method of choice for determining local 
cerebral blood flow.
2.2.2 Practical Approach
The effects of saline, SKF 38393 and LY 171555 on local 
cerebral blood flow was determined in 18 rats by quantitative 
autoradiography using iodoantipyrine as a tracer (Sakuruda et al. 
1978). Rats were prepared for autoradiographic investigations as 
described previously. Local blood flow was determined 40 minutes 
after drug administration so as to coincide with the time of median 
specific activity of ^C-2-deoxyglucose in brain tissue in those 
experiments used for the determination of glucose use. *^C- 
iodoantipyrine (50 jiCi in 0.7 ml of saline) was infused intravenously 
over the 60 second sampling period by on a "ramped” infusion 
schedule. The use of a progressively increasing infusion rate 
prevented the attainment of steady state arterial concentrations and 
so maximise the resolution of high flow and low flow areas on the 
autoradiogram. During the infusion period 15 to 18 timed blood 
samples were absorbed onto preweighed filter discs from blood which 
was allowed to flow freely from a partially occluded arterial 
catheter. The time at which each sample drop was collected was 
recorded and used together with the concentration of radioactivity in 
the sample to describe the history of arterial tracer throughout the 
experimental period. At the end of the sampling period the rat was 
sacrificed by decapitation, its brain removed and processed for 
autoradiography as described previously. The filter discs were 
returned to their respective scintillation vials and reweighed. 
Whole blood samples were bleached with hydrogen peroxides and 
processed for liquid scintillation analysis as described. The volume 
of whole blood for each sample was subsequently calculated from the 
sample weight, corrected for the specific gravity of whole blood
(1.05 g/ml) and used to compute the integral of ^C-concentration 
over the 60 second period.
Local tissue concentrations for each of the 60 brain
regions examined was determined by densitometrical analysis as 
described previously. Local values for blood flow were then 
calculated using the equation derived by Kety (1960).
2.3 y/>.The Measurement of Local Cerebral Glucose Utilisation
Local rates of cerebral glucose utilisation were measured using 
the autordiographic ^C-2-deoxyglucose technique (Sokoloff et al. 
1977).
2.3.1 Theory
The unique biochemical properties of the 2 -deoxyglucose 
molecule provides the theoretical basis for the 2 -deoxyglucose 
technique. 2-deoxy-D-glucose, a chemical analogue of glucose shares 
many of the biochemical characteristics of the native substrate. 
Deoxyglucose competes for the same bidirectional transport mechanism 
which normally carries glucose across the blood-brain barrier 
(Bachelard, 1971; Oldendorf, 1971, Pardridge et al. 1982 a,b; 
Gjedde and Diemer, 1983). Once they have entered into cerebral 
tissue both 2 -deoxyglucose and glucose are phosphorylated by 
hexokinase, the first and rate limiting enzyme of the glycolytic 
pathway (Sols and Crane, 1954). However, it is at this point that 
the metabolic fates of 2-deoxyglucose and glucose diverge. Glucose- 
6 -phosphate is largely converted to fructose-6 -phosphate by 
phosphohexoseisomerase and is ultimately oxidised to carbon dioxide
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The model describes the fate of glucose and ^C-2- 
deoxyglucose in a single homogenous tissue of the brain. ^C- 
2 -deoxyglucose and glucose share and compete for the same 
carrier facilitated transport mechanisms.
The constants , ^2 an<* ^3 represent the rate 
constants for carrier mediated transport of ^C-2-deoxyglucose 
from plasma to tissue, for the carrier mediated transport back 
to plasma, and for the phosphorylation to 2 -deoxyglucose-6 - 
phosphate by hexokinase, respectively. , K£ and Kg are 
the equivalent rate constants for the natural substrate, 
glucose.
and water via the citric acid cycle. A small proportion of glucose- 
6 -phosphate (approximately 3%) is diverted to anabolic processes via 
the pentose phosphate (phosphogluconate) pathway (SiesjU, 1978).
In contrast the metabolism of 2-deoxyglucose essentially ceases 
after the hexokinase reaction (Tower, 1958; Horton et al. 1973). 
Deoxyglucose-6 -phosphate is not a substrate for phosphohexose- 
isomerase nor glucose- 6 -phosphate dehydrogenase. Moreover, 
deoxyglucose-6 -phosphate is not transported across the blood-brain 
barrier (Sokoloff et al. 1977; Nelson et al. 1986). It is a 
substrate for glucose-6 -phosphatase (glucose-6 -phosphohydrolase), 
however, the activity of this enzyme is low in vivo and the loss of 
2 -deoxyglucose negligible up to 1 hour after the administration of an 
intravenous pulse of deoxyglucose (Sokoloff et al. 1983). A 
proportion of deoxyglucose-6 -phosphate is diverted into the 
production of glycogen and related compounds (Nelson et al. 1984; 
Sokoloff, 1986; Pentreath et al. 1982). However, these processes 
are slow in mammalian tissue (accounting for approximately 2 % of 
total - 45 minutes after deoxyglucose administration) and
represent relatively stable secondary products of hexokinase activity 
(Sokoloff, 1986). Thus, so long as the interval of time following 
the intravenous administration of deoxyglucose is sufficiently short 
to allow for the assumption of negligible 2 -deoxyglucose-6 -phosphate 
loss (i.e. less than 1 hour), the accumulation of 2 -deoxyglucose and 
its secondary products in brain tissue can be used to quantify the 
rate of glucose phosphorylation (R-).
R. = Concentration of Deoxyglucose Products at Time T (4) 
[Isotope Correction Factor] x [Integrated specific activity
in precursor pool]•
This equation represents a specific application of the general 
equation for measuring rates of biochemical reactions with 
ratioisotopes. The isotope correction factor is a constant, 
composed of the Michaelis-Menten kinetic constants for glucose and 
deoxyglucose, which corrects for kinetic differences between the rate 
of phosphorylation of glucose and deoxyglucose by hexokinase.
Unfortunately, the integrated specific activity in the 
precursor pool cannot be measured readily and must be calculated from 
measurements made in arterial blood by correcting for the lag in the 
equilibration of the precursor pool with that of plasma. To apply 
this correction requires an acurate knowledge of the kinetic rate 
constants which describe the movement of 2 -deoxyglucose into and out 
of the tissue precursor pool (K^* and K£*) and its phosphorylation by 
hexokinase (£3 *)* These principles have been mathematically defined 
and incorporated into equations (5); the operational equation of the 
method (Figure 6 ). This method may be used to measure local rates of 
glucose utilisation under a variety of experimental conditions, 
provided that the following requirements are fulfilled.
1) Deoxyglucose-6 -phosphate, or its metabolites, remain trapped 
within cerebral tissue for the duration of the sampling period.
2) Plasma glucose levels and local rates of glucose consumption 
remain constant throughout the experimental period.
3) Tracer theory is upheld with respect to 2-deoxyglucose and 2- 
deoxyglucose-6 -phosphate•
FIGURE 6
Operational Equation for the 2-Deoxyglucose Method.
where LCGU is the local rate of glucose consumption in a homogenously 
perfused area of brain tissue C^* is the total concentration in
tissue (Cg + (M ), T represents the time at which the animal is 
sacrificed. The "lumped constant", LC, converts the steady state 
rate of ^C-2-deoxyglucose phosphorylation to rates of glucose
phosphorylation and is composed of the relative distribution ratios
*between brain tissue and arterial plasma (X), the michaelis-menten 
kinetic constants of glucose and 2 -deoxyglucose, and a factor 0  which 
corrects for the fraction of glucose-6 -phosphate which is lost from 
the metabolic pool. The other symbols are the same as defined in 
Figure 5.
2.3.2 A Critical Appraisal of the 2-deoxyglucose Method
The assumption that the products of 2-deoxyglucose metabolism, 
once formed, remain trapped within brain tissue is fundamental to the 
validity of the 2-deoxyglucose method. This premise appeared 
reasonable since 2 -deoxyglucose-6 -phosphate and its metabolites 
(glycogen, glycolipids and glycoproteins) are relatively stable 
products which remain trapped within cerebral tissues. It was 
recognised that 2 -deoxyglucose-6 -phosphate is a substrate for 
glucose-6 -phosphatase. However, substantial biochemical evidence 
indicated that the activity of this enzyme is exceedingly low in 
brain tissue (Hers and De Duve, 1950; Hers, 1957; Raggi et al. 
1960; Prasannan and Subrahmanyan, 1968) with the result that the 
loss of 2 -deoxyglucose-6 -phosphate is negligible over the 45 minute 
experimental period (Sokoloff et al. 1977).
The validity of the 2-deoxyglucose method as a measure of 
function related glucose utilisation has been called into question by 
reports of significant phosphatase in cerebral tissue in vivo 
(Hawkins and Miller, 1978; Sacks et al. 1983; Huang and Veech, 
1982). However, careful examination of these studies reveals 
fundamental flaws in each.
In a study by Sacks et al. (1983), the arteriovenous difference 
in following a bolus injection of ^^C-2-deoxyglucose was shown to 
be negative. Thus, they concluded that since no ^^C-2-deoxyglucose- 
6 -phosphate could be detected in the blood samples, there must be 
significant phosphatase activity in brain tissue (Sacks et al. 1983).
Studies of arteriovenous differences in 2-deoxyglucose can be used to 
assess phosphatase activity only if the pools of 2 -deoxyglucose in 
plasma and in brain tissue are in equilibrium (Gjedde, 1984; Nelson 
et al. 1986). Since the study by Sacks et al. (1983) was performed 
under conditions where arterial tracer concentrations were rapidly 
declining, their conclusions concerning phosphatase activity were 
invalid.
In the study by Hawkins and Miller (1978) the authors compared 
the actual concentration of deoxyglucose-6 -phosphatase in brain 
tissue with that predicted by the Sokoloff equation. Since the 
predicted value was some 2 to 3 fold higher than the actual 
deoxyglucose-6 -phosphate concentration, Hawkins and Miller concluded 
that the discrepancy between the measured predicted values was due to 
high phosphatase activity. This conclusion has been challenged by 
Sokoloff (1982) and others (Nelson et al. 1986) who argued that the 
lumped constant used by Hawkins and Miller (1978) to predict 
deoxyglucose-6 -phosphate levels (i.e. 1.10) was too high. Indeed if 
the calculations were performed using the appropriate lumped constant 
(0.483) the predicted values would be indistinguishable from that 
measured by biochemical assay (Sokoloff, 1982; Nelson et al. 1986).
In 1982, Huang and Veech reported that the half life of 
glucose-6 -phosphate in brain tissue was approximately 2 0  minutes. 
Obviously* such high levels of phosphatase activity, if correct, 
would completely invalidate the 2-deoxyglucose method. The principle 
behind the study by Huang and Veech is simple but sound. Metabolism 
of 2- H-glucose as far as fructose-6 -phosphate results in the loss of 
the tritum label. By contrast, the ^C-moiety is retained at this 
stage of the glycolytic pathway. A proportion of the fructose-6 -
i
phosphate is converted back to glucose-6 -phosphate which then could 
be returned to the glucose pool by glucose- 6 -phosphatase. 
Significant phosphatase activity would, therefore, result in an
1 / Q
increase in the C/ H ratio in the glucose pool. The validity of 
this approach depends upon purification techniques which yield 
glucose which is uncontaminated by products of glucose metabolism. 
However, recent studies have shown that the separation methods used 
by Huang and Veech result in a glucose fraction which is contaminated 
by glucose metabolites which have lost the ^H, but not the label 
(Nelson et al. 1985, 1986). Indeed a repetition of the Huang and 
Veech study, but with more rigorous purification techniques has 
failed to demonstrate significant phosphatase activity in brain 
tissue (Nelson et al. 1985).
Recent cytochemical studies have suggested that the glucose-6 - 
phosphatase enzyme is located on the luminal side of the endoplasmic 
reticulum, or microsomes derived therefrom (Arion et al. 1980). 
Tissues displaying high phosphatase activity (viz. the liver), 
possess a translocase enzymes which serves to ferry substrate from 
the cytoplasm to the phoshatase in the lumen of the endoplasmic 
reticulum (Arion et al. 1980). This translocase enzyme appears to be 
absent from cerebral tissue (Fishman and Karnovski, 1986), with the 
result that the phosphatase has to rely on passive diffusion to 
obtain substrate. Thus, not only is activity of glucose 6 - 
phosphatase low in brain tissue but the enzyme may also be physically 
separated from its substrates.
Although, the weight of evidence would support the view that 
the phosphatase activity is not sufficient at 45 minutes to
compromise the method, it is recognised that phosphatase is not zero,
and may become an important limitation if the measurement period
exceeds 1 hour (Sokoloff, 1982, 1986). The underestimation of
glucose use due to phosphatase activity is of particular relevance to
18clinical studies using Fluoro-deoxyglucose in conjunction with 
positron tomission - tomography where the measurement period can 
extend to 2 hours (Reivich et al. 1979). To overcome this problem 
the Sokoloff equation has been revised to include a term which 
represents the rate of loss of phosphorylated label (Sokoloff, 1982). 
However, for experiments of 45 minutes duration the original Sokoloff 
equation may suffice (Sokoloff et al. 1983).
In theory, the 2-deoxyglucose method is applicable only to 
those experiments where plasma glucose and local rates of glucose 
utilisation remain constant throughout the experimental period. A 
subsequent modification of the operational equation permits the 2 - 
deoxyglucose method to be used under conditions of moderate dynamic 
fluctuations in plasma glucose (Savaki et al. 1980). Interestingly, 
a comparison of the Savaki model with the original equation has 
revealed that the original method can accommodate moderate dynamic 
changes (+. 1 0 %) in plasma glucose without seriously impairing the 
accuracy of the measurement (Sharkey and McCulloch - unpublished 
observations).
The assumption that in conscious animals local rates of glucose 
use remain constant throughout the 45 minute experimental period is 
unrealistic. However, although rates of glucose utilisation are 
measured over 45 minutes, the results are weighted towards the early 
part of the experiment, particularly over the period between 5 and 15
minutes after 2-DG administration. Consequently, studies should be 
designed so that the behavioural state under investigation will be 
sustained for at least 15 minutes (Sokoloff et al. 1983). As the 
drugs used in this thesis produced sustained alterations in behaviour 
they do not present any major problems for glucose use determination.
The lumped constant, corrects for the relative abilities of 
glucose and 2-deoxyglucose to enter the tissue metabolic pool. As it 
has to be determined in a separate group of animals it represents a 
potential source of error in the estimation of local rats of glucose 
phosphorylation. To date, the value of the lumped constant has been 
determined in the rat, cat, dog, sheep, monkey and human (for review 
see Sokoloff, 1986). These studies have indicated that although 
interspecies differences in the value of the lumped constant do occur 
(0.344 in monkey to 0.568 in adult human) the values within each 
species remain relatively constant over a wide range of experimental 
conditions (Sokoloff, 1979, 1986; Crane et al. 1981; Gjedde, 1984). 
Indeed, the only conditions where significant alterations in the 
lumped constant have been observed have been in severe hypoglycaemia 
(plasma glucose less than 5 mM) and hyperglycaemia (plasma glucose 
greater than 17 mM) and in studies involving pathological alterations 
in brain structure (Suda et al. 1981; Schuier et al. 1981; Ginsberg 
and Reivich, 1979). These constraints are of particular relevance to 
studies involving dopamine receptor agonists. The administration of 
dopamine receptor agonists can result in marked increases in plasma 
glucose (McCulloch et al. 1982 a; Tyce, 1976). In the case of LY 
141865 plasma glucose levels can exceed 24 mM (Figure 7). At these 
levels the 2 -deoxyglucose method would be compromised by significant
alterations in the rate constants and lumped constant (Schuier et al. 
1981; Sokoloff et al. 1983). The hyperglycaemic effects of LY 
141865 can be largely attenuated by fasting (Figure 7), however, 
care must be taken to ensure that the period of starvation does not 
exceed 18 hours as it has been shown that longer periods of fasting 
result in the significant use of ketone bodies as an energy substrate 
(Gjedde and Crone, 1975; Ruderman et al. 1974). For this reason the 
animals participating in the present studies were fasted for a period
I
of 12 - 15 hours prior to surgery.
2.3.3 Practical Considerations
Measurement of local cerebral glucose utilisation was initiated 
thirty minutes after drug administration by an intravenous pulse of 
^C-2-deoxy-D-glucose (50 uCi in 0.7 ml of saline, infused over 30 
seconds). Over the succeeding forty-five minute sampling period 
fouteeen timed arterial blood samples were withdrawn for the 
determination of plasma ^ C  and glucose profiles. Plasma was then 
prepared by the immediate centrifugation of arterial whole blood 
samples for approximately thirty seconds in a table-top 
microcentrifuge (Beckman). Aliquot of plasma (18.7 microlitres) from 
each sample were pipetted into plastic scintillation vials and 
processed for liquid scintillation analysis. A further ten 
microlitres of plasma was taken from each sample for the 
determination of plasma glucose levels in a semiautomated glucose 
analyser. At the end of the sampling period the animal was
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Plasma glucose levels in fasted (dashed line) and unfasted 
(solid line) rats following the intravenous administration of 
the dopamine D£ receptor agonist LY 141865 (10 mg/kg).
Calculated levels of unphosphorylated 2-deoxyglucose expressed 
as a fraction of total brain isotope (CT ) in six grey and 
white matter regions of the rat brain, 45 minutes after the 
intravenous delivery of tracer to the fasted (normoglycaemic) 
and unfasted (hyperglycaemic) rats.
sacrificed by decapitation and the brain processed for 
autoradiography.
Rates of glucose utilisation for each brain region were derived 
from a) the local tissue concentration, b) the plasma
histories of and glucose and c) the appropriate rate constants 
for 2 -deoxyglucose in grey and white matter by means of the 
operational equation as derived by Sokoloff and his associates 
(Sokoloff, 1977). The values of the rate constants K^*, K2*, Kg* and 
the lumped constant were as follows
Grev Matter White Matter
Kj* 0.189 (min""^  ) 0.079 (min™*)
k2* 0.245 (min“ )^ 0.133 (rain-1)
k3* 0.052 (min-*) 0 . 0 2 (min-^)
(Sokoloff et al. 1977) 
Lumped constant = 0.483.
2.4 A Data Handling System for Fingerprinting Neuropharmacological 
Responses.
2.4.1 The Model
The method proposed involves ranking brain regions according to 
their responsiveness over a chosen concentration range. Hierarchies 
of regional responsiveness are derived from a function which is 
defined as -
J - l
f  “  Z i  ( X c 
i = 1
where Xc and Xj are the natural logarithms of the mean glucose use 
values obtained for the control group and drug treatment group, 
respectively. J-l describes the number of concentrations examined 
for the drug under investigation (usually 3 or 4).
The function offers a number of advantages over alternative 
ranking procedures (percentage changes or degree of statistical 
significance). First, the model makes use of all data from the dose 
response curve for each brain region, and not just one selected 
concentration. Second, the use of logged data serves to minimise the 
distorting influences associated with heteroscedasticity, and third, 
squaring the differences permits the analysis of bidirectional 
changes and serves to increase the sensitivity of the method.
-XJ (6)
2.4.2 Evaluation of the Fingerprinting Model
If the fingerprinting model is to be of value, the system of 
ranking ' t '  values must be reliable and reproducible.
a) Reliability of the Fingerprinting Method
The reliability of the fingerprinting approach was evaluated by 
means of the Bootstrap approach (Efron, 1982) in which the data set 
for each drug is compared with 1 0 0  simulated data sets, each having 
the same overall mean and variance structure as the original data. 
In order to perform analysis of this type a model (of repeated 
measures form) was constructed which describes observations made in a 
given brain area in terms of its contribution to the overall mean 
value of the region.
The Repeated Measures Model 
Xijk
where - xijk* denotes the value in region (i) of animal (k) which 
has received drug treatment (j), is the mean response
for region (i) after drug treatment (j), Aj^, represents 
"the animal effect"; the contribution made by animal k to 
the overall response to treatment (j). denotes the
background variability of the data.
U- •
ij + Ajk
£ * *iijk (7)
0If it is assumed that there is constant variance between animals (r ) 
and within animals ( a  ), independent of the type of observations 
being studied and the magnitude of U^j then
Ajk H (Oj r 2)
Eijk H < ° 1  "*>
A
where N (0j  ^ ) denotes the normal distribution (N) with mean (0) and 
variability (r ).
The assumption of constant variance is common to all the 
repeated measures analyses used in this thesis (drug interactions, 
flow/glucose use relationships and drug fingerprinting procedures). 
At first sight this assumption would appear to be invalid since 
obvious differences in variance exists, particularly between regions 
of high and low numerical value (if SEM of +. 26 for control auditory 
cortex blood flow with a SEM of +. 1 was observed in white matter). 
However, the assumption of exact equality of variance is not 
considered to be critical unless the variances are substantially 
different (Scheffe, 1959; McCulloch et al. 1982a). In practice this 
problem of heteroscedasticity can be largely overcome by employing 
logged data (McCulloch et al. 1982a).
In order to stimulate new data sets estimates of^ijk* t an(*
2 •<r were obtained using the MINITAB computing package. The variance
9 9parameters r and a  were estimated via two way analysis of variance
of each drug concentration and pooled to yield overall estimates of
variance for each drug response (see Appendix 1). The calculated
2 2\estimates of mean values ( ^j^) and variance parameters (£ and £ )
were used subsequently to generate a series of 1 0 0  simulated data
sets of exactly the same format as the original data. The 'f' values 
were then calculated for each of the simulations and compared with 
the original data set via correlation. For simplicity correlations 
were calculated between 'f' values rather than ranking position as 
the same results should be obtained by both procedures. The 
robustness of the method was further tested by repeating the 
Bootstrap procedure both with increased variance (up to 16 fold). A 
second correlation program analysed the relationship between the 
simulated data of two different drugs. This procedure allows a 
comparison to be made between simulated correlations and the actual 
correlation obtained from the original data set and so gives an 
estimate of the reliability about the original correlation.
b) Reproducibility
An investigation of the reproducibility of the fingerprinting 
model was performed by comparing the responses observed in the same 
animals by two independent investigators. The original 
autoradiograms and blood data for the apomorphine studies of 
(McCulloch et al. 1982 b) were reanalysed using the same 
densitometrical criteria used for the studies of LY 17155 and SKF 
38393. In a series of preliminary investigations, the responses 
measured by the two investigators were compared by the correlation 
programs and the reliability assessed as before.
c) Application of the Fingerprinting Model
Having established that the model is indeed reliable, and 
reproducible (Appendix 1), it was used to compare the effects of SKF
38393 and LY 171555 on function-related glucose use with those 
produced by apomorphine (generated for the reproducibility study).
The reproducibility of the method also permitted the comparison 
of the functional responses evoked by SCH 23390 with published data 
for putatively D£ selective concentrations of haloperidol (McCulloch 
et al. 1982 c).
3. DRUGS AND TRACERS
The following pharmacological agents were kindly donated for 
the purpose of these studies:- SKF 38393 (Smith, Kline and French, 
Welwyn Garden City, England); LY 141865 and LY 171555 (Eli Lilly, 
Indianapolis, USA); SCH 23390 (Schering - Plough, Bloomfield New 
Jersey, USA). Other pharmacological agents used were - 
Alpha Chloralose (BDH Chemical, Poole, England); Apomorphine 
(Janssen Pharmaceuticals, Belgium); Halothane (May and Baker, 
Dagenham, England); Heparin (Paines and Byrne, Greenford, England); 
Saffan (Glaxovet, Harefield, England); Xylocaine (Astra 
Pharmaceuticals, Kings Langley, England).
2[^C]-deoxy-D-glucose and 4[N-methyl-^C]-iodontipyrine were 
obtained at a specific activity of 280 mCi/mmol and 60 mCi/mmol from 
New England Nuclear (Boston, Massachusetts, USA).
CHAPTER III
RESULTS
1. DOPAMINE RECEPTOR SUBTYPES IN CEREBRAL ARTERIOLES
1.1 Vasomotor Responses of Feline Pial Arterioles in Situ to
Dopamine Receptor Agonists.
The injection of approximately 5 microlitres of artificial
cerebrospinal fluid (CSF) into the perivascular space surrounding
individual pial arterioles (diameter 43 - 230 urn) had no significant
effect on arteriolar calibre (Table 4).
Perivascular microapplication of artificial CSF containing 
— ft —Aapomorphine (10 M to 10 M) resulted in a dose-related increase in 
the calibre of pial arterioles (Table 4, Figure 8). Significant 
increases in pial arteriolar calibre were observed following 
microinjections of 10~^M apomorphine (23% increase with respect to
preinjection calibre) with the maximum response (31% increase) at
—5 . —10 M. At the highest concentration examined, 10 ^M, the vasomotor
response to apomorphine was not significantly different from that 
produced by the administration of CSF.
The D^ agonist SKF 38393 (10~^M to 10~^M) provoked dose- 
dependent dilatations of pial arterioles. Significant increases in 
arteriolar calibre were observed at 10"“®M SKF 38393 (15% increase in
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Alterations in pial arteriolar calibre produced by the 
perivascular microapplication of the dopamine receptor agonists 
apomorphine (•), SKF 38393 (■), and LY 141865 ( A ) .  Data are 
presented as mean +_ SEM.
calibre) with the maximum dilatations occuring at 10~^M (+24%). The 
dose-response curve to SKF 38393 was also biphasic with 
concentrations in excess of 10"~^M provoking progressively smaller 
increases in arteriolar calibre.
The D£ agonist LY 141865 was examined at five concentrations 
(10""^M to 10~^M). Significant dilatations of pial arterioles 
occurred only at the highest concentrations tested (10“^H and 10”^M) 
with the largest increases in calibre (+25%) occurring at 10~^M.
The rank order of potency, with respect to threshold and 
approximate ED^q values (SKF 38393 > apomorphine > LY 141865) was 
consistent with a mediated dilatation of the cerebral vasculature. 
No significant correlation could be demonstrated between the 
magnitude of the dilatory response elicited by any of the agents 
tested and the preinjection calibre of the vessel.
1.2 Antagonism of Vasomotor Responses
The perivascular microapplication of the putatively selective 
receptor antagonist SCH 23390 (10”*^M - 10~^M) did not 
significantly alter the calibre of pial arterioles (Figure 9a). The 
concomitant administration of SCH 23390 potently antagonised the 
arteriolar dilatation produced by apomorphine (10”^M) or SKF 38393 
(10~^M) - (Figure 9b), with pA£ values between 8 and 9. SCH 23390, 
even at high concentrations (10”^M) did not significantly alter the 
non-specific vasodilatatory response produced by acidic CSF (pH 6.8) 
(calibre increase by acidic CSF was 32.9 +. 4.2%, n=9 as compared to
31.1 + 4.3%, n=8 for acidic CSF containing 10“^M SCH 23390).
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9a.
9b.
Alterations in pial arteriolar calibre following the 
perivascular microapplication of SCH 23390 (10“  ^- 10”^H). 
There was no significant alterations in arteriolar calibre at 
any of the concentrations examined. Data are presented as mean 
calibre change +. SEM.
The effect of the concomitant microapplication of SCH 23390 
(10-^M - 10*"^M) on the arteriolar dilatation produced by 
apomorphine (10“^M) or SKF 38393 (lO^^M). The dilitatory 
response to both agonists is attenuated significantly by SCH 
23390 (lO^^M and 10~^M). Data are presented as mean calibre 
change + SEM. *p<0.05 with respect to agonist alone.
2. LOCAL CEREBRAL GLUCOSE UTILISATION
2.1 Effects of the Putatively Selective Dopamine Receptor Agonists
SKF 38393 and LY 171555 Upon Local Cerebral Glucose Utilisation
in the Rat.
2.1.1 General Results and Observations
The intravenous administration of the putatively selective D^ 
agonist SKF 38393 (1-30 mg/kg) provoked distinctive behavioural and 
physiological responses in experimental animals. Overt behavioural 
responses behaviours were characterised by frequent bouts of grooming 
and sniffing with occasional episodes of dyskinetic jaw movements 
interspersed with periods of quiescence (particularly at 10 and 30 
mg/kg). Animals receiving SKF 38393 (1 mg/kg) appeared more alert 
between bouts of grooming and sniffing as compared to animals treated 
with larger doses of the drug. At no time during the measurement did 
any animal receiving SKF 38393 display gnawing or any other 
stereotyped behavioural response. There was a transient, increase in 
arterial pressure immediately after administration of SKF 38393 with 
blood pressure returning rapidly to pre-drug levels (Appendix 2.1). 
At the time of administration of 2-deoxyglucose mean arterial 
pressure was not significantly different from control values. No 
significant alterations in core temperature, arterial blood gases or 
plasma glucose concentration were detected at any concentration of 
SKF 38393 examined.
Administration of the putatively selective D2  agonist LY 171555 
(0.1-5 mg/kg) was associated with characteristic changes in the 
behavioural and physiological status of the treated animals. Small 
doses of LY 171555 (0.1 mg/kg) resulted in intermittent episodes of 
sniffing and yawning. With increasing doses the sniffing behaviour 
was replaced by marked hyperactivity interspersed with intense and 
protracted gnawing of the lead support bricks. These behaviours were 
most marked with LY 171555 (0.5 mg/kg) with the intensity of the 
response subsiding at the higher doses. In addition to the 
behavioural changes described, low doses of LY 171555 (0.1 and 0.5 
mg/kg) provoked a mild hypotensive response which tended to persist 
throughout the experimental period at the 0.5 mg/kg dose (Appendix 
2.1). LY 171555 administration resulted in a dose-related increase 
in plasma glucose concentrations. However, even at the highest 
concentration of LY 171555 examined, (5 mg/kg) the increase in plasma 
glucose was small (<4mM) and remained relatively constant throughout 
the period of measurement.
There were minimal alterations in respiratory variables 
following the administration of SKF 38393 or LY 171555, with the 
exception of a slight acidosis at the lowest concentration of the D£ 
receptor agonist.
2.1.2 Local Cerebral Glucose Utilisation
The effects of the selective dopamine receptor agonists SKF 
38393 and LY 171555 upon function-related glucose utilisation in 59 
anatomically distinct regions of the rat brain are presented in
Appendix 2. There were a number of distinctive features in the 
distribution and dose dependency of the alterations elicited by each 
of these dopamine receptor agonists.
The administration of the Dj receptor agonist SKF 38393 failed 
to significantly modify the rate of glucose use in the majority of 
brain regions at any of the concentrations examined. In two brain 
areas (anterior cingulate cortex and anteromedial thalamic nucleus) 
SKF 38393 provoked dose-dependent reductions in glucose utilisation 
(Figure 10). In addition glucose use within the inferior olivary 
body and ventrolateral thalamic nucleus were affected by various 
concentrations of SKF 38393 although there was little evidence of 
true dose dependency in these responses (Figure 11). In 9 brain 
regions (including the stratum superficiale of the superior 
colliculus, the rostral neocortex and trigeminal nucleus) SKF 38393 
significantly increased glucose use at a single concentration, most 
commonly 1 mg/kg (Figure 11). These significant alterations in 
glucose use, however, were not dose-dependent. There was a tendency 
for similar though non-significant increases in glucose utilisation 
in many brain regions of animals receiving SKF 38393 (1 mg/kg). 
These may reflect the mild behavioural stimulation observed in these 
animals.
The administration of the D£ agonist LY 171555 (0.1 - 5 mg/kg) 
failed to significantly alter glucose use in the majority of brain 
regions investigated. In 24 of the 59 regions examined LY 171555 
failed to provoke any significant change in glucose use at any of 
the concentrations examined. However, in each of these 24 areas 
small reductions in glucose use (approximately 10%) were noted with
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Log-dose response curves from six brain area of the rat brain 
in which the rate of glucose utilisation was significantly increased 
by the intravenous injection of SKF 38393.
Data are presented as mean percentage change +. SEM. *p<0.05.
high concentrations of this !>£ agonist (Figure 12). In a further 13 
brain areas no significant alterations in glucose use were observed 
in those animals receiving 0 . 1  - 1 .5 mg/kg, although significant 
reductions (approximately 24%) were evident at the largest 
concentration examined (Figure 13). These 37 brain regions, in which 
glucose use was insensitive to the J>2 agonist, LY 171555, encompassed 
most of the brain and included the dorsal caudate nucleus, lateral 
habenula, all nuclei involved in the processing of auditory 
information, the anterior cingulate cortex and caudal neocortex.
In 22 brain areas LY 171555 consistently effected marked and 
dose-dependent alterations in glucose utilisation. Of these 22 
regions, 2 1  exhibited an increased glucose use whereas a reduction in 
glucose utilisation was observed only within the molecular layer of 
the hippocampus (Figure 14). The threshold for all significant 
increases in glucose use was in excess of 0 . 1  mg/kg with the maximal 
responses occurring at 0.5 mg/kg. At the largest concentration 
examined (5 mg/kg), the increase in glucose use provoked by LY 171555 
within these 2 1  areas were generally less than the maximal response 
occurring at 0.5 mg/kg. This tendency towards depressed glucose 
utilisation was observed throughout the CNS, both in regions which 
were sensitive and in those which were insensitive to modification by 
this D2  receptor agonist.
The administration of LY 171555 was associated with dose- 
related increases in glucose utilisation particularly in those areas 
of cortex and subcortex which subserve motor function (Figure 15). 
Within cortex, dose-related increases in glucose use were restricted
FIGURE 12
C *-No _
* s« c 
=  o
5 °
® Ito oo
J JpO w
20
0 ■
-2 0  J
r
0.1
Parietal Cortex
1
( mg/kg )
1
10
Lateral Habenular Nucleus
-20 -1
0.1
( mg/kg )
"1
10
O _  20 i
~ c 
•.= o 3 «
© E co o o ± - 
o 
2  &  
O  w
0 -
-20 J
P"
0.1
Lateral Amygdala
( mg/kg )
” 1
10
-20
0.1
Hypothalamus
1
( mg/kg )
10
Log-dose response curves from four areas of the rat brain in 
which the rate of glucose utilisation was not significantly affected 
by LY 171555 at any of the concentrations examined (0.1 - 5 mg/kg). 
Data are presented as mean percentage change +. SEM.
FIGURE 13
« 8  
(0 c 
2  ° 5  ° 
© E (0 o  
o  i:
=2 JPO w
f= 0 -
-20
-40
Anterior Cingulate Cortex
0.1
( mg/kg )
10
0 -
-20 -
-40 -*
Medial Prefrontal Cortex
r
0.1
n
10
( mg/kg )
Medial Geniculate Body
13 o W iz
~  c
5  8
°  E
§ J
a £
0 -
-20
-40
0.1
( mg/kg )
n
10
0 -
-2 0 -
-40 -1
Interpeduncular Nucleus 
T X
o.i
( mg/kg )
1
10
c  ^
•S o  
(3 3^ 
.2 c
■2 O
•I
8  2
§■# 
O w
0 -
-20 -
-40
Dorsal Raphe Nucleus
o.i
( mg/kg )
1
10
r
0.1
Mammillary Body
o
-2 0 -
-40 J
1
10
( mg/kg )
Log-dose response curves from six areas of the rat brain which 
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Representative autoradiographs from coronal sections of rat 
brain at the level of the medial geniculate bodies. Glucose use is 
proportional to relative optical density in the autoradiograms. A 
c r e s y l  v i o l e t  s t a i n e d  s e c t i o n  is i n c l u d e d  (Fig. B) for the 
h i s t o l o g i c a l  i d e n t i f i c a t i o n s  of the m o l e c u l a r  l a y e r  of the 
hippocampus (mol), the pars compacta (SNc) and pars reticulata (SNr) 
of the substantia nigra. (A) Saline control: the molecular layer
of the hippocampus and the pars compacta of the substantia nigra 
appear as well defined bands of high optical density with respect to 
surrounding tissue. (C) SKF 38393 (30 mg/kg): pars compacta of the
substantia nigra and molecular layer of the hippocampus remain well 
defined. (D) LY 171555 (0.5 mg/kg): a focal decrease in glucose
use within the molecular layer of the hippocampus results in the loss 
of the distinctive band of high optical density observed in controls. 
A similar loss of definition within the pars compacta of the 
substantia nigra is due to a relatively more pronounced increase in 
glucose use in the adjacent pars reticulata of the substantia nigra 
(see Fig. 4).
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intravenous administration of low concentrations (0.5 mg/kg) of LY 
171555. Data are presented as mean percentage change from control 
+ SEM. *p<0.05.
to sensory motor (by 54% following the administration of 0.5 mg/kg LY 
171555) and area 8  of frontal cortex (37%). These alterations were 
organised in a columnar fashion and were confined not only to layer 
IV but also to layer VI (see Figure 16). Marked increases in glucose 
use were also evident within the basal ganglia and motor nuclei of 
the thalamus. Of these, the largest increases in glucose use were 
found within the subthalamic nucleus (by 64%: Figure 17)
ventrolateral thalamic nucleus (45%) and red nucleus (39%: Figure
14). Proportionately smaller increases in glucose use occurred in 
the globus pallidus (30%) and pars reticulata of the substantia nigra 
(33%: Figure 18a). In contrast glucose use in the pars compacta of
the substantia nigra was not significantly altered (Figure 18a). 
Within the caudate nucleus glucose utilisation was topographically 
heterogeneous. Dose-dependent increases occurred in the ventral 
aspect of the caudate nucleus (19%) whilst the dorsal portion 
remained relatively insensitive to LY 171555 (Figure 18b).
Some of the most pronounced increases in glucose use following 
LY 171555 administration were found within the medulla, in particular 
the spinal nucleus of the trigeminal nerve (64%) and cuneate nucleus 
(44%: Figure 19).
Small punctate areas of increased glucose use were observed in 
cerebellar cortex after the administration of this D£ receptor 
agonist (see Figure 19). However the variability in the anatomical 
position of these alterations precluded accurate densitometrical 
analysis.
FIGURE 16
Representative autoradiographs ffom coronal brain sections at 
the level of the caudate nucleus. Glucose use is proportional to 
r e l a t i v e  o p t i c a l  d e n s i t y  w i t h i n  the a u t o r a d i o g r a m s .  The 
acetylcholinesterase stained section (Fig. B) demonstrates the 
heterogenous nature of acetylcholinesterase activity w i t h i n  the 
caudate nucleus. (A) Saline controls: within sensory motor cortex
layer IV appears as a band of uniformly high optical density relative 
to surrounding cortical layers. Optical density within the caudate 
appears relatively homogenous. (B) SKF 38393 (30 mg/kg): no marked
alterations in relative optical density in caudate nucleus and layer 
IV of sensory motor cortex relative to saline controls. (D) LY 
171555 (0.5 mg/kg): note the laminar bands of relatively increased
optical density (and glucose use) which traverse sensory m o t o r  
cortex. These increases in relative optical density are evident both 
in layer IV and in layer VI of cortex. In addition, the caudate 
nucleus appears regionally heterogenous w ith marked increases in 
glucose use (and relative optical density) within the ventromedial 
portion).
Representative autoradiographs obtained from coronal sections 
of rat brain at the level of the subthalamic nucleus. Glucose use is 
proportional to relative optical density autoradiographs. A cresyl 
violet stained section (Fig. B) is included for the histological 
identification of the subthalamic nucleus (STN). (A) Saline 
control: optical density of the subthalamic nucleus appears similar
to the adjacent thalamus. (C) SKF 38393 (30 mg/kg): no significant
alterations in relative optical density relative to controls are 
evident. (D) LY 171555 (0.5 mg/kg): the marked elevation in
glucose use within the subthalamic nucleus is evidenced by a relative 
increase in optical density within this area.
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18a. Log-dose response curves from the substantia nigra pars 
compacta ( O )  and pars reticulata ( • )  following the 
intravenous administration of LY 171555.
18b. Log-dose response curves from the dorsal [ □ ] and ventral ■ 
portions of rat caudate nucleus following the intravenous 
adminstration of LY 171555.
FIGURE 19
Cu
Sp.V
Representative autoradiograms from coronal brain sections at 
the level of p o s t e r i o r  c e r e b e l l u m .  G l u c o s e  u t i l i s a t i o n  is 
proportional to relative optical density within the autoradiogram. A 
c r e s y l  v i o l e t  s t a i n e d  s e c t i o n  (Fig. B) is i n c l u d e d  for the 
identification of the cuneate nucleus (Cu), and the spinal nucleus of 
the trigeminal nerve (Sp.V). (A) Saline control: both the spinal
trigeminal and cuneate nuclei are indistinguishable from the 
surrounding medullary tissue. Cerebellar cortex appears uniform in 
optical density. (C) SKF 38393 (30 mg/kg). The slight increase in 
relative optical density of the spinal trigeminal and cuneate nuclei 
reflect the mild stimulation in glucose use in these areas noted at 
this concentration of SKF 38393. C e r e b e l l a r  c o r t e x  r e m a i n s  
relatively uniform in optical density. (D) LY 171555 (0.5 mg/kg). 
Marked increases in glucose use within the cuneate and trigeminal 
nuclei are evidenced by the high optical density of these nuclei 
relative to surrounding tissue. In addition note the small punctate 
areas of increased optical density within cerebellar cortex.
2.2 Effects of the Putatively Selective Dopamine D^ Antagonist, SCH
23390 on Local Cerebral Glucose Utilisation in the Rat.
2.2.1 General Results and Observations
The intravenous injection of the putatively selective 
receptor antagonist SCH 23390 (0.05 - 1 mg/kg) failed to produce 
significant alterations in any of the cardiovascular or respiratory 
variables monitored as compared to vehicle treated control animals 
(Appendix 3). Animals that received the largest concentration of SCH 
23390 (1 mg/kg) displaced significantly greater arterial plasma 
glucose concentrations than vehicle treated rats. Since the elevated 
glucose levels were within the "normal" physiological range and did 
not vary significantly over the period of glucose use determination, 
the principles of the 2 -deoxyglucose method were upheld.
The administration of SCH 23390 resulted in dose-dependent 
reductions in spontaneous motor activity. Immediately following 
infusion of SCH 23390 spontaneous motor activity ceased while the 
animal remained quiet, its eyes closed and ears pricked. In animals 
receiving 1 mg/kg this behaviour persisted throughout the entire 
experimental period, (85 minutes). In contrast, appparently normal 
locomotor behaviour had returned after 30 minutes in those animals 
receiving 0.05 mg/kg of SCH 23390.
2.2.2 Local Cerebral Glucose Utilisation
The effects of SCH 23390 on local rates of glucose utilisation
in 59 anatomically discrete regions of the rat brain are presented in 
Appendix 3.
The rate of glucose use, within 50 of the 59 brain regions 
examined, was minimally altered by SCH 23390 at any of the 
concentrations tested. Highly focal alterations in glucose 
utilisation were elicited by 0.1 mg/kg SCH 23390, with prominent 
increases in glucose use evident within the lateral habenula (24%: 
Figure 20) and nucleus accumbens (36%), and these were evident in the 
autoradiograms. In addition significant reductions in glucose 
use were observed within the posterioventromedial nucleus of the 
thalamus (-13%) and pars reticulata of the substantia nigra (-12%).
The largest concentration of SCH 23390 examined (1 mg/kg) 
provoked increases in glucose use within the nucleus accumbens and 
the lateral habenula which were measurably less than those produced 
by 0.1 mg/kg. This tendency towards depressed glucose use 
(approximately 1 0 %) was evident throughout all brain structures 
examined but was most prominent and attained significance within the 
thalamus [posterior nucleus (-13%), ventromedial nucleus (-20%), 
posterioventromedial nucleus (-16%), medial geniculate body (-2 0 %) 
the superficiale layers of the superior colliculus (-16%)], visual 
cortex (-19%) and the pars reticulata of the substantia nigra (-14%) 
(Figure 21).
No significant alterations in glucose use were evident 
following 0.05 mg/kg of SCH 23390 in any brain region which was 
examined.
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FIGURE 20
Saline
Control
SCH 23390 
( 0.1mg/kg )
*
100 JL
I i -\V i i I
0 0 .0 5 0.1 1.0
SCH 23390 (m g/kg)
Effect of SCH 23390 upon Local Glucose Utilisation in 
the Lateral Habenular Nucleus.
LEGEND TO FIGURE 20
Upper Left. Autoradiograph at the level of the habenular nuclei of a 
saline-treated control rat. The lateral habenula can be identified 
as the well defined band of relatively high optical density, lying on 
top of the medial thalamus. The optical density of the lateral 
habenula appears similar to that of the overlying cortex.
Upper Right. Autoradiograph at the level of the habenular nuclei of 
a rat which had received 0.1 mg/kg, SCH 23390. Glucose use is 
markedly increased and appears much darker on the autoradiograph than 
the overlying cortex.
Lower. Log-dose response curve of glucose utilisation in the lateral 
habenular nucleus following the administration of SCH 23390. Data 
are presented as mean glucose use ( umol.l00g-^min- )^ +. SEM. 
*p<0.05.
FIGURE 21
40
2 -  30 -
2 0  -
1 0 -
0
N u c l e u s  Accumbens 
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T-*V i l
0.05 0.1
SCH 23390 ( mg/kg )
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2 -io
-20 J
Posterioventromedial Thalamic 
Nucleus
I A I 1 I
0 0.05 0.1
SCH 23390 ( mg/kg )
- 1
1.0
Log-dose response curves from 2 areas of the rat brain (nucleus 
accumbens and posterioventromedial thalamic nucleus) which displayed 
significant alterations in rates of glucose use following the 
administration of SCH 23390. Data are presented as mean percentage 
from control +. SEM. *p<0.05.
2.3 Interaction Between LY 171555 and SCH 23390
2.3.1 General Results and Observations
The prior administration of SCH 23390 (0.5 mg/kg) completely 
abolished the stereotyped behaviour produced by LY 171555 (0.5 
mg/kg). Upon receiving LY 171555 rats became transiently hyperactive 
with jerking and side-to-side movements of the upper body. 
Thereafter, the hyperactive response was progressively replaced by 
extended periods of quiescence interspersed with bouts of sniffing. 
No animal receiving both drugs displayed the gnawing or biting 
behaviours characteristic of D2  agonist administration at any time 
following LY 171555 administration.
Cardiovascular and respiratory parameters were unaffected by 
interaction of SCH 23390 and LY 171555 (Appendix 3.1).
2.3.2 Local Cerebral Glucose Utilisation
The effects of the interaction between the D£ receptor agonist 
LY 171555 (0.5 mg/kg) and the Dj antagonist SCH 23390 on local 
cerebral glucose utilisation are presented in Appendix 3.
Analysis of co-variance (of repeated measured form) revealed 
that pretreatment with SCH 23390 significantly altered the effect of 
D2  agonist LY 171555 on local cerebral glucose utilisation (P = 
0.0001). However, inter-regional analysis demonstrated that SCH 
23390 pretreatment did not affect uniform changes in glucose use
throughout the brain (Greenhouse Geisser probability = 0.0079). 
Further analysis of this regional heterogeneity performed by means of 
a Student's-t comparison between the LY 171555 (agonist) and the SCH 
23390 + LY 171555 (interaction) groups (Appendix 3) revealed that the 
prior administration of SCH 233900 significantly affected glucose use 
in 29 of the 59 brain regions examined.
SCH pretreatment significantly attenuated the widespread 
increases in glucose utilisation produced by LY 171555 in those areas 
of cortex and subcortex which subserve somatosensory and motor 
functions (Figure 22). Of these, the most pronounced reductions in 
glucose use were observed within sensory motor cortex (-40% with 
respect to LY 171555 treatment value), ventrolateral thalamus (-34%) 
and subthalamic nucleus (-32%). In addition, SCH 23390 pretreatment 
produced significant reductions in glucose utilisation within a 
number of brain areas which were not sensitive to LY 171555 or SCH 
23390 alone. In particular, the prior administration of SCH 23390 
depressed glucose use in all rostral cortical areas examined, 
including the anterior cingulate cortex (-19%). The decrease in 
glucose use within the anterior cingulate cortex was accompanied by 
a proportionately similar reduction in the anteromedial thalamus 
(-20%). Reduced functional activity within frontal cortical areas 
was also reflected in lower rates of glucose utilisation within the 
white matter tracts of the corpus callosum. The prior 
admininstration of SCH 23390 significantly increased glucose use in 
only 3 of the 59 areas examined, namely the nucleus accumbens (+24%), 
lateral habenular nucleus (+23%) and superior olivary body (+21%).
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Attenuation of the increases in glucose use produced by LY 
171555 (0.5 mg/kg, ■ ) by the prior administration of the 
antagonist SCH 23390 (0.05 mg/kg □ ) in four brain areas; sensory 
motor cortex (SMc), subthalamic nucleus (STN), pars reticulata of the 
substantia nigra (SNr) and globus pallidus (GP). In each of the 
brain areas the antagonist pretreatment significantly attenuated the 
glucose use response. Data are presented as mean percentage change 
from saline-treated control values + SEM.
3. FUNCTIONAL PROFILES OF DOPAMINERGIC ACTIVITY
Having established the reproducibility and reliability of the 
'fingerprinting' approach for drug analysis (see Appendix 1), this 
method was used to examine and compare the effects of dopamine 
receptor agonists, and antagonists upon local cerebral glucose 
utilisation.
3.1 Agonist Studies
In this study the data sets for the SKF 38393, LY 171555 and 
apomorphine (generated for the reproducibility study in Appendix 1) 
treatments were analysed using the 'f' function and hierarchies of 
regional 'f' values constructed. In the previous section it was 
noted that widespread reductions in glucose use were observed at the 
highest concentrations of LY 171555 examined (5 mg/kg). As these 
widespread reductions in glucose use occurred at concentrations which 
were higher than that required to promote stereotypy (a response 
normally associated with J>2 receptor activation), they may reflect 
the action of LY 171555 on mechanisms other than via dopamine D£ 
receptors. Non-specific drug effects would confound the 
interpretation of the drug's actions and so the 5  mg/kg concentration 
was omitted from the analysis.
The intravenous administration of the receptor agonist, SKF 
38393 resulted in a relatively narrow range of 'f' values (0.18 - 
0.005). Inspection of the hierarchy of 'f' values resulted from SKF 
38393 (1 - 30 mg/kg) administration confirmed the view that the 
anteromedial thalamus and anterior cingulate cortex (ranked 59 and 58 
respectively) were profoundly influenced by this Dj receptor agonist,
whereas sensory motor cortex (ranked 8  of the 5 9  areas) and 
subthalamic nucleus (5) were minimally affected (Table 5). As noted 
previously the majority of brain areas were insensitive to SKF 38393 
administration. As a consequence, those areas in which significant, 
though non-dose dependent, alterations in glucose use that were 
observed following Scheffe analysis (Appendix 2) were generally found 
to occupy high ranking positions (i.e. trigeminal nucleus (57), 
ventrolateral thalamus (55), superficial layers of the superior 
colliculus (51).
Administration of the D 2  agonist LY 171555 (0.1 - 1.5 mg/kg) 
produced a wider range of 'f' values (0.49 - 0.0006) (Table 6 ). In 
accordance with Scheffe analysis (Appendix 2) the most prominent 
responses, and consequently highest ranking positions, were found in 
brain areas subserving motor function; trigeminal nucleus (59) 
subthalamic nucleus (58), sensory motor cortex (56). Anteromedial 
thalamus (43) and anterior cingulate cortex (30) possessed 
intermediate ranking positions whereas the lateral habenula was 
towards the bottom of the hierarchy (2 ).
Of the three dopamine agonists examined, apomorphine produced 
the most marked behavioural and metabolic responses (Appendix 4). 
Consequently, the range of 'f' values (2.003 - 0.005) was greater 
than than produced by the other two agents. Inspection of the 
hierarchy of regional responsiveness to apomorphine administration 
(Table 7) revealed that the pattern of alterations in glucose use 
produced by this mixed receptor agonist contained elements of
both the Dj and D2  agonist responses. Hence, glucose use was 
increased within motor areas as was observed following LY 171555 
administration. Similarly, reductions in functional activity within 
the anterior cingulate cortex and anteromedial thalamus associated
with SKF 38393 administration also occurred following apomorphine 
administration. However, the action of apomorphine upon local 
cerebral glucose use was not merely a composite of the SKF 38393 and 
LY 171555 responses. Although, both apomorphine and LY 171555 
increased glucose use within the basal ganglia (substantia nigra, 
caudate nucleus, globus pallidus, subthalamic nucleus and red nucleus 
inter alia), the hierarchy of regional responses produced by these 
two agonists were markedly different.
The reliability of each data set was examined by comparing the 
original values with 100 simulated data sets (fl - flOO) having 
precisely the same mean and variability structures (Efron, 1982). 
For each drug the correlation between the original and simulated data 
was high; indicating that the hierarchy constructed for each drug 
was reliable.
Correlation (F^, fp, i = 1-100 
SKF 38393 = 0 . 9 2
LY 171555 = 0.99
Apomorphine = 0.94
The initial impression that the three dopamine receptor agonists 
provoked markedly different patterns of regional responsiveness was 
borne out by plots of the 'f' values (Figure 23). Correlation 
analysis between the sets of 'f' values confirmed this view.
Correlation (SKF 38393, LY 171555) = 0.085
Correlation (SKF 38393, Apomorphine) = 0.161
Correlation (LY 171555, Apomorphine) = 0.241
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The reliability of these correlation values were examined by 
the Bootstrapping approach and revealed that simulated correlations 
were close to, and normally distributed about these measured 
correlation values. Hence, the measured correlation values are 
probably good approximations of the true relationship.
3.2 Antagonist Studies
The 'fingerprinting' approach was found to be sufficiently 
robust to permit the comparison of deoxyglucose data generated by 
different investigators (Appendix 1). The method, therefore, was 
used to compare the pattern of altered glucose use provoked by the 
putatively selective Dj receptor antagonist SCH 23390 (0.05 - 1 
mg/kg: Table 8 ) with that generated for the classical neuroleptic 
haloperidol (0.01 - 1 mg/kg: Table 9) from the published data of
McCulloch et al. 1982.
The administration of Dj selective concentrations of SCH 23390 
had little effect on local cerebral glucose utilisation in the 49 of 
the 59 brain regions examined (Table 8 ). Consequently, most of the 
'f' values were tightly grouped around the median value of 0 . 0 2  
(Figure 24a). However, a few brain areas did display 
moderate/minimal sensitivity to SCH 23390 (Table 8 ). Of these, the 
most prominent responses occurred within the nucleus accumbens (f = 
0.177, rank number 59), lateral habenular nucleus (f = 0.088, rank 
number 58) and motor nuclei of the thalamus (Table 8 ).
The pattern of altered glucose use provoked by haloperidol was 
markedly different from that produced by SCH 23390 (Figure 24). 
Haloperidol provoked more widespread alterations on function related 
glucose use, than SCH 23390 with 21 of the 35 regions examined 
displaying some degree of sensitivity to this D£ antagonist (Table 
9). The brain region in which glucose use was most affected by 
haloperidol administration was the genu of the corpus callosum (f = 
0.343). By contrast SCH 23390 had little effect upon glucose use 
within this brain area (f = 0.028). The lateral habenular nucleus, 
ventrolateral thalamus and nucleus accumbens were among the most 
sensitive brain areas to alteration by haloperidol or SCH 23390 
(Tables 8  and 9). However, although haloperidol and SCH 23390 were 
equipotent in provoking increases in glucose use within the nucleus 
accumbens, the antagonist proved to be only 1/3 as potent as 
haloperidol in the lateral habenula and ventrolateral thalamus 
(Figure 25 a)•
Marked differences in responses elicited by SCH23390 and 
haloperidol were also evident within the substantia nigra. In the 
pars compacta the overall response to haloperidol was some 15 fold 
greater than to SCH 23390 (f = 0.007), while in the pars reticulata 
glucose use was preferentially affected by the antagonist, SCH 
23390 (f = 0.043 for SCH 23390, f = 0.021 for haloperidol (Figure 
25 b).
The reliability of the SCH 23390 and haloperidol data sets were 
determined by the Bootstrapping approach (with the measured 'f' 
values compared with 100 simulations of the data sets). The
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FIGURE 24
SCH 23390
median v a l u e 0.02
HALOPERIDOL
median value = 0.07
Distribution of ' t '  values following the administration of SCH 
23390 and haloperidol.
FIGURE 25
□  Haloperidol 
H  S C H  23390
N Accumbens Lateral Habenula VI Thalamus
Comparison of the effects of the d opamine 
receptor antagonists SCH 23390 and haloperidol 
upon local cerebral glucose utilisation in 
three brain; the nucleus accumbens, lateral 
habenula and ventrolateral thalamic nucleus*
resulting correlations between the simulated and measured data sets:
Correlation (F^, f^)s i = 1-100 
SCH 23390 = 0.704
Haloperidol = 0.668
These analyses revealed that the hierarchy was well maintained, 
although in each case the product moment correlation coefficient was 
less than would have been expected.
A plot of the 'f' values for the 35 brain regions common to 
both the SCH 23390 and haloperidol studies suggested that the 
hierarchy of altered glucose use produced by these agents were 
dissimilar (Figure 26 a): a view confirmed by correlation analysis
(correlation coefficient = -0.005). Evaluation of this correlation 
value by the Boostrapping approach revealed that the simulated values 
were close to (median value -0.009) and roughly normally distributed 
about the measured value for the SCH 23390 haloperidol comparison 
(Figure 26 b).
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LEGEND TO FIGURES 26 a and 26 b
26a. Relationship between the hierarchies of regional responsiveness 
to SCH 23390 and haloperidol. Each data point represents the 
'f' value generated from the dose response curves of a single 
brain region to haloperidol and SCH 23390.
26b. The reliability of the ('f' SCH 23390, 'f' haloperidol) 
correlation, as analysed by the Bootstrapping procedure. The 
frequency and distribution curve was constructed and 1 0 0  
correlation estimates obtained using simulations of the SCH 
23390 and haloperidol data sets (see pages 87-89 for 
description).
LEGEND TO TABLES 5 - 9
Hierarchies of responsiveness were constructed for each drug 
treatment by ranking the values of the 'f' function for each brain 
region. Brain regions were assigned to one of the five interval 
groups.
Extremely Sensitive 
Sensitive
Moderately Sensitive 
Minimally Sensitive 
Insensitive
values of 'f' greater than 0.4 
values of 'f' less than 0.4
values of 'f' less than 0 . 2
values of 'f' less than 0 . 1
values of 'f' less than 0.05
Brain areas are ranked from least sensitive (rank number 1) to
/
most sensitive.
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4. EFFECTS OF SKF 38393 AND LY 171555 UPON LOCAL CEREBRAL BLOOD
FLOW AND THE FLOW/GLUCOSE USE RELATIONSHIP 
4.1 General Results and Observations
Administration of the selective agonist SKF 38393 and D£ 
agonist LY 17155 resulted in the characteristic alterations in 
behaviour, as described previously: SKF 38393 (30 mg/kg) provoked an 
increase in the frequency and intensity of episodic sniffing and 
licking behaviour whereas the administration of LY 171555 produced 
intense and protracted gnawing of the lead support bricks. With both 
agents the characterisitic behavioural patterns persisted throughout 
the experimental period. Neither SKF 38393 nor LY 171555 affected 
significant alterations in cardiovascular or respiratory status at 
the time of blood flow measurement (Appendix 4:1). Rectal 
temperature was maintained close to 37°C by means of a heating lamp.
4.2 Local Cerebral Blood Flow
The effects of the putatively selective Dj agonist SKF 38393 
(30 mg/kg) and D£ receptor agonist LY 171555 (0.5 mg/kg) on the local 
levels of blood flow in 59 anatomically discrete brain regions are 
presented in Appendix 4.
The D£ receptor agonist LY 171555 affected significant 
increases in local blood flow within 18 of the 5 9  brain areas 
examined. Of these 18 regions, 15 primarily subserve motor function
(viz. sensory motor cortex, basal ganglia and motor thalamic nuclei). 
In addition to these areas, significantly elevated levels of blood 
flow were found within the visual cortex, basolateral nucleus of the 
amygdala and cerebellar white matter (Figure 27).
SKF 38393, the selective receptor agonist failed to provoke 
significant alterations in local blood flow in 52 of the 59 brain 
regions under investigation. Following SKF 38393 administration 
blood flow was significantly reduced in 7 areas (anterior cingulate 
cortex, anteromedial thalamus, nucleus accumbens, mamillary body, 
visual cortex) and (the lateral nucleus of the amygdala).
4.3 Relationship Between Local Blood Flow and Glucose Utilisation
As discussed previously there exists a close correlation 
between local levels of blood flow and metabolic rate under normal, 
physiological conditions. Thus, areas of highest metabolic activity 
(viz. primary auditory structures) receive the highest levels of 
blood flow whilst areas of intermediate (medial geniculate body) and 
low metabolic rate (white matter) receive correspondingly 
intermediate and low levels of perfusion.
By plotting average blood flow against average glucose use 
values for each of the 59 brain regions examined revealed, as 
expected, a close linear relationship between these two parameters in 
saline treated control animals (Figure 28a). The ratio of average 
blood flow to glucose use, obtained from the gradient of the best 
fitting straight line was 1.78. Using the same procedure ratios of 
1.77 and 1.92 were calculated for the SKF 38393 and LY 171555 treated 
groups respectively (Figure 28 b,c).
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+ SEM.
LEGEND TO FIGURE 27
Upper:
Significant increases in blood flow and glucose use within the 
sensory motor cortex following the administration of the D£ agonist 
LY 171555. By contrast, SKF 38393 had little effect on blood flow or 
glucose use in sensory motor cortex.
Middle:
Local blood flow and glucose use in parietal cortex are 
minimally altered by SKF 38393 and LY 171555.
Lower:
Parallel reductions in blood flow and glucose use within the 
anterior cingulate cortex following the administration of the D^ 
agonist SKF 38393. By contrast, LY 171555 had little effect upon 
blood flow or glucose use within the anterior cingulate cortex.
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The non-independent nature of the data sets generated by these 
autoradiographic techniques precludes the use of linear regression 
analysis to test the relationship between blood flow and glucose use 
(McCulloch et al. 1982). A more appropriate form of statistical 
analysis has been described recently (McCulloch et al. 1982). To 
minimise the problem of heteroscedasticity this model requires that 
data sets are transformed to their logarithms. A plot of transformed 
data reveals a linear relationship between mean flow and glucose use 
having unit slope and intercept (Figure 29). Thereafter, 
comparisons of drug treatments on the flow-glucose reltio.nship can be 
performed by comparison of the values for each treatment.
Analysis of variance between the treatment groups revealed that 
neither SKF 38393 nor LY 171555 significantly altered the 
relationship between flow and glucose use. Moreover, analysis of the 
variance within each group failed to identify any brain region where 
the flow-glucose use relationship deviated significantly from derived 
line. Thus, the fundamental relationship between blood flow and 
glucose utilisation remained intact and unaltered by the 
administration of selective or D£ receptor agonists.
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4.4 Relationship Between Local Blood Flow and Glucose Utilisation
in the Caudate Nucleus
The effects of the putatively selective D^ agonist SKF 38393 
(30 mg/kg) and D£ agonist LY171555 (0.5 mg/kg) upon local rates of 
blood flow and glucose utilisation within 1 0  subregions of the 
caudate nucleus are presented in Table 5:8.
The administration of SKF 38393 failed to alter glucose use 
significantly in any of the 1 0  subregions of the caudate nucleus 
examined. In contrast, significant reductions in blood flow were 
observed in two of the three levels (middle and anterior). At each 
of these two levels blood flow was reduced in all four quadrants, 
although the reductions in tissue perfusion were most prominent 
within dorsomedial portions (Figure 30).
LY 171555 administration failed to provoke significant 
alterations in mean values of glucose use or blood flow in any of the 
three levels examined. However, each level the alteration in glucose 
use was not uniformly distributed throughout the nucleus. Dose- 
related increases in glucose use within the ventral, but not dorsal, 
caudate nucleus following LY 171555 administration, a significant 
increase in glucose use was observed within the ventromedial aspect 
(+19%). Proportionately similar increases in glucose use were 
observed within the ventrolateral quadrant (+15%) at the same level 
and in the ventral portion (+19%) of the more caudal, (peripallidal) 
level although in both areas the alteration in glucose use just 
failed to attain statistical significance after Bonferroni correction 
for multiple comparisons. There was no evidence of medial-lateral
FIGURE 30
Representative autoradiographs from coronal sections of rat 
brain at the mid caudate level.
A) Saline treated control a n i m a l ( B l o o d  Flow). Optical density 
(.and blood flow) appears relatively homogeneous throughout the 
caudate nucleus.
B) LY 171555 (0.5 mg/kg) treated animal (Blood Flow). Marked 
heterogeneity in optical density (and blood flow) within the caudate 
nucleus, with the ventrolateral portion notably darker than the rest 
of the nucleus.
C) Saline treated control a n i m a l ( G l u c o s e  Use). Optical density 
(and glucose use) appear relatively homogeneous throughout the 
caudate nucleus.
1 7 1 5 5 5  (0.5 m g / k g )  t r e a t e d  a n i m a l  ( G l u c o s e  Use). 
Heterogeneous pattern of optical density evident within the caudate 
nucleus w ith marked increases in optical density (and Glucose Use) 
within the ventromedial but not ventrolateral portions of the 
nucleus. This pattern of altered glucose use is evidently different 
from the blood flow response evoked by LY 171555 within the caudate 
nucleus (B).
differences in glucose use following LY 171555 administration. In 
contrast marked medial to lateral differences in blood flow were 
immediately apparent upon visual inspection of the autoradiograms of 
LY 171555 treated animals (Figure 31). At the middle caudate level 
LY 171555 provoked a large (+57%) focal increase in blood flow in the 
ventrolateral quadrant but failed to significantly affect perfusion 
rate in the adjacent ventromedial portion (Figure 31). Similarly, at 
the most rostral level LY 171555 a significant reduction (-18%) in 
blood flow within the mediodorsal portion while increasing flow in 
dorsolateral quadrant (Figure 32).
An examination of the flow-glucose use relationship within the 
various subregions of the caudate nucleus revealed a complex pattern 
of responses (Figure 32). In six of the ten areas examined neither 
flow nor glucose use were significantly affected following LY 171555 
administration. In two subregions (ventral and ventrolateral 
portions at the caudal and medial levels respectively) both flow and 
glucose use increased, however, in both areas the relative 
circulatory response was some threefold greater than the increase in 
metabolism. In a third region LY 171555 affected significant 
reductions in local blood flow but failed to alter glucose use. 
Similarly, in the one area where glucose use was significantly 
increased (the ventromedial quadrant of the middle level), blood flow 
was unaffected. These data suggest indicate that uncoupling of the 
flow-glucose use relationship may occur within discrete subregions of 
the caudate nucleus. This view was borne out by analysis of 
covariance between the drug and saline treated groups. In saline- 
treated animals the relationship between blood flow and glucose use
was maintained. Furthermore, the flow/glucose use relationship did 
not deviate significantly from the derived line in any of the caudate 
subregions examined. In contrast, no significant correlation could 
be demonstrated between blood flow and glucose use in the caudate of 
LY 171555 or SKF 38393 treatment groups.
Thus, although the overall flow-glucose use relationship is 
maintained, within the caudate nucleus and in the brain as a whole 
focal uncoupling occurs within discrete subregions of the caudate 
nucleus following the administration of SKF 38393 or LY 171555.
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CHAPTER IV
DISCUSSION
The concept that cerebral blood flow is regulated to meet the 
metabolic requirements of the brain was first proposed almost a 
century ago (Roy and Sherrington, 1890). This close relationship 
between cerebral blood flow and metabolic rate has been demonstrated 
under a wide variety of physiological and drug-induced conditions 
(Purves, 1972; Sokoloff, 1981; Des Rosiers et al. 1974; McCulloch 
and Kelly, 1982; Kelly and McCulloch, 1983 c). However, in recent 
years it has been demonstrated that a number of pharmacologically 
diverse agents (anaesthetics, calcium antagonists, neurotoxins and 
prostaglandin synthetase inhibitors) can fundamentally alter the 
relationship between flow and metabolism by acting directly on the 
cerebral vasculature (Celik et al. 1982; Mies et al. 1981; Mohammed 
et al. 1985; McCulloch et al. 1982 d).
Dopamine receptors mediate relaxation of vascular smooth 
from renal, mesenteric and splenic beds (Goldberg and Toda 1975; 
Schmidt and Imbs, 1980; Brodde, 1982; Schmidt et al. 1986). In 
these peripheral vascular beds the administration of dopamine 
receptor agonists is associated with increases in tissue blood flow 
(McDonald and Golberg, 1963; Goldberg et al. 1986). The presence of 
dopamine neurons innervating cerebral arterioles would suggest that 
dopamine receptor agonists may act directly on receptors on the 
cerebral vasculature to increase cerebral blood flow. Indeed, a
direct vasomotor action has been advocated to account for the 
excessive increases in cerebral blood flow relative to metabolic rate 
that have been observed by many authors following the administration 
of dopamine receptor agonists (Carlsson et al. 1975; Nahorski and 
Rogers, 1976; Berntman et al. 1978; Ingvar et al. 1983; Lindvall 
et al. 1982; Leenders et al. 1985). However, this view has been 
challenged by authors who have reported alterations in blood flow 
parallel to those of metabolic rate, both in magnitude and time 
course (McCulloch et al. 1982 a). These latter authors advocate that 
the alterations in cerebral blood flow observed following dopamine 
receptor agonist administration occur as an indirect consequence of 
drug-induced changes in metabolic rate.
In this thesis I have sought to examine systematically the 
relative importance of the cerebrovascular and metabolic components 
of the blood flow response elicited by new and highly selective 
dopamine receptor agonists. The studies performed were threefold. 
In the first series of experiments, I examined the vasomotor 
responses elicited by the putatively selective Dj agonist SKF 38393 
and receptor agonist LY 141865 upon feline pial arterioles in
situ. In the second series of experiments the 2-deoxyglucose
quantitative autoradiographic technique was used to characterise the 
functional consequences associated with the pharmacological 
manipulation of and D2  receptor subpopulations. Finally, in the 
third section the influence exerted by dopamine receptors upon local 
cerebral blood flow and on the relationship between flow and glucose 
use was investigated.
1. DOPAMINE RECEPTOR SUBTYPES AND THE CEREBRAL CIRCULATION: 
ACTIONS ON CEREBROVASCULAR SMOOTH MUSCLE
Dopamine receptors mediating relaxation of cerebrovascular 
smooth muscle have been demonstrated in isolated cat middle cerebral 
arteries (Edvinsson et al. 1978) and on the cerebrovasculature of a 
variety of other species including man (Toda, 1976, 1983; Forster et 
al. 1983; Oudart et al. 1981, 1982). The presence of dopamine 
receptors mediating vasodilatation of the cerebrovasculature is 
fundamental to the argument that dopamine receptor agonists increase 
cerebral blood flow primarily through an action on cerebrovascular 
(Berntman et al. 1978; Toda 1983; Leenders et al. 1983, 1984, 1985; 
Ingvar et al. 1983; Carlsson et al. 1975). However, by equating the 
vasomotor responses produced by dopamine receptor agonists in 
isolated vessel preparations, with the alterations in cerebral tissue 
perfusion observed in vivo, the studies advocating direct vascular 
responses are open to criticism.
Inherent in the vascular hypothesis is the assumption that the 
vessels under study are representative of the cerebral circulation as 
a whole (i.e. changes in vessel calibre are concomitant with 
alterations in cerebral blood flow). Several lines of evidence 
suggest that the large inflow tract vessels (basilar artery and major 
vessels of the Circle of Willis), commonly used in isolated vessels 
preparations are not characteristic of the intraparenchymal 
vasculature (Purves, 1982; McCulloch and Edvinsson, 1984). These 
large vessels do not exhibit many of the responses which are 
consistent with the circulatory response to physiological stimuli 
(autoregulation to changes in systemic pressure, hypercapnia on
hypoxia) (Purves, 1972). Moreover, recent studies have shown that 
inflow tract vessels contribute little (<7%) to total cerebrovascular 
resistance (Tuor and Farrar, 1985). Thus, even large changes in 
vessel calibre would have minimal effects on cerebral blood flow. By 
contrast pial vessels constitute a more relevant portion of the 
cerebral vasculature for studying vasomotor reactivity by virtue of 
their significant contribution to cerebrovascular resistance. 
However, in vivo studies have shown that the changes in pial vessels 
calibre to hypercapnia and altered blood pressure are consistent with 
the observed changes in cerebral tissue perfusion (Purves, 1972; 
McCulloch and Edvinsson, 1984). The use of large concentrations of 
phenoxybenzamine to inhibit adrenergic and serotoninergic mediated 
contraction may fundamentally compromise attempts to characterise the 
dopamine receptor mediating relaxation of cerebrovascular smooth 
muscle. In addition to its potent adrenergic and serotoninergic 
blocking properties high concentrations of phenoxybenzamine can also 
interact with other receptor populations, including both and D£ 
dopamine receptors. Moreover, ligand binding studies have shown 
that, at the high concentrations employed in isolated vessel studies, 
phenoxybenzamine differentiates between the two dopamine receptor 
subpopulations; blocking all receptor sites while sparing a 
proportion of the sites (Marchias and Bockaert, 1980; Walton et 
al. 1978; Hamblin and Creese, 1982). Hence, the present studies 
which demonstrate the dopamine receptor agonists provoke dilatation 
of pial arterioles, in situ, and without the need for preconstriction 
or adrenergic blockade provides a more relevant basis for the 
vascular hypothesis (i.e. that dopamine receptor agonists can alter 
cerebral blood flow by interacting directly with dopamine receptors 
on cerebral vascular smooth muscle).
In the present study the hierarchy of agonist potency in 
dilating pial arterioles (SKF 38393 > apomorphine > LY 141865) is 
indicative of a mediated relaxation of cerebrovascular smooth 
muscle, A similar conclusion has been reached by studies 
demonstrating the presence of dopamine sensitive adenylate cyclase 
activity within the intraparenchymal and extracerebral vessels of the 
cat and rat (Nathanson and Glaser, 1979; Amenta et al. 1984; Baca 
and Palmer, 1978). Although an increase in intracellular cAMP is 
associated with the action of a dopamine and other vasodilator 
substances (adenosine, papaverine, serotonin and B-adrenergic 
agonists) there is, as yet, no evidence linking cAMP generation to 
cerebrovascular dilatation.
A Dj mediated relaxation of isolated human basilar arteries has 
been proposed by Forster et al. (1982), although in this 
preparation SKF 38393 was found to be a weak partial agonist. The 
reason for the lack of efficacy of SKF 38393 in the Forster study is 
unclear. One possible explanation may lie in the use of an 
incubation cocktail containing indomethacin, propranolol, 
phenoxybenzamine and PGF£ (Forster et al. 1982), for in isolated 
vascular preparations where a similar incubation mixture was used the 
efficacy of SKF 38393 was markedly reduced (Brown et al. 1980; 
Woodman et al. 1980; Hilditch and Drew, 1981) while in studies where 
only phenoxybenzamine and PGF2  were employed, SKF 38393 observed 
that SKF 38393 had a much higher affinity for dopamine receptors 
(Schmidt et al. 1982; Brodde et al. 1981).
Further evidence that dopamine D^ receptors mediate relaxation 
of cerebrovascular smooth muscle was obtained using SCH 23390; the 
most potent selective D-^  receptor antagonist presently available 
(Goldberg et al. 1984; Kebabian et al. 1984). It was found that SCH
23390, at concentrations of 1-10 nM inhibits the vasodilator 
responses of pial arterioles to apomorphine and SKF 38393. These 
values are in close agreement with the concentration of SCH 23390 
required to inhibit dopamine stimulated adenylate cyclase (IC^q : 4-
11 nM: Iorio et al. 1983; Hyttel et al. 1983: Itoh et al. 1984) or
O
to competively antagonise H-flupentixol binding at Dj sites IC^q=1-4 
nM: Cross et al. 1983 a,b; Hyttel et al. 1983; Christensen et al.
1984), and so provide strong evidence that SKF 38393 and apomorphine 
dilate pial arterioles by interacting with dopamine D^ receptors.
The mechanisms underlying the weak dilator activity of LY 
141865 are unclear. A D^ mediated dilatation is unlikely since LY 
141865 failed to stimulate dopamine sensitive adenylate cyclase, even 
at the high concentrations (lO^M) (Scatton, 1982). However, it has 
been reported that high concentrations of LY 141865 can interact with 
histamine - H£ receptors (ED^q = 1.2 uM: Ruffolo and Shaar, 1983),
whose stimulation effects dilatation of pial arterioles in situ (Wahl 
and Kuschinsky, 1979).
On the basis of the data presented it is proposed that the 
dopamine receptor mediating dilatation of feline pial arterioles is 
of the Dj subtype. Moreover, the presence of D^ receptors in small 
cerebral arterioles suggests that agents stimulating D^ receptors 
could increase CBF by a direct action on cerebrovascular dopamine 
receptors.
2. DOPAMINE RECEPTOR SUBTYPES AND FUNCTION-RELATED GLUCOSE
UTILISATION
Inherent in the concept of function-related glucose utilisation 
is the premise that alterations in the rate of 2 -deoxyglucose
phosphorylation are, in some way, indicative of changes in functional 
activity. What evidence supports this view?
Some of the most elegant demonstrations of the relationship 
between local functional activity and glucose utilisation have been 
obtained from studies of specific sensory systems under controlled 
experimental conditions. By far the most extensively studied sensory 
system has been the primary visual system. In primates and cats the 
2 -deoxyglucose method has been used to define orientation and ocular 
dominance columns in visual (striate) cortex (Kennedy et al. 1976; 
Horton and Hubei, 1981; Schoppman and Stryker, 1981; Tieman and 
Tumosa, 1983). Moreover, combined electrophysiological and 2- 
deoxyglucose investigations have found that the columns in visual 
cortex observed in deoxyglucose studies correspond precisely with the 
orientation columns described by electrophysiologists (Schoppmann and 
Stryker, 1981). The 2-deoxyglucose method has also been used to 
differentiate between the different cortical patterns evoked by 
colour and black and white stimuli (Crawford et al. 1982). Studies 
in rats have demonstrated quantitative relationships between the 
frequency and intensity of retinal stimulation and local rates of 
glucose utilisation within components of the visual system (Miyaoka 
et al. 1979; Toga and Collins, 1981). Although less extensively 
studied function-related alterations in glucose use have been mapped 
following manipulation of the olfactory and somatosensory systems 
(Collins, 1980; Sokoloff, 1986 for reviews).
2 -deoxyglucose autoradiography has also been used to map the 
tonographic organisation of the auditory system (Ryan et al. 1982; 
Webster et al. 1984; Servier et al. 1984). C ombined 
electrophysiological and 2 -deoxyglucose studies have confirmed that 
the pattern of increased glucose use observed within the cat inferior
colliculus following the stimulation of the auditory system by 
isofrequency sound corresponds with the isofrequency contours 
observed in electrophysiological studies (Serviere et al. 1984). 
Furthermore, studies in the avian homologue of the auditory cortex 
(the auditory neostriatum) have demonstrated that the rate of 2 - 
deoxyglucose uptake following tone stimuli parallels the rate of 
spike activity observed within this region (Theurich et al. 1984). 
The relationship between electrical activity and metabolic rate was 
observed in isolated nerve preparations 60 years ago (Gerard, 1927). 
More recent studies have demonstrated a quantitative relationship 
between spike frequency and glucose utilisation in neural tissue in 
vivo (Yarowski et al. 1983, 1985; Kadekaro et al. 1985). The 
increase in glucose use in response to increased impulse activity is 
thought to be related to the activation of Na+/K+ ATPase the enzyme 
which restores the ionic distribution across the nerve membrane 
following an action potential. Thus, increases in the electrical 
activity of a neuron would precipitate larger ionic fluxes across the 
cell membrane and, therefore, would require greater ATPase activity 
to restore the ionic balance. In accordance with this view Mata et 
al. (1980) found that electrical stimulation or pharmacological 
depolarisation (by veratridine, an alkaloid which increases sodium 
conductance) of posterior pituitary cells enhanced 2 -deoxyglucose 
uptake. This increase in glucose utilistion could be blocked by 
preventing depolarisation with tetrodotoxin or blocking ATPase 
activity with ouabain (Mata et al. 1980).
Together the studies cited provide a sound basis for the 
hypothesis that alterations in local cerebral glucose utilisation 
reflect changes in functional activity and not merely substrate 
utilisation.
1. Effects of Dopamine Receptor Agonists
Stimulation of central dopamine systems results in marked 
alterations in glucose utilisation within a limited number of 
neuroanatomically discrete brain areas. It is important to emphasise 
that function related alterations in glucose use are not indicative 
exclusively of the activation of dopamine receptors within the region 
being investigated. Rather, the anatomical distribution of altered 
rates of glucose utilisation is indicative of polysynaptic neuronal 
pathways in which activity can be modified by dopamine receptor 
activation (McCulloch, 1982; Savaki, 1984). In the present study, 
the distribution of dose-dependent alterations in glucose use 
following the stimulation of different dopamine receptor subtypes 
suggests that the neuronal systems most markedly influenced by 
dopamine receptors involve the basal ganglia, thalamus and cerebral 
cortex. With the exception of a single limbic thalamo-cortical 
circuit, it is the J>2 dopamine receptor subtype rather than the Dj 
subtype which is responsible for dose-dependent modifications in 
glucose use. Although the stimulation of central dopamine receptors 
alters glucose use in a number of brain areas, in the majority of 
brain regions examined, the activation of dopaminergic mechanisms 
failed to modify function related glucose use.
Faradic or pharmacological stimulation of dopaminergic systems 
results in marked increases in glucose use within the basal ganglia 
(caudate nucleus, globus pallidus, subthalamic nucleus and substantia 
nigra) (Brown and Wolfson 1978; McCulloch et al. 1982 b; Weschler et 
al. 1979; Porrino et al. 1984 b; Esposito et al. 1984; Savaki et 
al. 1983). Each of these basal ganglia structures possesses both 
subtypes of dopamine receptor and are interconnected by extensive
neuronal pathways (Figure 33). Until now, no systematic attempt has 
been made to identify the dopamine receptor subtype responsible for 
the functional disturbances in the basal ganglia.
The present data suggest that the increased functional activity 
within the basal ganglia associated with dopamine receptor activation 
is mediated via the I> 2 receptor population. The importance of I>2 
receptors within the basal ganglia is further supported by the 
demonstration that increased glucose use within the basal ganglia is 
closely related to the promotion of stereotypy (Porrino et al; 1984); 
a behaviour which can be initiated only by D 2  receptor agonists 
(Seeman, 1981). However, the hypothesis that dopaminergic influences 
on the basal ganglia are selectively mediated via D2  receptors may be 
too simplistic. Behavioural investigations have demonstrated that 
apomorphine or LY 171555 induced stereotypy can be blocked not only 
by the D 2  antagonist metochlopramide but also by the selective 
antagonist SCH 23390 (Molloy and Waddington, 1985; Iorio et al.
1983).
The importance of dopamine D 2  receptor in eliciting local 
alterations in glucose use has been proposed on the basis of 
semiquantitative investigations of 2-deoxyglucose uptake (Palacios 
and Wiederold, 1985). Although the distribution of altered 2- 
deoxyglucose uptake resulting from the administration of D2  agonists 
(Palacios and Wiederhold, 1985) displays many similarities to the 
alterations in glucose use elicited by LY 171555 in the present study 
(e.g. significant changes within the subthalamic nucleus, neocortex 
and thalamus) there are a number of inherent weaknesses in the use of 
semiquantitative deoxyglucose uptake as a measure of local cerebral 
glucose utilisation. Radioisotope levels in the CNS at time of 
sacrifice comprise 2-deoxyglucose-6-phosphate (the index of metabolic
FIGURE 33
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Diagrammatical Representation of Some of the 
Connections of the Basal Ganglia
Me: motor cortex, CP: caudate-putamen, Ac: nucleus accumbens, Am: 
amygdaloid complex, SNc, Snr: substantia nigra pars compacta, pars 
reticulata, hi: habenula, VTA: ventral tegmental area, VL, VM: 
ventrolateral and ventromedial nuclei of the thalamus. Areas 
receiving dopaminergic projections are shaded.
activity) and deoxyglucose (which is related to residual plasma 
levels). If ^C-2-deoxyglucose is administered intravenously and 
plasma glucose levels are maintained within the normal range, then 
deoxyglucose-6-phosphate constitutes the major portion (approximately 
95%) of isotope within the CNS after 45 minutes (Sokoloff et al. 
1977; Kelly and McCulloch, 1983 a (Figure 7a)). However, the 
administration of dopamine receptor agonists can increase plasma 
glucose levels (Tyce 1976; McCulloch et al. 1982 b) (e.g. up to 22 
mM with LY 141865, 10 mg/kg, in non-fasted animals; see Figure 7b). 
The consequence of hyperglycaemia and the intraperitoneal route of 
administration of 2-deoxyglucose tracer is that total 2-deoxyglucose 
uptake into the CNS poorly reflects actual rates of glucose use 
(Kelly and McCulloch, 1983 a). These errors are further compounded
by the use of optical density ratios (Palacios and Wiederhold, 1985)
/
to derive a semiquantitative estimation of 2-deoxyglucose uptake 
(Kelly and McCulloch, 1983 b). The methodological differences 
between the measurement of local rates of glucose utilisation 
(present study) and local indices of 2-deoxyglucose uptake (Palacios 
and Wiederhold, 1985) are the most probable basis for key the 
differences between the two studies (e.g. the failure to demonstrate 
differences in glucose use within the anterior cingulate cortex and 
trigeminal nerve, and their demonstration of reduced rates of glucose 
use within the superficial layers of the superior colliculus; a 
region in which no significant change in glucose use occurred in the 
present study). Moreover, the present study provides a more 
comprehensive pharmacological (the effects of multiple doses of each 
drug explicitely described) and neuroanatomical description of the 
effects of dopamine receptor agonists with a rigorous model for 
determining function related glucose use.
Although the neuroanatomical location of dopamine receptors 
responsible for initiating functional alterations in the basal 
ganglia cannot be determined by the present approach alone, there 
exists a body of evidence which points to the caudate nucleus as 
being the main site of initiation. Firstly, intrastriatal injections 
of dopamine can provoke increases in glucose use within the 
substantia nigra and subthalamic nucleus similar to that provoked by 
systemically administered dopamine agonists (Brown and Wolfson,
1983). Secondly, systemic administration of apomorphine and LY 
171555 (but not SKF 38393) results in an increase in the firing rate 
of nigral and pallidal neurons whereas their local microapplication 
onto cells in the pallidus or substantia nigra failed to provoke 
significant alterations in their firing rates (Walters et al. 1983).
The neostriatum possesses marked topographical heterogeneity in 
its anatomical connections (Goldman and Nauta, 1979), indices of 
neurotransmitter distribution (Herkenham and Pert 1981; Graybiel et 
al. 1981; Graybiel, 1984) and functional response to pharmacological 
challenge or electrical stimulation (McCulloch et al. 1983; Sharp 
and Evans, 1982). There is evidence that within the caudate the 
topographical distribution of receptors is relatively uniform 
(Scatton and Dubois, 1985) whereas the D 2  population appears 
relatively heterogeneous with gradients of increasing densities in 
both the caudal-rostral and medial-lateral planes (Joyce et al. 1985; 
Altar and Marshall, 1985). Furthermore, the topographical 
distribution of both dopamine D£ binding sites and cholinergic 
neurons appear to be in close register (Joyce and Marshall, 1985; 
Marshall et al. 1983). The heterogeneous alterations in glucose use 
provoked by the selective D£ agonist LY 171555 with significant 
increases restricted to the ventral portion of the caudate nucleus
are consistent with the known antomical distribution of D£ receptors 
in the striatum. These results are similar to the findings of 
earlier studies in which apomorphine administration provoked 
increased glucose use within the acetylcholinesterase rich areas of 
the ventral striatum (McCulloch et al. 1983). They further 
demonstrate the importance of the D£ receptor population of the 
ventral striatum, particularly as the ventral striatum has been 
implicated as a site for the initiation of dopamine-induced oral 
stereotypies (Iversen and Koob, 1977; Arnt, 1985).
In contrast to LY 171555, the selective receptor agonist SKF 
38393 failed to provoke significant changes in glucose use within the 
striatum. This observation supports the conclusions of biochemical 
investigations where activation of D£ but not receptors within the 
striatum modulates cholinergic transmission both in vitro (Stoof and 
Kebabian, 1981, 1982; Plantje et al. 1983) or in vivo (Scatton,
1982).
The dopaminergic innervation of cerebral cortex is limited to a 
few areas associated with limbic function, such as prefrontal, 
anterior cingulate, and piriform cortices (Lindvall and BjBrklund,
1984). In contrast to most dopaminergically innervated regions, 
which contain both dopamine and D£ receptor populations, there is 
increasing evidence that cerebral cortex may possess only the 
population (Thierry et al. 1984; Jastrow et al. 1984; Altar et al.
1985). Anterior cingulate cortex was the only region in which 
consistent alterations in glucose utilisation were elicited by the 
receptor agonist SKF 38393. In contrast glucose use proved 
relatively insensitive to the agonist LY 171555 in this brain 
area. The function related alterations in glucose use in anterior 
cingulate cortex (and in the anterior thalamus nucleus with which it
has extensive reciprocal connections) provide evidence for a 
functional role of dopamine D^ receptor upon limbic mechanisms via 
these two brain areas. Administration of the selective D2  agonist LY 
171555 provoked dose-dependent increases in local glucose use within 
sensory motor and frontal cortices. Since these areas appear to 
contain few, if any, dopamine D 2  receptors (Alter and Marshall,
1985) and receive no substantial dopaminergic innervation (Lindvall 
and BjSrklund, 1984) the increases in glucose use within sensory 
motor and frontal cortices probably reflect alterations in thalamo­
cortical function initiated at the level of the striatum (McCulloch 
et al. 1979; McCulloch, 1982; Savaki, 1984; Collins, 1980). The 
laminar and columnar organisation of the enhanced cortical glucose 
use following D 2  receptor activation and the parallel increases in 
glucose utilisation within the sensory and motor relay nuclei of the 
thalamus (VM, VL) following LY 171555 administration emphasise the 
importance of the thalamus in mediating dopaminergic influence of 
cortical function.
Although extensive dopaminergic projections to the limbic 
system exist (Ungerstedt, 1971; Lindvall and BjSrklund, 1982), the 
consequences of dopamine receptor activation, as assessed by 
alterations in function-related glucose use, have in general been 
small and highly variable (McCulloch, 1982). The role of dopamine as 
a neurotransmitter in the hippocampus remains controversial. 
Originally the presence of low concentrations of dopamine in the 
hippocampus was attributed to its role as a precursor of 
noradrenaline (Lindvall et al. 1974 b). However, there is now 
evidence that dopamine may play a true n euro transmit ter role within 
the hippocampus as shown by the presence of both D^ (Bischoff et al. 
1980; Bernado and Prince, 1982; Dawson et al. 1985, Ouimet et al.
1984) and D 2  receptor sites (Bischoff et al. 1980) and of specific 
dopamine uptake mechanisms (Scatton et al. 1985). In the present 
investigation we found that the D 2  receptor agonist LY 171555 
provoked a dose related decrease in glucose use within the molecular 
layer of the hippocampus while, in contrast, the receptor agonist 
SKF 38393 failed to significantly affect glucose use. In the 
electrophysiological investigations, dopamine induced hyperpolaris­
ation of hippocampal pyramidal cells was mediated by an increase in 
adenyl cyclase, and by definition receptor mediated (Beraado and 
Prince 1982). However, it should be noted that the latter studies 
were focused on the CA1 pyramidal cells of the dorsal hippocampus 
whereas, in the present studies, glucose use was measured in the 
molecular layer of the ventral hippocampus at the level of the medial 
geniculate body. Therefore, the findings of Bernado and Prince 
(1982) and the present study are not strictly comparable on 
neuroanatomical grounds.
An indirect dopaminergic action via the septohippocampal 
pathway may underlie the reductions in glucose use observed in the 
ventral hippocampus following the administration of LY 171555. The 
septohippocampal pathway is a major source of cholinergic imput to 
the hippocampus (Shute and Lewis, 1961). Cholinergic neurons within 
the medial septum and nucleus of the diagonal band project via the 
fimbria to the hippocampus and dentate gyrus. Ligand binding studies 
have demonstrated the existence of distinct populations of muscarinic 
and nicotinic receptors within both the dorsal and ventral 
hippocampus. n-bungarotoxin labelled nicotinic receptors are 
located primarily within the stratum lancunosum moleculare of the
O
ventral hippocampus while H-QNB (3-quinuclidinyl benzilate) labelled
muscarinic sites have been found within all levels of the hippocampus 
(see Rotter et al. 1984 for review).
Neurochemical studies have indicated that dopamine neurons 
within the septum may influence the activity of cholinergic fibres 
projecting to the hippocampus. Inhibition of dopaminergic activity 
within the septum (whether by local injections of haloperidol into 
the septum or by 6-hydroxydopamine lesions of the ventral tegmental 
area) results in an increase in the turnover of acetylcholine (Ach) 
within the hippocampus (Robinson et al. 1978 a), while conversely, 
the administration of apomorphine reduces Ach turnover within the 
hippocampus (Robinson et al. 1978 b). It has, therefore, been 
proposed that dopaminergic neurones within the septum may tonically 
inhibit cholinergic neurones of the septohippocampal pathway 
(Robinson et al. 1978 a). This inhibition of cholinergic 
transmission in the hippocampus may underlie the alterations in 
glucose use observed following the administration of LY 171555.
In the present studies, administration of the D£ agonist LY 
171555 provoked dose-related increases in glucose use within the 
lateral septal nucleus which were accompanied by significant 
reductions in glucose use within the stratum lancunosum moleculare of 
the ventral hippocampus. In contrast significant reductions in 
glucose use within the dentate gyrus were observed only at the 
highest concentrations examined. The specificity of the action of LY 
171555 upon glucose use within this nicotinic-receptor rich layer of 
the hippocampus would appear to indicate that the activation of J>2 
receptors within the septum may underlie the reduction in glucose use 
observed within this molecular layer of the hipocampus. However, 
interpretation of the present study involving systemic drug 
administration should be viewed with circumspection as this route of
drug administration does not provide sufficient information on the 
site of action of any agent. Nevertheless, the possibility of D£ 
mediated effects upon nicotinic transmission with the hippocampus 
should receive further investigation.
The nucleus accumbens and lateral habenula represent two of the 
major points of interaction between the limbic and motor systems 
(Nauta and Domesick, 1984). Both receive a discrete dopaminergic 
innervation from the ventral tegmental area (Phillipson and Griffith, 
1980; Phillipson and Pycock, 1982; Skagerberg et al. 1984; 
Lindvall and BjBrklund; 1978), and both areas possesss both D^ and D£ 
receptor populations (Dawson et al. 1985; Jastrow et al. 1984). The 
present observations, where increased glucose utilisation in the 
nucleus accumbens was observed at a single concentration of each 
agonist, provide little insight into the extent to which dopamine 
receptors can influence glucose use in this region or into which 
receptor subtype may be involved. Manipulation of central dopamine 
systems generally, but not invariably, result in alteration in 
glucose use within the lateral habenula nucleus (McCulloch et al. 
1980 b; Brown and Wolfson, 1983; Pizzolato et al. 1984, 1985). 
Systemic administration of dopamine receptor agonists such as 
apomorphine and amphetamine decreased glucose use within the habenula 
(Wescher et al. 1979; McCulloch et al. 1980 b) while neuroleptics 
such as haloperidol increase glucose use (McCulloch et al. 1980 b; 
Pizzolato et al. 1984, 1985). However, in the present study we were 
unable to demonstrate significant changes in glucose use following 
administration of the D^ agonist SKF 38393 or any but the highest 
dose of the D£ agonist LY 171555. The apparent lack of efficacy of
these selective and D£ agents upon glucose use within the lateral 
habenula constitutes one major difference with respect to the 
dopamine receptor agonists examined hitherto. The minimal effect of 
Dj and J>2 agonists upon glucose use in the habenula is in excellent 
accord with the minimal functional altertions which are associated 
with electrical stimulation of mesencephalic dopamine systems 
(Porrino et al 1984 a). Similarly, the large increases in glucose 
utilisation within the substantia nigra pars reticulata following the 
administration of apomorphine or amphetamine contrast sharply with 
the relatively modest elevation achieved with LY 171555.
The present report provides a comprehensive description of the 
distribution of changes in function related glucose use associated 
with the selective activation of dopamine receptor subtypes. These 
observations emphasise the importance of the D£ receptor subtype in 
the functional disturbances associated with the activation of central 
dopamine systems. Although the distribution of altered glucose use 
following the activation of D£ receptors with LY 171555 is broadly 
similar to that evoked by apomorphine, a number of clear differences 
exist. In conclusion we have demonstrated that the administration of 
selective and D2  dopamine agonists provoke distinct alterations in 
local cerebral glucose use. The marked increases in glucose use 
associated with the stimulation of central dopamine systems appears 
to be predominately mediated via the D2  receptor population as they 
are provoked by the D 2  agonist LY 171555 but not by the agonist 
SKF 38393. Activation of the subpopulation with SKF 38393 results 
in focal decreases in glucose use within the anterior cingulate 
cortex and in its projection field, the anterior thalamic nucleus.
2. Effects of Dopamine Receptor Antagonists
Prior to the development of SCH 23390, antipsychotic activity 
in man and the antagonism of dopaminergically induced behavioural 
changes in animals were generally believed to be mediated via the D£ 
receptor popultion (Seeman, 1981; Costall and Naylor, 1981). Indeed 
the poor correlation between adenylate cyclase activity and dopamine- 
related functions fostered the view that the D^ receptor was a 
"receptor looking for a role" (Stoof and Kebabian, 1984). However, 
in the light of studies with the novel D^ antagonist SCH 23390 views 
concerning the relative importance of D^ and D£ receptors in brain 
function may have to be revised. For, despite displaying more than 
1000 fold selectivity for D^ receptors over D£ receptors in 
radioligand binding and adenyl cyclase assays in vitro, SCH 23390 
produces catalepsy and potently inhibits the stereotyped behaviours 
produced by apomorphine and other dopaminomimetics in vivo (Iorio et 
al. 1983; Christensen et al. 1984; Mailman et al. 1984; Molloy et 
al. 1984), actions previously thought to be mediated solely by the D£ 
receptor (Seeman, 1981). The studies comprising this part of the 
thesis addressed three aspects of the actions of SCH 23390 on brain 
function: 1) how are the actions of SCH 23390 expressed in terms of
alterations in function-related glucose utilisation? 2) how do the 
actions of SCH 23390 compare with those of the classical neuroleptic 
and potent D£ antagonist haloperidol? and 3) how does SCH 23390 
affect the pattern of altered glucose use produced by the D2  agonist 
LY 171555?
The selectivity of SCH 23390 as an antagonist of D^ receptors 
is based primarily on in vitro biochemical studies (Iorio et al. 
1981, 1983; Christensen et al. 1984; O'Boyle and Waddington, 1984;
Plantje et al. 1984; Schulz et al. 1985). It is, therefore, 
appropriate to question the selectivity of this agent in vivo. 
Over the concentration range examined in the present studies SCH 
23390 did not prevent the electrical activity produced by presynaptic 
doses of apomorphine in dopamine cells of the substantia nigra (Mereu 
et al. 1985). Nor did it affect tyrosine hydroxylase activity or 1- 
dopa accumulation in the striatum (Onali et al. 1985; Iorio et al.
1983), actions thought to be mediated via D£ receptor activation. 
Furthermore, at concentrations as high as 3 mg/kg SCH 23390 protects 
Dj but not D£ receptors from inactivation by the neurotoxic agent N- 
ethoxycarbonyl-2-ethoxy 1, 2-dihydroquinoline (Meller et al. 1985). 
Thus, over the concentration range examined in this thesis, SCH 23390 
would be expected to act primarily on receptors. However, the 
possibility that non-dopaminergic effects, particularly 
serotoninergic (Ohlstein and Berkowitz, 1985) cannot be excluded.
In the present studies SCH 23390 provoked highly focal 
alterations in glucose use, with significant alterations evident in 
only 4 of the 59 brain regions examined (lateral habenula, nucleus 
accumbens, pars reticulata of the substantia nigra and the 
posterioventromedial thalamic nucleus). These findings are 
consistent with the view that the blockade of central dopamine 
systems does not provoke widespread alterations in function-related 
glucose utilisation (McCulloch, 1982). However, it is the highly 
focal alterations in glucose use which provide insight into the 
mechanisms of action of SCH 23390.
An increase in local glucose use within the lateral habenular 
nucleus has been demonstrated following the administration of every 
neuroleptic hitherto examined irrespective of its dopamine receptor 
subtype specificity (Table 11). Although a number of non-neuroleptic
agents have been shown to increase glucose use within the lateral 
habenula (oxytremorine, caffeine estrogen) this response may prove 
useful in predicting neuroleptic activity of test compounds.
There is evidence that, although the lateral habenula nucleus 
receives direct dopaminergic input from the ventral tegmental area 
(Kizer et al. 1976; Phillipson and Pycock, 1982), other studies 
indicate that the function-related alterations in glucose use are 
initiated in the caudate nucleus and expressed via the internal 
segment of the globus pallidus (entopeduncular nucleus). Firstly, 
reduction of nigrostriatal activity 6-hydroxydopamine lesions of the 
nigrostriatal pathway or kainate lesions of the striatum result in 
increased glucose use within the lateral habenula (Ferron et al. 
1979; Wooten 1981; Kozlowski and Marshall, 1983; Kelly et al. 
1982) while intrastriatal dopamine or apomorphine reduce metabolic 
activity within the habenula (Kozlowski and Marshall, 1980; Brown 
and Wolfson, 1983). Furthermore, the increase in glucose use in the 
habenula produced by lesions of the nigrostriatal pathway is markedly 
attenuated by lesions of the entopeduncular nucleus (Wooten, 1981). 
In contrast faradic stimulation of the ventral tegmental area did not 
significantly alter glucose use within this nucleus (Porrino et al. 
1984; Esposito et al. 1984), thereby signifying that the activation 
of the mesohabenular pathway is not responsible for the metabolic 
changes observed in this diencephalic nucleus following manipulation 
of central dopamine systems. Thus, it would appear that dopamine- 
related alterations in habenular glucose use, like the effect upon 
the basal ganglia, are initiated at the level of the caudate nucleus.
The increase in glucose use within the lateral habenula 
associated with reduced dopaminergic transmission suggests that the 
pathway is under a tonic inhibitory influence by the striato-
entopeduncular-habenular pathway. This inhibitory influence appears 
to require the presence of functional and D£ receptor subtypes 
since the increase glucose use selective and D£ antagonists 
produce increases in glucose use within the habenula while only mixed 
Dj/D2  agonists reduce metabolic activity within this nucleus (Table 
11). The necessary activation of both and D 2 receptors 
populations would also explain why neither SKF 38393 nor LY 171555 
significantly altered glucose use within the lateral habenular. At 
variance with this view is the reduction in habenular glucose use 
produced by the putatively selective D 2  agonist bromocryptine 
(Pizzolato et al. 1985). It should be emphasised, that although 
bromocryptine has a low affinity for receptors, it does interact 
with adrenergic and serotonin receptors (Lew et al. 1977) 
particularly at the high concentrations employed by Pizzolato and his 
associates (20-400 mg/kg).
Specific lesion techniques combined with adenylate cyclase or 
ligand binding assays have indicated that the and D 2  receptor 
populations within the substantia nigra may be differentially 
located. Several groups have reported that 6-hydroxydopamine lesions 
of the substantia nigra or median forebrain bundle does not 
significantly alter cyclase activity which is localised in the pars 
reticulata (Spano et al. 1976; Kebabian and Saavedra, 1976; Gale et 
al. 1977). Cyclase activity, however, was largely abolished by the 
destruction of the gabaergic/substance P-ergic striato-nigral 
projection system (Spano et al. 1976, 1977; Gale et al. 1977). In 
contrast ligand binding studies have demonstrated that JH-spiperone 
(D2  receptor) binding is significantly reduced by 6-hydroxydopamine 
lesions of the mesencephalic dopamine neurones but is largely 
unaffected by destruction of the descending striato-nigral projection
TABLE 11
Dopminergic Influences Upon Local Glucose Utilisation 
in the Lateral Habenular Nucleus
Receptor • 
Preference
Metabolic Activity 
in the Lateral 
Habenula
Reference
Inhibition
SCH 23390 Di Increase Present Study.
YM 09151-2 D2 Increase Palacios and Wiederhold, 1985.
Sulpiride D2 Increase Palacios and Wiederhold, 1984.
Clozapine D2 Increase Palacios and Wiederhold, 1984.
Haloperidol d2 >D1 Increase McCulloch et al. 1980.
Pizzolato et al. 1984.
Pimozide D2 > Increase Garnita and Gallistrel, 1982.
Gallistrel et al. 1985.
Droperidol D2 > D, Increase Oguchi et al. 1982.
Fluphenazine D2 /Di Increase Wooten, 1979.
Reserpine “i 1 d2 Increase Palacios and Wiederhold, 1984.
Nigral Lesion V D2 Increase Wooten and Collins, 1981.
Striatal Lesion h . Increase Kelly et al. 1982.
Lesion Entopeduncular Increase Wooten, 1979.
Stimulation
-
SKF 38393 No Change Present Study.
LY 171555 D2 No Change Present Study.
Apomorphine D1 1 D2 Decrease McCulloch et al. 1982.
Amphetamine Di /D2 Decrease Weschler et al. 1979.
system (Murrin et al. 1979; Quik et al. 1979).
These data suggest that receptors are localised mainly on 
the terminals of striato-nigral fibres in the pars reticulata of the 
substantia nigra whilst D£ receptors occur primarily on the dopamine 
neurons of the pars compacts. In the present study the 
administration of the Dj antagonist, SCH 23390, reduced glucose 
utilisation within the pars reticulata of the substantia nigra while 
glucose use within the pars compacts was minimally affected. These 
findings contrast with the pronounced increases in glucose use 
observed within the pars compacta following administration of D£ 
selective concentrations of haloperidol (McCulloch et al. 1982 c). 
Furthermore, although significant reductions in glucose use were 
observed in the pars reticulata of haloperidol-treated animals, the 
concentration required was some 1000 fold greater than that required 
to increase glucose use within the pars compacta (McCulloch et al. 
1982 c). Thus, SCH 23390 would appear to selectively alter function 
related glucose use within the rich cells of the pars reticulata 
of the substantia nigra whilst haloperidol differentially interacts 
with cells from the pars compact. This concept is supported by 
biochemical and electrophysiological studies performed on the 
substantia nigra of unanaesthetised rats, (the distorting influences 
of anaesthesia within the substantia nigra has been discussed 
previously, see Introduction). In these studies SCH 23390 increased 
cell firing rate of cells within the pars reticulata in a manner 
similar to that produced by other neuroleptics (Mereu et al. 1985; 
Onali et al. 1984; Walters et al. 1986), but unlike haloperidol SCH 
23390 did not reverse the inhibition produced by low (presynaptic)
concentrations of apomorphine in the dopamine cells of the pars 
compacta (Mereu et al. 1985).
In a recent semiquantitative study Palacios and Wiederhold 
reported that oral administration of SCH 23390 failed to 
significantly alter 2-deoxyglucose uptake in any of the brain regions 
examined. The reason for the discrepancies between the present 
quantitative study and the semiquantitative studies of Palacios and 
other has been addressed previously (see Methods Section, previous 
discussion). However, one additional factor may underly the lack of 
efficacy of SCH 23390 in the Palacios study, namely the use of oral 
administration of SCH 23390. Several groups have remarked on the low 
efficiency of orally administered SCH 23390, as compared to 
parenterally administered (Iorio et al. 1983; Christensen et al. 
1984; Mailman et al. 1984). A large "first pass" metabolism of SCH 
23390, resulting in subthreshold concentration of SCH 23390 reaching 
the brain has been proposed to account for the low efficacy of 
enteral administration SCH 23390 (Mailman et al. 1984).
The present studies have demonstrated that pretreatment with 
low concentrations of the antagonist SCH 23390 abolishes the 
stereotyped gnawing produced by the D£ agonist LY 171555; findings 
which are consistent with reports that SCH 23390 can block the 
stereotyped behaviours produced by the T>2 agonist RU24213 (O'Boyle et 
al. 1984 b) apomorphine (Iorio et al. 1983; Christensen et al. 1984; 
Mailman et al. 1984; Molloy and Waddington, 1985), 6,7 ADTN 
(Christensen et al. 1984) methylphenidate (Christensen et al. 1984) 
and amphetamine (Iorio et al. 1983; Mailman et al. 1984; 
Christensen et al. 1984) as well as the selective agonist SKF 
38393 (Molloy and Waddington, 1984).
Underlying the inhibition of stereotypies were widespread 
reductions in glucose use, particularly within motor systems, i.e. 
those areas most affected by LY 171555 administration (see agonist 
section). As discussed previously the increases in glucose use 
within the striatum are localised within the ventral striatum. In 
keeping with this finding the present study revealed that SCH 23390 
is more effective in reducing glucose use in the ventral rather than 
the dorsal striatum. This idea is supported by a recent study which 
claimed that the stereotyped behaviours produced by apomorphine could 
be selectively blocked by the intracerebral microinjection of a 
variety of neuroleptics, including SCH 23390 or sulpiride into the 
ventral striatum (Arnt, 1985).
Recently a number of authors have suggested that the efferent 
pathways from the striatum are under the control of different 
receptor subpopulations (Ungerstedt et al. 1983) and in dopamine 
receptor agonists Herrera-Marschitz and Ungerstedt 1984 a,b; 
Waszczak et al. 1984). Behavioural studies in rats 6-hydroxydopamine 
lesions of the nigrostriatal pathway have demonstrated that SCH 23390 
selectively blocks the rotational response induced by SKF 38393 but 
not that produced by pergolide whereas the selective D£ antagonist 
spiroperidol attenuated the pergolide response but not that produced 
by SKF 38393 (Arnt and Hyttel 1984; Arnt, 1985). The rotation 
evoked by the mixed D^/D2  agonist, apomorphine could not be 
completely blocked by SCH 23390 or haloperidol, however the 
administration of these antagonists successfully blocked the 
apomorphine response (Arnt, 1985). Since kainic acid lesions of the 
substantia nigra in 60HDa treated rats reverses the direction of
apomorphine while having little effect on pergolide induced rotation 
Herrera-Marschitz and Ungerstedt, 1984 a) postulated that the 
nigrostriatal pathway is controlled by receptor mechanisms whereas 
striopallidal pathways are affected by D£ mechanisms (Herrera- 
Marschitz and Ungerstedt, 1984 a; Ungerstedt, 1983). A similar view 
has been proposed by Waszcak and her colleagues who reported that 
systemically administered apomorphine provoked a uniform increase in 
the firing rate of pallidal neurones while producing no consistent 
alterations within the pars reticulata of the substantia nigra. If 
these two striatal efferent systems are controlled by different 
receptor mechanisms then the co-administration of SCH 23390 and LY 
171555 should selectively block the strio-nigral pathway, leaving the 
striopallidal system relatively unaffected. However, it was found 
that glucose use within the globus pallidus and pars reticulata were 
depressed by a proportionately similar amount (24% and 27% 
respectively). Thus, the present studies do not support the concept 
that striatonigral and striatopallidal pathways are influenced by 
different receptor mechanisms.
3. Evaluation of Dopaminergic Influences Upon Function-Related
Glucose Use by the Fingerprinting Approach
The ability to quantify changes in functional status 
simultaneously in every anatomical component of the brain visible on 
the autoradiograms with 2-deoxyglucose, provides a unique perspective 
on the effects of drug administration upon brain function. 
Nevertheless, the 2-deoxyglucose technique has failed to make a major 
impact on the field of neuropharmacology.
One of the principle problems with pharmacological studies 
employing 2-deoxyglucose autoradiography is associated with the 
interpretation and analysis of the vast quantities of data generated 
(i.e large numbers of brain areas and multiple drug concentrations). 
Hitherto, the effects of drug administration upon function-related 
glucose use has been interpreted on the basis of the acquisition of 
some notional level of statistical significance or on the percentage 
change in glucose use at a single drug dose. However, in each case 
only a small proportion of the data generated- is used in the 
interpretation of the drug response. Furthermore, the acquisition of 
notional levels of statistical significance can be influenced by the 
form of analysis adopted. For example, McCulloch and his associates 
(McCulloch et al. 1982) reported significant alterations in local 
glucose use in 18 of the 43 brain areas examined following the 
administration of apomorphine to rats. However, an independent 
reanalysis of the same autoradiograms (Appendix 4) revealed 
significant alterations in glucose use in only 7 of the 43 brain 
areas investigated by McCulloch et al. This latter form of analysis 
would have resulted in a completely different interpretation of the 
effects of apomorphine on local cerebral glucose utilisation. For 
example, one of the major findings of the apomorphine studies by 
McCulloch et al. (1982) was that alterations in glucose use within 
specific thalamic nuclei were accompanied by parallel changes within 
their cortical projection areas. Apomorphine administration results 
in parallel increases in glucose use within ventrolateral thalamus 
and sensory motor cortex, while concomitantly producing 
proportionately thalamic nucleus and in its cortical projection area,
the anterior cingulate cortex. However, when the autoradiograms from 
these apomorphine treated animals were reanalysed using the 
densitometrical criteria and statistical procedures adopted within 
this thesis, no significant alterations could be demonstrated in 3 of 
these 4 brain areas.
The fingerprinting approach offers considerable advantages over 
percentage change ranking at a single drug concentrations or 
acquisition of notional levels of statistical significance in that 
analysis is performed on all the data available for each brain area. 
Furthermore, the reliability studies described in Appendix 1 have 
shown that the hierarchies for apomorphine generated by independent 
investigators using different densitometrical criteria are highly 
correlated.
The value of the fingerprinting approach in analysing the dis­
tribution of metabolic changes in response to drug administration has 
been highlighted recently in a study of the effects of diazepam and 
the gaba agonists muscimol and 4,5,6,7-tetrahydroisoxazolo-[-5, 
4c]pyridin-3-ol (THIP) on local cerebral glucose utilisation (Ford et 
al. 1985). Each agent was found to reduce glucose use in almost 
every region of the brain. Fingerprinting analysis revealed a close 
correlation between the regional hierarchies generated for muscimol 
and THIP. However, these patterns of regional responsiveness 
differed markedly from that produced by diazepam. Thus, although 
gaba and benzodiazepine receptors may interact within the same 
receptor complex to reduce functional activity, the fingerprinting 
approach was able to discriminate between agents producing similar 
pharmacological effects, via different receptor mechanisms.
In the present studies the fingerprinting approach was used to 
examine the more complex pattern of altered glucose use produced by 
pharmacological manipulation of central dopamine systems. From the 
pattern of altered glucose use produced by apomorphine, it would 
appear that this dopamine receptor agonist possesses actions which 
are similar to those evoked by SKF 38393 (reduction in glucose use 
within anterior cingulate cortex-anteromedial thalamic circuit) and 
LY 171555 (increase in glucose use within areas of the brain 
associated with motor function). These findings are consistent with 
the view that apomorphine can interact with both Dj and D£ receptor 
populations (Seeman et al. 1981). However, the pattern of glucose 
use provoked by apomorphine could not be viewed simply as the 
cumulative effects of SKF 38393 and LY 171555. Stimulation of 
somatosensory and motor areas of the brain is associated with D£ 
receptor activation (Walters et al. 1983, 1986; Palacios and
Wiederhold, 1985) and these areas feature prominently within the 
hierarchies of regional responsiveness to apomorphine and LY 171555. 
However, even within these areas, the sensitivity of these brain 
areas to apomorphine was markedly different than that to LY 171555.
For example, if we examine the hierarchy of responsiveness for 
four regions of the rat brain which are involved in motor function 
(substantia nigra pars reticulata, globus pallidus and sensory motor 
cortex) we find that in apomorphine treated animals the hierarchy of 
responsiveness is (SNr > STN > GP > SMc). However, in LY 171555 
treated animals the hierarchy is (STN > SMc > SNr > GP). 
Neuroleptics are characterised by an increase in local glucose 
utilisation within the lateral habenula. Consistent with this view
are the findings that the lateral habenula is among the most 
sensitive brain regions to both the antagonist SCH 23390 and I >2 
antagonist haloperidol. The fingerprinting approach also provided 
support for the view, based on electrophysiological studies (Mereu et 
al. 1985), that haloperidol and SCH 23390 may have differential 
effects within the pars compacta and pars reticulata of the 
substantia nigra. In the present studies, it was found that the 
value generated for haloperidol adminstration to the pars compacta of 
the substantia nigra was some fifteenfold greater than that produced 
for SCH 23390. Conversely, the 'f' value for SCH 23390 in the pars 
reticulata was twice that for haloperidol. These findings are 
consistent with the neuroanatomical localisation of D£ receptors on 
the pars compacta and D| receptors in the pars reticulata of the 
substantia nigra (Gale et al. 1977; Seeman, 1981).
An important feature of the SCH 23390 response was that the 'f' 
values for all but a few key brain areas were tightly grouped around 
zero. The high specificity of the response to SCH 23390 would sugest 
this potent neuroleptic may exhibit fewer clinical side effects than 
haloperidol.
DOPAMINE RECEPTOR SUBTYPES AND THE CEREBRAL CIRCULATION: INFLUENCES
ON LOCAL CEREBRAL BLOOD FLOW AND THE FLOW/GLUCOSE USE RELATIONSHIP
On the basis of the studies undertaken in the first two 
sections of this thesis it is proposed that dopamine-induced 
dilatation of the cerebral vasculature is mediated via the D^
receptor subtype while alterations in function-related glucose 
utilisation are initiated in all but a few discrete brain areas by 
the D2  receptor population. This apparent difference in the receptor 
characteristics of cerebral vascular and neural tissues may be used 
to examine the relative importance of the vascular and metabolic 
components of the circulatory response to dopamine receptor agonists. 
For the administration of a selective agonist would be expected to 
dilate the cerebral vasculature while having minimal effects on 
glucose utilisation. Conversely, the administration of a selective 
D£ agonist would elicit marked metabolic effects while having little 
effect on the vascular receptor. This hypothesis was subsequently 
tested using SKF 38393 and LY 171555.
The administration of the selective agonist LY 171555 
(0.5mg/kg) significantly increased local blood flow within those 
brain areas in which elevated rates of glucose use had been observed 
in the glucose use studies (sensory motor and frontal cortices, basal 
ganglia and ventral thalamus inter alia). Moreover, the increases in 
blood flow were in general similar in magnitude to the changes in 
glucose use observed following the administration of this D2  agonist. 
Administration of the agonist SKF 38393 effected little change in 
local cerebral blood flow, with the exception of a few discrete brain 
areas (e.g. anterior cingulate cortex and anteromedial thalamus). 
These observations are of crucial importance in delineating the 
functional significance of the vascular dopamine receptor in 
mediating the increases in cerebral blood flow associated with the 
systemic administration of dopamine agonists. For despite being a 
potent vasodilator of the pial vasculature in situ, this agonist
failed to stimulate cerebral blood flow and, in fact, provoked 
parallel reductions in blood flow and glucose use within the anterior 
cingulate cortex, an area rich in receptors.
The reason why a number of authors observe disproportionately 
large increases in cerebral blood flow relative to metabolic activity 
following the administration of dopamine receptor agonists while 
other studies using the same agents do not, has never been adequately 
addressed. The results of the studies presented in this thesis 
clearly indicate that a direct vasomotor action is unlikely to be the 
primarily mediator of large increases in blood flow. However, a 
number of alternative explanations exist.
With the notable exception of the clinical studies of Leenders 
and his associates (Leenders et al. 1984, 1985) every study which has 
reported an excessive increase in cerebral perfusion have been 
performed under conditions of pronounced hypertension. It is widely 
accepted that homeostatic mechanisms ensure that cerebral perfusion 
remains relatively constant over a wide range of blood pressures 
(Harper, 1966; Purves, 1972; Strandgaard and Paulson, 1984). 
However, recent evidence has suggested that the administration of 
dopamine receptor agonists prevents the cerebral circulation from 
autoregulating at elevated blood pressures, with the result that the 
mechanical stress on the cerebral vasculature produced by the high 
intraluminal pressure (at 150 mm Hg) is sufficient to disrupt the 
blood-brain barrier (Carlsson and Johansson, 1978; Tuor and 
McCulloch, 1986) and significantly alter the normal flow-glucose use 
relationship (Tuor and McCulloch, 1985). Thus, in studies of this 
type the increases in cerebral blood flow are more likely to be due 
to mechanical stress rather than a mediated dilatation.
In a recent clinical study by Leenders et al. (1984, 1985) the 
infusion of 1-dopa was reported to significantly increase blood flow 
within the basal ganglia and overlying frontal cortex while having 
minimal effects upon local metabolic activity within these brain 
areas. In contrast to the aforementioned studies the investigations 
of Leenders were performed under normotensive conditions. However, 
their conclusion that 1-dopa increases cerebral blood flow by 
stimulating cerebrovascular dopamine receptors appears to be 
unfounded as the circulatory response to 1-dopa could be blocked by 
bulbocapnine, a potent dopamine receptor antagonist which does not 
readily cross the blood-brain barrier. Thus, Leenders own data would 
argue against a direct vascular action of 1-dopa.
It would appear, therefore, that the excessive increases in 
blood flow, observed by some investigators is the results of 
mechanisms other than via the stimulation of vascular dopamine 
receptors. Furthermore, the results of the present studies with SKF 
38393 and LY 171555 and of the previous studies with apomorphine 
(McCulloch et al. 1982 a) clearly show that metabolic activity is the 
primary determinant of cerebral blood flow following the 
administration of dopamine receptor agonists.
This view would appear to be challenged by the detailed studies 
of the caudate nucleus. Although, LY 171555 effected focal 
alterations in blood flow and glucose use particularly within the 
ventral caudate nucleus, inspection of the autoradiographs suggested 
that the pattern of altered blood flow within the caudate nucleus did 
not match that of glucose use. This impression which was subsequently 
borne out by analysis of the flow/glucose relationship in 10 
subregions of the caudate nucleus. These findings are clearly at 
variance with the close coupling of flow to glucose use observed
throughout the rest of the brains of these same animals.
An apparent uncoupling of the flow/glucose use relationship may 
result from experimental artefact (due to differences in the temporal 
resolution characteristics of CBF and glucose use studies) or from 
drug effects resulting in hypertension or systemic hypercapnia. 
Ingvar and his associates (1983) have argued that any transient 
increases in glucose utilisation might be "diluted out" over the 45 
minute sampling period, while the secondary increases in blood flow 
would be readily detected over the shorter 1 minute blood flow 
experiment. However, in the present studies the possibility of 
transient drug effects resulting in an apparent uncoupling of flow to 
metabolism is unlikely since blood flow and glucose use measurements 
were initiated 40 and 30 minutes after drug administration. Rigorous 
control of the cardiovascular and respiratory status of experimental 
animals (Appendix 5.1) also served to obviate the possible 
complicating effects of hypertension and hypercapnia on cerebral 
blood flow.
LY 171555 significantly elevated local blood flow and glucose 
utilisation in the ventral caudate nucleus, while having only minimal 
effects upon the more dorsal aspects of the nucleus. However, the 
pronounced medial to lateral difference in blood flow was not 
accompanied by corresponding changes in glucose use. Thus, although 
similar increases in glucose use were observed within both the medial 
and lateral parts of the ventral caudate, following LY 171555 
administration, the circulatory responses within these two areas were 
markedly different. A possible explanation for the distinctive 
circulatory responses of the medial and lateral caudate nucleus to LY 
171555 may lie in the peculiar vascular anatomy of the striatum.
Anatomical studies have shown that the more lateral portions of the 
caudate nucles are supplied by branches of the middle cerebral artery 
whereas more medial portions are supplied by branches of the anterior 
cerebral artery (Yamori et al. 1976; Rieke et al. 1981). 
Differential reactivity of vessels within the middle cerebral and 
anterior cerebral artery territories may underlie the different blood 
flow responses observed between the medial and lateral caudate 
nucleus. Supporting this view are recent reports of differential 
sensitivity in the major cerebral vessels to a variety of 
neurotransmitters (see McCulloch and Edvinsson, 1984 for review), 
including preliminary evidence for dopamine (Hamel et al. 1985). 
Testing the hypothesis, at present, is not possible. The anatomical 
positioning of the anterior cerebral artery precludes the examination 
of vasomotor responses by the pial vessel approach and in vitro 
investigators using rat middle and anterior cerebral arteries have 
proved to be impracticable (Edvinsson - personal communication).
Following the administration of LY 171555, the area displaying 
the largest increases in local blood flow (ventrolateral portion at 
the middle caudate level) corresponds to the subregion of the caudate 
nucleus containing the highest concentration of D£ receptors (Jastrow 
et al. 1984; Altar et al. 1985; Nock et al. 1986). Within this 
subregion of the caudate nucleus the mgnitude of the circulatory 
response to LY 171555 was almost four times greater than the observed 
increase in glucose use. These observations would suggest that LY 
171555 is increasing blood flow within the ventrolateral caudate 
nucleus via J>2 receptor mechanisms on, Or close to, cerebral vessels.
A similar pattern of heteogeneous blood flow has been reported 
following the administration to intact and 6-hydroxy-dopamine 
lesioned rats (Ingvar et al. 1983). On the grounds that the
circulatory response to apomorphine was enhanced within the lateral 
caudate nucleus by lesions of the nigrostriatal pathway while glucose 
use in this area remained relatively unaffected, Ingvar and his 
associates postulated that this increase in blood flow was probably 
due to the stimulation of‘supersensitive vascular dopamine receptors. 
However, the precise location of these receptors remains obscure. A 
direct stimulation of dopamine receptors on the cerebral vasculature 
would be the most obvious site of action for this dilatory response. 
However, both in vitro (Foster et al. 1983) and in situ (present pial 
vessel studies) investigations have indicated that it is the D^ and 
not the I> 2 receptor which mediates dilatation of cerebral vessels. 
Nevertheless, the existence of D£ receptors subserving dilatation of 
resistance vessels within the ventrolateral caudate nucleus cannot, 
at present, be excluded.
A D£ mediated inhibition of sympathetic neurons innervating 
cerebral vessels could underlie the observed increase in local 
perfusion within the ventrolateral caudate nucleus. Indeed, a I> 2  
mediated inhibition of sympathetic activity has been reported to 
subserve the vasodilatory actions of LY 171555 in peripheral vascular 
tissues (Hahn and McDonald, 1983, 1984; Lokhandwala and Steenberg,
1984). However, in contrast to the situation pertaining in 
peripheral vascular beds, the cerebral vasculature does not receive a 
tonic constriction by the sympathetic system (Edvinsson and 
MacKenzie, 1977; Harper and McCulloch, 1984). Consequently, even if 
a D 2  mediated inhibition of the sympathetic innervation of the 
cerebral vasculature does occur, it would not result in an increase 
in local blood flow.
Despite displaying pronounced vasodilator activity in the pial 
vessel preparation, SKF 38393 administration resulted in a 
generalised decrease in blood flow within the head and body of the 
caudate nucleus. As there was no evidence of parallel reductions in 
glucose use at these levels it would appear that SKF 38393 was acting 
directly on the microvasculature within the rostral caudate nucleus 
to reduce blood flow. Significant reductions in local blood flow 
within the caudate nucleus have also been reported following 
electrical stimulation of the nigrostriatal pathway or the release of 
tissue dopamine stores by amphetamine (Lavyne et al. 1977). Thus, 
the reductions in local blood flow observed in the present study 
would appear to indicate that, in this area at least, D^ receptors 
mediate constriction of the local microvasculature. However, the 
possibility that the reductions in local blood flow observed in the 
present study and that of Lavyne et al. (1977) may be mediated via 
non-dopaminergic mechanisms cannot be discounted. It is well 
recognised that in cerebral, as well as in peripheral vessel 
preparations, dopamine provokes a dose-related constriction by 
stimulating o i -adrenergic receptors (Goldberg and Toda, 1975; Toda 
1976; Edvinsson et al. 1978). SKF 38393 is generally thought to 
exhibit low adrenergic activity (Pendleton et al. 1978; Hahn and 
Wardell, 1980). However, Lang and Woodman (1982) have demonstrated 
that SKF 38393 provokes a dose-related decrease in coronary blood 
flow; a response which could be abolished by ^ (-adrenoceptor blockade 
by phentolamine of yohimbine. A similar flC'-adrenoceptor mediated 
vasoconstriction of caudate microvessels would provide an equally 
plausible explanation for the reductions in blood flow observed in 
the present study.
At present it is not possible to determine whether the 
observed reductions in blood flow within the caudate nucleus are 
mediated via adrenergic or dopaminergic receptor mechanisms. The 
small calibre and inaccessability of intraparenchymal vessels 
preclude the examination of vasomotor responses by current in 
vitro or in situ approaches. Furthermore, detailed 
pharmacological studies of cerebral perfusion in vivo would not 
be feasible due to the complexity of an experimental design 
involving multiple concentrations of various agonists and 
antagonists and their interactions.
It is recognised that receptors mediate relaxation of 
vascular smooth muscle from renal, mesenteric and splenic beds ( 
Brodde 1982, Schmidt et al 1986 ) and that the administration of 
agonists can provoke increased local blood flow within these 
areas. However in 58 of the 59 brain regions examined in the 
present studies, neither SKF 38393 nor LY 171555 provoke 
independant vascular responses with the result that the 
flow/glucose use remained unaltered. Moreover, even within the 
one brain area where cerebrovascular dopamine receptors may 
contribute significantly to the level of local tissue perfusion 
(viz the caudate nucleus) it was the D 2  receptor agonist rather 
than the agonist which provoked the increase in local blood 
flow. Thus the present studies demonstrate that vascular 
receptors do not contribute significantly to the circulatory 
responses elicited by dopamine receptor agonists. This absence of 
a significant increase in blood flow following the administration 
of SKF 38393 calls into question the relevance of studying the 
vasomotor responses of cerebral vessels. In contrast to 
dopaminergic actions on the peripheral vasculature, the response
of individual cerebral arterioles to dopamine receptor agonists 
provides little insight into the circulatory responses to these 
agents in vivo. The dichotomy between the vasomotor responses 
elicited by pharmacological agents in vitro and their circulatory 
responses in vivo is not unique to dopamine systems. A similiar 
situation also occurs following the pharmacological manipulation 
of other monoamine neurotransmitter systems within the central 
nervous system ( gaba and noradrenergic systems). Despite the 
demonstration of noradrenergic and gaba mediated vasomotor 
responses on cerebral vessels (Edvinsson and McKenzie 1977, 
Edvinsson and Krause 1979) the stimulation of these systems by 
systemic drug administration does not alter the flow/metabolism 
relationship.
In conclusion, the studies within this thesis clearly 
demonstrate that, in the vast majority of brain areas, local 
metabolic activity is the primary determinant of tissue 
perfusion. However, within a few brain regions, other factors may 
play a significant role in determining levels of blood flow. The 
precise role of the cerebrovascular dopamine receptor is unclear 
and is worthy of further investigation.
APPENDIX 1
VALIDATION OF THE 'FINGERPRINTING' METHOD
APPROACH
A reproducibility study on the 'fingerprinting' method was 
carried out on glucose use data generated by two independent 
investigators from the same animals.
The 2-deoxyglucose autoradiograms from a series of 19 control 
and apomorphine (0.1 - 5 mg/kg) treated animals were analysed by Dr. 
J. McCulloch in Bethesda (USA) and by J. Sharkey in Glasgow (UK) 
using different densitometrical approaches and on different 
densitometers. Local cerebral glucose use values calculated for each 
data set were subsequently used to investigate the reproducibility of 
the fingerprinting model.
In the initial analyses, systematic differences between the USA 
and UK data sets were examined. For each animal the USA/UK 
difference for each of 39 brain regions were obtained. Regional and 
inter-animal differences between the two data sets were examined by 
two-way ANOVAR differences.
Hierarchies of regional responsiveness were constructed for 
each data set and compared via correlation analysis. The reliability 
of the hierarchies and of the product moment correlation coefficient 
were determined using the principles of the Boostrapping method (i.e. 
comparison of the original data set with 100 simulated data sets 
having the same overall mean and variability structure) as described 
previously (see Methods section).
RESULTS
Preliminary Analysis
Plots of local cerebral glucose use values for each of the 19 
animals revealed a strong linear relationship betweeen the UK and USA 
data, but with the USA data generally numerically higher than the UK 
measurements. However, the close correlation was marred by a few 
brain regions which consistently deviated from the line of identity. 
The anomolous regions included prefrontal cortex, amygdala, 
cerebellar hemisphere and vermis (Figure 34).
Interval estimates for USA/UK differences revealed values 
significantly greater than zero in 14 of the 19 animals. The 
positive trend for the USA/UK differences would suggest that the USA 
data was higher than that generated in the UK. This impression was 
confirmed by a two-way analysis of variance on the USA/UK differences 
which revealed significant regional and inter-animal differences 
between the two data sets.
Analysis of Fingerprinting Model
Analysis of the 'f' values generated by the two investigators 
confirmed the close linear correlation (0.875) between the two data 
sets, although the value was somewhat lower than would be expected 
from the same autoradiograms.
The reliability of the rankings generated by both investigators 
were good, with the correlation coefficients between the original and 
100 simulated data sets being 0.96 and 0.94 for the USA and UK 
analyses respectively.
FIGURE 34
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Influences of different densitometrical approaches upon 
local cerebral glucose use values of rats which received 
apomorphine (5mg/kg). Each data point represents the mean glucose 
use value for a single brain region. The best fitting straight 
line of gradient (m) is given. Am: lateral amygdala, Pf:
prefrontal cortex, Vm: cerebellar vermis.
Simulations of the USA vs UK correlation were close to, but 
generally less than, the calculated value of 0.875. This biasing of 
highly correlated data downwards is predicted by the Bootstrapping 
method and indicates that the true correlation coefficient for these 
two data sets is higher than the measured value of 0.875. Therefore, 
taking into account the downward biasing of the correlation 
coefficient and the inclusion of data from anomolous brain regions 
(i.e. prefrontal cortex) the reproducibility of the fingerprinting 
model would appear to be adequate to permit the comparison of data 
generated by different investigators.
COMMENTARY
*
The studies presented in this section indicate that a 
neuropharmacological 'fingerprint' of a drug could, indeed be 
reliably constructed from ranking of brain regions according to their 
functional responses to drug administration. Moreover, this 
hierarchy could be reproducibly constructed by independent 
investigators using different densitometrical criteria. Bearing in 
mind that the reproducibility studies were performed on the same 
autoradiograms (and with the same blood data) the correlation between 
the two data sets (0.875) was lower than would have been expected. 
The relatively low correlation between the two data sets probably 
reflects the different densitometrical criteria adopted by the two 
investigators.
The USA data set was generated by placing a small ( 3 x 3  pixel) 
measuring frame over the darkest portion of the region under 
examination, irrespective of its precise anatomical position within 
the region of interest. This approach confers a high degree of 
sensitivity’to the densitometry but with a loss of anatomical 
precision and an increase in the variability of the data (as a result 
of the small number of pixels used to evaluate the optical density of 
the region). In contrast, the UK analysis approach was to increase 
the anatomical precision of the measurements by adopting more rigid 
anatomical criteria and to increase the accuracy by using a larger 
measuring frame, (up to 10 x 10 pixels in large brain areas) wherever 
possible. The use of larger measurements areas on a predetermined 
position within a brain area would be expected to dilute highly focal 
alterations in optical density and so yield glucose use values which 
were systematically lower than those produced by the USA approach. 
Moreover, if focal alterations in optical density were not 
consistently found within the same subregion the'fixed position' 
measurement approach dilute or even fail to detect marked alterations 
in optical density. These expectations were borne out by two-way 
analysis of variance on the USA/UK differences which revealed 
systematically lower (approximately 12%) glucose use values in the UK 
data set. Moreover, in a number of large brain regions where focal 
alterations in glucose use occurred (i.e. cerebellum cortex and 
vermis, see Figure 19) the response was not marked in the UK data.
The different responses observed by the two investigators 
within prefrontal cortex was caused by the use of different 
anatomical criteria to define this brain region. Traditionally,
prefrontal cortex is defined as that area of neocortex which receives 
its principle thalamic projections from the mediodorsal thalamic 
nucleus (Rose and Woolsey, 1948). However, in the rat the 
mediodorsal thalamus projects to two distinct cortical fields; a 
perirhinal area located oh the dorsal bank of the rhinal sulcus; and 
an anteromedial field located rostral and dorsal to the genu of the 
corpus callosum (Divac et al. 1978 a,b). In the original (USA) 
apomorphine studies prefrontal cortex was examined in the sulcar 
region whereas the UK study analysed the anteromedial subdivision. 
However, it should be emphasised that despite the different 
densitometrical approaches the correlation between the two data sets 
was high and the hierarchy of regional responsiveness well preserved.
APPENDIX 2
Local Rates of Glucose Utilisation Following the Administration
of
SKF 38393 and LY 171555.
Table 2:1
Cardiovascular and respiratory variables for each treatment
group.
Tables 2:2 - 2:7
Local cerebral glucose utilisation was measured in conscious 
rats following the intravenous injection of saline (n=6), SKF 38393 
at the concentrations of 1 mg/kg (n=5), 10 mg/kg (n=5), and 30 mg/kg 
(n=4) or LY 171555 at the concentrations of 0.1 mg/kg (n=6), 0.5 
mg/kg (n=5), 1.5 mg/kg (n=5), and 5 mg/kg (n=5).
Data are presented as mean glucose use ( pmol.lOOg ^min
+ SEM.
*p<0.05.
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APPENDIX 3
Local Rates of Glucose Utilisation Following the Administration
of
SCH 23390.
Table 3:1
Cardiovascular and respiratory parameters for each treatment
group.
Table 3:2 - 3:7
Local cerebral glucose utilisation was measured in conscious 
rats following the intravenous injection of saline (n=5) or SCH 23390 
at concentrations of 0.05 mg/kg (n=3), 0.1 mg/kg (n=5) and 1 mg/kg 
(n=4). In a further four animals the effects of SCH 23390 (0.05 
mg/kg) pretreatment on the glucose use responses elicited by LY 
171555 (0.5 mg/kg) was examined.
Data are presented as mean glucose use ( pmol.l00g~’*min""^)
+ SEM.
*p<0.05.
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APPENDIX 4
Local Rates of Glucose Utilisation Following the Administration
of
Apomorphine.
Glucose utilisation was measured in conscious rats following the 
intravenous injection of saline (n=6), or apomorphine at 
concentrations of 0.15 mg/kg (n=3), 0.5 mg/kg (n=4), 1.5 mg/kg (n=3) 
and 5 mg/kg (n=3).
Data are presented as mean glucose use (pmol.lOOg ^min 
+ SEM.
*p<0.05.
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APPENDIX 5
Effects of SKF 38393 and LY 171555 
on
Local Cerebral Blood Flow and Glucose Use.
Table 5:1
Cardiovascular and respiratory status for the three groups of 
animals in which local cerebral blood flow was determined.
Table 5:2 - 5:7
Blood flow and glucose use were measured in different groups of 
rates following the intravenous administration of saline, SKF 38393 
(30 mg/kg) or LY 171555 (0.5 mg/kg).
The data are presented as mean blood flow (ml.l00g“^min“ )^ 
£  SEM and mean glucose use ( jimol.l00g“*min~^) ±  SEM.
Statistical analysis was performed using Student's t-test with 
Bonferroni correction for multiple comparisons.
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